Biomarkers for facioscapulohumeral muscular dystrophy

Abstract

The present disclosure, in some aspects, provides one or more biomarkers (e.g., plasma biomarkers or circulating biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., plasma biomarkers or circulating biomarkers) described herein is regulated by DUX4. Methods (e.g., non-invasive methods) of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided. The present disclosure, in other aspects, provides one or more biomarkers (e.g., transcriptome biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., transcriptome biomarkers) described herein is regulated by DUX4. Methods of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided.

Description

BIOMARKERS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYRELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 63 / 659,319 filed June 12, 2024, entitled “BIOMARKERS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY,”; and U.S. Provisional Patent Application No. 63 / 702,626 filed October 2, 2024, entitled “BIOMARKERS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY,” the entire contents of which are herein incorporated by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The content of the electronic sequence listing (D082470090WO00-SEQ- CBD.xml; Size: 50,402 bytes; and Date of Creation: June 3, 2025) is herein incorporated by reference in its entirety.FIELD OF THE INVENTION

[0003] The present application relates to biomarkers (e.g., plasma biomarkers or circulating biomarkers and transcriptomic biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD).BACKGROUND

[0004] Muscular dystrophies (MDs) are a group of diseases characterized by the progressive weakness and loss of muscle mass. These diseases are caused by mutations in genes which encode proteins needed for healthy muscle tissue. Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly inherited type of MD which primarily affects muscles of the face, shoulder blades, and upper arms. Other symptoms of FSHD include abdominal muscle weakness, retinal abnormalities, hearing loss, and joint pain and inflammation. FSHD is the most prevalent of the nine types of MD affecting both adults and children, with a worldwide incidence of about 1 in 8,300 people. FSHD is caused by aberrant production of double homeobox 4 (DUX4), a protein that regulates gene expression. The DUX4 gene, which encodes the DUX4 protein, is located in the D4Z4 repeat region on chromosome 4 and is typically expressed in adult testes and thymus, and in 2-cell stage embryos, after which it is repressed by hypermethylation of the D4Z4 repeats which surround and compact the DUX4 gene. Two types of FSHD, Type 1 and Type 2 have been described. Type 1, which accounts for about 95% of cases, is associated with deletions of D4Z4 repeats in the subtelomeric regionof chromosome 4. Unaffected individuals generally have more than 10 repeats arrayed in the subtelomeric region of chromosome 4, whereas the most common form of FSHD (FSHD1) is caused by a contraction of the array to fewer than 10 repeats, associated with decreased epigenetic repression and variegated expression of DUX4 in skeletal muscle. Two allelic variants of chromosome 4q (4qA and 4qB) exist in the most distal unit of the D4Z4 repeats. 4qA is in cis with a functional polyadenylation consensus site. Contractions on 4qA alleles are pathogenic because the DUX4 transcript is polyadenylated and stable. Type 2 FSHD, which accounts for about 5% of cases, is associated with mutations of the SMCHD1 gene on chromosome 18. Type 2 FSHD may also be associated with the DNMT3B gene or LRIF1 gene. Besides supportive care and treatments to address the symptoms of the disease, there are no effective therapies for FSHD.SUMMARY

[0005] The present disclosure, in some aspects, provide newly identified biomarkers (e.g., plasma biomarkers or circulating biomarkers, FSHD transcriptome biomarkers, and inflammatory biomarkers) that may be used in methods for diagnosis FSHD, and / or methods for assessing the treatment efficacy of a therapeutic agent for FSHD. The biomarkers (e.g., plasma biomarkers or circulating biomarkers, FSHD transcriptome biomarkers, and inflammatory biomarkers) disclosed herein are highly sensitive, may be used in non-invasive methods, enables early detection and / or continuous monitoring of FSHD. In some embodiments, a biomarker described herein is selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1. In some embodiments, a biomarker described herein is selected from KHDC1L, FAM110A, and TNNT2). In some embodiments, a biomarker described herein is selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1. In some embodiments, a biomarker described herein is selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2. In some embodiments, a biomarker described herein is selected from IL6, IFNG, and LGALS3. In some embodiments, a biomarker described herein is selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, IL6, IFNG, LGALS3, or combination thereof.

[0006] The present disclosure, in some aspects, provides a method comprising: (i) measuring the expression level of one or more plasma biomarkers in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the one or moreplasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the method further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD. In some embodiments, the method further comprises: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more plasma biomarkers in the subject.

[0007] Also provided herein, in some aspects, is a method comprising: (i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and (ii) measuring the expression level of one or more plasma biomarkers in a subject. In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more plasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

[0008] In some embodiments, the one or more plasma biomarkers are selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof. In some embodiments, the one or more plasma biomarkers are selected from KHDC1L, FAM110A, TNNT2, and combinations thereof. In some embodiments, the expression levels of the one or more biomarkers is upregulated in the subject, relative to those of a healthy subject or a subject that does not have FSHD.

[0009] In some embodiments, the one or more biomarkers are selected from KHDC1L, TNNT2, and combinations thereof.

[0010] In some embodiments, the expression levels of the one or more plasma biomarkers are measured in a blood sample obtained from the subject.

[0011] In some embodiments, the subject is continuously monitored for the expression level of the one or more plasma biomarkers.

[0012] Also provided herein, in some aspects, is a method comprising: (i) measuring the expression level of one or more FSHD transcriptome biomarkers in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the one or more FSHD transcriptome biomarkers, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the method further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD. In some embodiments, the method further comprises: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more FSHD transcriptome biomarkers in the subject.

[0013] Also provided herein, in some aspects, is a method comprising: (i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and (ii) measuring the expression level of one or more FSHD transcriptome biomarkers in a subject.

[0014] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

[0015] In some embodiments, the one or more transcriptome biomarkers are one or more FSHD transcriptome biomarkers selected from TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2, or combinations thereof.

[0016] In some embodiments, the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

[0017] In some embodiments, the expression levels of the one or more transcriptome biomarkers are upregulated in the subject, relative to those of a healthy subject or a subject that does not have FSHD.

[0018] In some embodiments, the one or more FSHD transcriptome biomarkers are selected from TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y 1 and TNNT2, or combinations thereof.

[0019] In some embodiments, the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

[0020] In some embodiments, the expression levels of the one or more FSHD transcriptome biomarkers are downregulated in the subject after administering to the subject a therapeutic agent for treating FSHD, relative to those prior to administering to the subject a therapeutic agent for treating FSHD.

[0021] In some embodiments, the one or more FSHD transcriptome biomarkers comprise TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y 1 and TNNT2, and combinations thereof.

[0022] In some embodiments, the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

[0023] In some embodiments, the expression levels of the one or more FSHD transcriptome biomarkers are measured in a muscle sample obtained from the subject.

[0024] In some embodiments, the muscle tissue sample is obtained via muscle biopsy.

[0025] In some embodiments, the subject is continuously monitored for the expression level of the one or more FSHD transcriptome biomarkers.

[0026] The present disclosure, in some aspects, provides a method comprising: (i) measuring the expression level of one or more inflammatory biomarkers in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the one or more inflammatory biomarkers, relative to those of a healthy subject or a subject that does not have FSHD.

[0027] In some embodiments, the method further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD.

[0028] In some embodiments, the method further comprises: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more inflammatory biomarkers in the subject.

[0029] Also disclosed herein, in some aspects, is a method comprising: (i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and (ii) measuring the expression level of one or more inflammatory biomarkers in a subject.

[0030] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more inflammatory biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

[0031] In some embodiments, the one or more inflammatory biomarkers is selected from IL6, IFNG, and LGALS3, or combinations thereof.

[0032] In some embodiments, the one or more inflammatory biomarkers are IL6, IFNG, and LGALS3.

[0033] In some embodiments, the expression levels of the one or more inflammatory biomarkers are upregulated in the subject, relative to those of a healthy subject or a subject that does not have FSHD.

[0034] In some embodiments, the one or more inflammatory biomarkers are selected from IL6, IFNG, and LGALS3, or combinations thereof.

[0035] In some embodiments, the one or more transcriptome biomarkers are, IL6, IFNG, and LGALS3.

[0036] In some embodiments, the expression levels of the one or more inflammatory biomarkers are downregulated in the subject after administering to the subject a therapeuticagent for treating FSHD, relative to those prior to administering to the subject a therapeutic agent for treating FSHD.

[0037] In some embodiments, the one or more inflammatory biomarkers comprise IL6, IFNG, and LGALS3, and combinations thereof.

[0038] In some embodiments, the one or more inflammatory biomarkers are IL6, IFNG, and LGALS3.

[0039] In some embodiments, the expression levels of the one or more inflammatory biomarkers are measured in a muscle sample obtained from the subject.

[0040] In some embodiments, the muscle tissue sample is obtained via muscle biopsy.

[0041] In some embodiments, the subject is continuously monitored for the expression level of the one or more inflammatory biomarkers.

[0042] In some embodiments, the therapeutic agent comprises a complex comprising an anti-transferrin receptor 1 (TfRl) antibody covalently linked to a molecular pay load that modulates DUX4 expression.

[0043] In some embodiments, the molecular payload comprises an oligonucleotide targeting DUX4.

[0044] In some embodiments, the anti-TfRl antibody comprises the CDRs of an anti- TfRl antibody provided in Table 4 or Table 5. In some embodiments, the therapeutic agent is a complex comprising a structure of formula (I): [ R11ni -R2, wherein each R1comprises a group of the formula (la):(la), or a pharmaceutically acceptable salt thereof, wherein R3comprises an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of SEQ ID NO: 22 and a structure (5’— >3’) of VP- mU*fG*mCmCmAmGmAmAmUmUmUmCmAfCmGmGmAmAmGmAmA*mC*mA (SEQ ID NO: 34), and a sense strand comprising a nucleobase sequence of SEQ ID NO: 21 and a structure (5’— >3’) ofmU*mU*mCmUfUmCmCmGfUfGfAmAmAfUmUmCmUmGfG*mC*mA (SEQ ID NO: 33), wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-0- methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5'- (E)-Vinylphosphonate; wherein R2comprises a Fab, and wherein the Fab comprises a CDR- Hl, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5.

[0045] In some embodiments, the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VE comprising the amino acid sequence of SEQ ID NO: 18.

[0046] In some embodiments, the Fab comprises a VH comprising an N-terminal pyroglutamate.

[0047] In some embodiments, the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; and wherein R1is covalently linked to R2at attachment point A; and wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab.

[0048] In some embodiments, each different amino acid residue is a lysine.

[0049] In some embodiments, the therapeutic agent is a complex comprising a structure of formula (I): [R^ni-R2, wherein each R1comprises a group of the formula (lb):(lb), or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’ -fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence between two nucleosides represents a phosphodiester intemucleoside linkage; and “VP” represents 5'-(E)-Vinylphosphonate, suchthat the oligonucleotide is an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21); wherein R2comprises a Fab, and wherein the Fab comprises a CDR-H1, a CDR- H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5.

[0050] In some embodiments, the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VE comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the Fab comprises a VH comprising an N-terminal pyroglutamate. In some embodiments, the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; and wherein R1is covalently linked to R2at attachment point A; and wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab. In some embodiments, each different amino acid residue is a lysine.

[0051] In some embodiments, the therapeutic agent is a complex comprising a structure of formula (I): [R^ni-R2, wherein R1comprises a group of the formula (Ic), in which the antisense strand and the sense strand form a double stranded oligonucleotide:(Ic), or a pharmaceutically acceptable salt thereof, wherein R2comprises a Fab comprising a CDR- Hl, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5. In some embodiments, the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the Fab comprises a VH comprising an N-terminal pyroglutamate. In some embodiments, the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein R1is covalently linked to R2at attachment point A; wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab. In some embodiments, each different amino acid residue is a lysine.

[0052] In some embodiments, the therapeutic agent is a complex comprising a structure of the formula (Id):or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-0-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’ -fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absencebetween two nucleosides represents a phosphodiester intemucleoside linkage; and “VP” represents 5’-(E)-Vinylphosphonate, such that the oligonucleotide is an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21; wherein R2comprises a Fab, and wherein the Fab comprises a CDR-H1, a CDR- H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5. In some embodiments, the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the Fab comprises a VH comprising an N-terminal pyroglutamate. In some embodiments, the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein nl is an integer representing the number of instances of the group enclosed by square brackets, wherein each instance of the group enclosed by square brackets is covalently linked to a different amino acid residue of the Fab. In some embodiments, each different amino acid residue is a lysine.BRIEF DESCRIPTION OF THE DRAWINGS

[0053] FIG. 1 shows a panel of 15 candidate plasma biomarkers for FSHD, including ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1. KHDC1L, FAM110A, and TNNT2 are differentially expressed between subjects having FSHD and healthy subjects.KHDC1L and TNNT2 are upregulated in subjects having FSHD, relative to a healthy subject. FAM1 10A is downregulated in subject having FSHD, relative to a healthy subject. The markers are based on the Somalogic healthy dataset of -2300 volunteers. The “TNNT2 / TNNC1 / TNNI3” means the detection methods used for detecting the level of the biomarker do not distinguish the three homologues.

[0054] FIGs. 2A-2B show the identification of KHDC1E as a candidate biomarker for FSHD. FIG. 2A shows decreased expression of KHDC1E mRNA following treatment withcomplexes comprising an anti-TfRl Fab conjugated to a DUX4-targeting siRNA (anti-TfRl- DUX4 siRNA complex) in primary muscle cells derived from FSHD patients in vitro. FIG. 2B shows circulating KHDC1L protein levels in FSHD patients is significantly higher than in healthy controls at baseline and at a 6-month follow-up.

[0055] FIG. 3. shows circulating TNNT2 protein levels in FSHD patients is significantly higher than in healthy controls at baseline and at a 6-month follow-up.

[0056] FIG. 4 shows the levels of nine FSHD transcriptome biomarkers, includingCCNA1, LEUTX, H3Y1, SLC34A2, TRIM43, ZSCAN4, PRAMEF6, KHDC1L, and MBD3L2 are downregulated following treatment with complexes comprising an anti-TfRl Fab conjugated to a DUX4-targeting siRNA (anti-TfRl -DUX4 siRNA complex) in primary muscle cells derived from FSHD patients.

[0057] FIG. 5 shows that the hTfRl / iFLExD FSHD mouse model recapitulates inflammatory pathways activated in FSHD patient muscle tissue.FIGs. 6A-6F show expression of inflammatory biomarkers in the hTfRl / iFLExD FSHD mouse model and FSHD patient muscle biopsies. FIG. 6A shows expression levels of interleukin-6 (116) in hTfRl / iFLExD mice treated with 1, 2, or 6 mg / kg siRNA-equivalent dose of anti-TfRl -DUX4 siRNA complex relative to vehicle and FIG. 6B shows expression levels of 116 in FSHD patient muscle biopsies. FIG. 6C shows expression levels of interferon-y (IFNG) in hTfRl / iFLExD mice treated with 1, 2, or 6 mg / kg siRNA-equivalent dose of anti- TfRl-DUX4 siRNA complex relative to vehicle and FIG. 6D shows expression levels of IFNG in FSHD patient muscle biopsies. FIG. 6E shows expression levels of Galectin-3 (LGAL3) in hTfRl / iFLExD mice treated with 1, 2, or 6 mg / kg siRNA-equivalent dose of anti-TfRl -DUX4 siRNA complex relative to vehicle and FIG. 6F shows expression levels of LGAL3 in FSHD patient muscle biopsies. From left to right in FIGs. 6A, 6C, and 6E, vehicle represents Tamoxifen-induced wild-type mice, Uninduced hTfRl / iFLExD mice (no tamoxifen treatment), and Tamoxifen-induced hTfRl / iFLExD mice, respectively.DETAILED DESCRIPTION

[0058] The present disclosure, in some aspects, provide newly identified biomarkers (e.g., plasma biomarkers or circulating biomarkers or FSHD transcriptome biomarkers or inflammatory biomarkers) that may be used in methods for diagnosis FSHD, and / or methods for assessing the treatment efficacy of a therapeutic agent for FSHD. The biomarkers (e.g., plasma biomarkers or circulating biomarkers or FSHD transcriptome biomarkers orinflammatory biomarkers) disclosed herein are highly sensitive, may be used in non-invasive methods, enables early detection and / or continuous monitoring of FSHD.

[0059] In some embodiments, a plasma biomarker described herein is selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1. In some embodiments, the plasma biomarker described herein is selected from KHDC1L, FAM110A, and TNNT2. In some embodiments, the plasma biomarker described herein is KHDC1L. In some embodiments, the plasma biomarker described herein is FAM110A. In some embodiments, the plasma biomarker described herein is TNNT2.

[0060] In some embodiments, a FSHD transcriptome biomarker described herein is selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, or combinations thereof. In some embodiments, a FSHD transcriptome biomarker described herein is selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2 or combinations thereof. In some embodiments, the FSHD transcriptome biomarkers described herein are TRIM43, EEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1.

[0061] In some embodiments, an inflammatory biomarker described herein is selected from IL6, IFNG, and LGALS3, or combinations thereof. In some embodiments, the inflammatory biomarkers described herein are IL6, IFNG, and LGALS3.

[0062] Further aspects of the disclosure, including a description of defined terms, are provided below.I. Definitions

[0063] Administering: As used herein, the terms “administering” or “administration” means to provide a complex to a subject in a manner that is physiologically and / or (e.g., and) pharmacologically useful (e.g., to treat a condition in the subject).

[0064] Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0065] Antibody: As used herein, the term “antibody” refers to a polypeptide that includes at least one immunoglobulin variable domain or at least one antigenic determinant,e.g., paratope that specifically binds to an antigen. In some embodiments, an antibody is a full- length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a Fab’ fragment, a F(ab’)2 fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a nanobody derived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgGl, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgAl, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region (abbreviated herein as VH), and / or (e.g., and) a light (L) chain variable region (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain, e.g., an Fc region. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In a particular embodiment, an antibody described herein comprises a human gamma 1 CHI, CH2, and / or (e.g., and) CH3 domain. In some embodiments, the amino acid sequence of the VH domain comprises the amino acid sequence of a human gamma (y) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, the VH domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the variable chain constant regions provided herein. In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branchedoligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a polypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[0066] CDR: As used herein, the term “CDR” refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known in the art, for example, by the Kabat definition, the IMGT definition, the Chothia definition, the AbM definition, and / or (e.g., and) the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; IMGT®, the international ImMunoGeneTics information system® www.imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P, Nucleic Acids Res., 29:207-209 (2001); Lefranc, M.-P, Nucleic Acids Res., 31:307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [Epub], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res.,33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. et al., Nucleic Acids Res., 43:D413-422 (2015); Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17: 132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk / abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[0067] There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term “CDR set” as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as LI, L2 and L3 or Hl, H2 and H3 where the “L” and the “H” designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems. Examples of CDR definition systems are provided in Table 1.Table 1. CDR Definitions1IMGT®, the international ImMunoGeneTics information system®, imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999)2Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-32423Chothia et al., J. Mol. Biol. 196:901-917 (1987))

[0068] CDR-grafted antibody: The term “CDR-grafted antibody” refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and / or (e.g., and) VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human CDR sequences.

[0069] Chimeric antibody: The term “chimeric antibody” refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[0070] Complementary: As used herein, the term “complementary” refers to the capacity for precise pairing between two nucleosides or two sets of nucleosides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleosides or two sets of nucleosides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (e.g., an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil- type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[0071] Conservative amino acid substitution: As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge orsize characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0072] Covalently linked: As used herein, the term “covalently linked” refers to a characteristic of two or more molecules being linked together via at least one covalent bond. In some embodiments, two molecules can be covalently linked together by a single bond, e.g., a disulfide bond or disulfide bridge, that serves as a linker between the molecules. However, in some embodiments, two or more molecules can be covalently linked together via a molecule that serves as a linker that joins the two or more molecules together through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker.

[0073] Cross-reactive: As used herein and in the context of a targeting agent (e.g., antibody), the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human transferrin receptor and non-human primate transferrin receptor) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross -reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross -reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[0074] DUX4: As used herein, the term “DUX4” refers to a gene that encodes double homeobox 4, a protein which is generally expressed during fetal development and in the testes of adult males. In some embodiments, DUX4 may be a human (Gene ID: 100288687), non- human primate (e.g., Gene ID: 750891, Gene ID: 100405864), or rodent gene (e.g., Gene ID: 306226). In humans, expression of the DUX4 gene outside of fetal development and the testesis associated with facioscapulohumeral muscular dystrophy. In addition, multiple human transcript variants (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001293798.2, NM_001306068.3, NM_001363820.1) have been characterized that encode different protein isoforms.

[0075] Facioscapulohumeral muscular dystrophy (FSHD): As used herein, the term “facioscapulohumeral muscular dystrophy (FSHD)” refers to a genetic disease caused by mutations in the DUX4 gene, SMCHD1 gene, DNMT3B gene, or LRIF1 gene that is characterized by muscle mass loss and muscle atrophy, primarily in the muscles of the face, shoulder blades, and upper arms. Two types of the disease, Type 1 and Type 2, have been described. Type 1 is associated with deletions in D4Z4 repeat regions on chromosome 4 which contains the DUX4 gene. In some embodiments, Type 1 is associated with deletions in D4Z4 repeat regions on chromosome 4 allelic variant 4qA which contains the DUX4 gene. Type 2 is associated with mutations in the SMCHD1 gene, DNMT3B gene, or LRIF1 gene (see, e.g., Jia et al., “Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings” Neuromuscul Disord. (2021), 31(11): 1101-1112. Both Type 1 and Type 2 FSHD are characterized by aberrant production of the DUX4 protein after fetal development outside of the testes. Facioscapulohumeral dystrophy, the genetic basis for the disease, and related symptoms are described in the art (see, e.g., Campbell, A.E., et al., “Facioscapulohumeral dystrophy: Activating an early embryonic transcriptional program in human skeletal muscle” Human Mol Genet. (2018); and Tawil, R. “Facioscapulohumeral muscular dystrophy” Handbook Clin. Neurol. (2018), 148: 541-548.) FSHD Type 1 is associated with Online Mendelian Inheritance in Man (OMIM) Entry # 158900. FSHD Type 2 is associated with OMIM Entry # 158901.

[0076] Framework: As used herein, the term “framework” or “framework sequence” refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4. Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred by others, represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions,and FRs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[0077] Human antibody: The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site- specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0078] Humanized antibody: The term “humanized antibody” refers to antibodies which comprise heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and / or (e.g., and) VL sequence has been altered to be more “human-like”, i.e., more similar to human germline variable sequences. One type of humanized antibody is a CDR-grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding non-human CDR sequences. In one embodiment, humanized anti-TfRl antibodies and antigen binding portions are provided. Such antibodies may be generated by obtaining murine anti-TfRl monoclonal antibodies using traditional hybridoma technology followed by humanization using in vitro genetic engineering, such as those disclosed in Kasaian et al PCT publication No. WO 2005 / 123126 A2.

[0079] Internalizing cell surface receptor: As used herein, the term, “internalizing cell surface receptor” refers to a cell surface receptor that is internalized by cells, e.g., upon external stimulation, e.g., ligand binding to the receptor. In some embodiments, an internalizing cell surface receptor is internalized by endocytosis. In some embodiments, an internalizing cell surface receptor is internalized by clathrin-mediated endocytosis. However, in some embodiments, an internalizing cell surface receptor is internalized by a clathrin- independent pathway, such as, for example, phagocytosis, macropinocytosis, caveolae- and raft-mediated uptake or constitutive clathrin-independent endocytosis. In some embodiments, the internalizing cell surface receptor comprises an intracellular domain, a transmembrane domain, and / or (e.g., and) an extracellular domain, which may optionally further comprise aligand-binding domain. In some embodiments, a cell surface receptor becomes internalized by a cell after ligand binding. In some embodiments, a ligand may be a muscle-targeting agent or a muscle-targeting antibody. In some embodiments, an internalizing cell surface receptor is a transferrin receptor.

[0080] Isolated antibody: An “isolated antibody”, as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds transferrin receptor is substantially free of antibodies that specifically bind antigens other than transferrin receptor). An isolated antibody that specifically binds transferrin receptor complex may, however, have cross-reactivity to other antigens, such as transferrin receptor molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and / or (e.g., and) chemicals.

[0081] Kabat numbering: The terms “Kabat numbering”, “Kabat definitions and “Kabat labeling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[0082] Molecular payload: As used herein, the term “molecular payload” refers to a molecule or species that functions to modulate a biological outcome. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, the molecular payload is a small molecule, a protein, a peptide, a nucleic acid, or an oligonucleotide. In some embodiments, the molecular payload functions to modulate the transcription of a DNA sequence, to modulate the expression of a protein, or to modulate the activity of a protein. In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a target gene.

[0083] Muscle-targeting agent: As used herein, the term, “muscle-targeting agent,” refers to a molecule that specifically binds to an antigen expressed on muscle cells. Theantigen in or on muscle cells may be a membrane protein, for example an integral membrane protein or a peripheral membrane protein. Typically, a muscle-targeting agent specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting agent (and any associated molecular pay load) into the muscle cells. In some embodiments, a muscle-targeting agent specifically binds to an internalizing, cell surface receptor on muscles and is capable of being internalized into muscle cells through receptor mediated internalization. In some embodiments, the muscle-targeting agent is a small molecule, a protein, a peptide, a nucleic acid (e.g., an aptamer), or an antibody. In some embodiments, the muscle-targeting agent is linked to a molecular payload.

[0084] Muscle-targeting antibody: As used herein, the term, “muscle-targeting antibody,” refers to a muscle-targeting agent that is an antibody that specifically binds to an antigen found in or on muscle cells. In some embodiments, a muscle-targeting antibody specifically binds to an antigen on muscle cells that facilitates internalization of the muscletargeting antibody (and any associated molecular payload) into the muscle cells. In some embodiments, the muscle-targeting antibody specifically binds to an internalizing, cell surface receptor present on muscle cells. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds to a transferrin receptor.

[0085] Oligonucleotide: As used herein, the term “oligonucleotide” refers to an oligomeric nucleic acid compound of up to 200 nucleotides in length. Examples of oligonucleotides include, but are not limited to, RNAi oligonucleotides (e.g., siRNAs, shRNAs), microRNAs, gapmers, mixmers, phosphorodiamidate morpholinos, peptide nucleic acids, aptamers, guide nucleic acids (e.g., Cas9 guide RNAs), etc. Oligonucleotides may be single- stranded or double-stranded. In some embodiments, an oligonucleotide may comprise one or more modified nucleosides (e.g., 2'-O-methyl sugar modifications, purine or pyrimidine modifications). In some embodiments, an oligonucleotide may comprise one or more modified intemucleoside linkages. In some embodiments, an oligonucleotide may comprise one or more phosphorothioate linkages, which may be in the Rp or Sp stereochemical conformation.

[0086] Recombinant antibody: The term “recombinant human antibody”, as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425- 445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29: 128-145; Hoogenboom H.,and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo. One embodiment of the disclosure provides fully human antibodies capable of binding human transferrin receptor which can be generated using techniques well known in the art, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et al., PCT publication No. WO 2005 / 007699 A2.

[0087] Region of complementarity: As used herein, the term “region of complementarity” refers to a nucleotide sequence, e.g., of an oligonucleotide, that is sufficiently complementary to a cognate nucleotide sequence, e.g., of a target nucleic acid, such that the two nucleotide sequences are capable of annealing to one another under physiological conditions (e.g., in a cell). In some embodiments, a region of complementarity is fully complementary to a cognate nucleotide sequence of target nucleic acid. However, in some embodiments, a region of complementarity is partially complementary to a cognate nucleotide sequence of target nucleic acid (e.g., at least 80%, 90%, 95% or 99% complementarity). In some embodiments, a region of complementarity contains 1, 2, 3, or 4 mismatches compared with a cognate nucleotide sequence of a target nucleic acid.

[0088] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds”, refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, that enables the antibody to be used to distinguish the specific antigen from others, e.g., to an extent that permits preferential targeting to certain cells, e.g., muscle cells, through binding to theantigen, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a KD for binding the target of at least about 10'4M, 10'5M, 10'6M, 10'7M, 10'8M, 10'9M, IO0M, 1041M, 1042M, IO3M, or less. In some embodiments, an antibody specifically binds to the transferrin receptor, e.g., an epitope of the apical domain of transferrin receptor.

[0089] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, e.g., a human patient that has or is suspected of having a disease. In some embodiments, the subject is a human patient who has or is suspected of having FSHD.

[0090] Transferrin receptor: As used herein, the term, “transferrin receptor” (also known as TFRC, CD71, p90, TFR1) refers to an internalizing cell surface receptor that binds transferrin to facilitate iron uptake by endocytosis. In some embodiments, a transferrin receptor may be of human (NCBI Gene ID 7037), non-human primate (e.g., NCBI Gene ID 711568 or NCBI Gene ID 102136007), or rodent (e.g., NCBI Gene ID 22042) origin. In addition, multiple human transcript variants have been characterized that encoded different isoforms of the receptor (e.g., as annotated under GenBank RefSeq Accession Numbers: NP_001121620.1, NP_003225.2, NP_001300894.1, and NP_001300895.1).

[0091] 2’-modified nucleoside: As used herein, the terms “2’ -modified nucleoside” and “2’ -modified ribonucleoside” are used interchangeably and refer to a nucleoside having a sugar moiety modified at the 2’ position. In some embodiments, the 2’ -modified nucleoside is a 2’-4’ bicyclic nucleoside, where the 2’ and 4’ positions of the sugar are bridged (e.g., via a methylene, an ethylene, or a (S)-constrained ethyl bridge). In some embodiments, the 2’- modified nucleoside is a non-bicyclic 2’-modified nucleoside, e.g., where the 2’ position of the sugar moiety is substituted. Non-limiting examples of 2’ -modified nucleosides include: 2’- deoxy, 2’-fluoro (2’-F), 2’-O-methyl (2’-O-Me), 2’-O-methoxyethyl (2’-MOE), 2’-O- aminopropyl (2’-O-AP), 2’-O-dimethylaminoethyl (2’-O-DMAOE), 2’-O- dimethylaminopropyl (2’-O-DMAP), 2’-O-dimethylaminoethyloxyethyl (2’-O-DMAEOE), 2’- O-N-methylacetamido (2’-0-NMA), locked nucleic acid (LNA, methylene-bridged nucleic acid), ethylene-bridged nucleic acid (ENA), and (S)-constrained ethyl-bridged nucleic acid (cEt). In some embodiments, the 2’ -modified nucleosides described herein are high-affinity modified nucleosides and oligonucleotides comprising the 2’ -modified nucleosides have increased affinity to target sequences, relative to an unmodified oligonucleotide. Examples of structures of 2’ -modified nucleosides are provided below:2'-O-methoxyethyl 'locked nucleic acid ethylene-bridged (S)-constrainedThese examples are shown with phosphate groups, but any internucleoside linkages are contemplated between 2’ -modified nucleosides.

[0092] Ranges: All ranges provided in the present disclosure are inclusive of the end points.

[0093] Biomarker: As used herein, the term “biomarker” refers to a gene, the expression of which (e.g., expression of RNA, protein, and / or relative levels of different isoforms) and / or activity differs in the presence or absence of a disease such as Facioscapulohumeral muscular dystrophy (FSHD), and / or is affected by the progression and / or severity of the disease. In some embodiments, a biomarker described herein is upregulated (e.g., exhibits increased expression and / or activity) in a subject having FSHD, relative to that of a health subject or a subject that does not have FSHD. In some embodiments, a biomarker described herein exhibits increased expression and / or activity (e.g., increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 2-fold, at least 5-fold, at least 10-fold or more), relative to that of a health subject or a subject that does not have FSHD. In some embodiments, a biomarker described herein is downregulated (e.g., exhibits decreased expression and / or activity) in a subject having FSHD, relative to that of a health subject or a subject that does not have FSHD. In some embodiments, a biomarker described herein exhibits decreased expression and / or activity (e.g., decreased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more), relative to that of a health subject or a subject that does not have FSHD. In some embodiments, a biomarker for FSHD provided herein isselected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, and TYRP1. In some embodiments, a biomarker for FSHD provided herein is selected from KHDC1L, FAM110A, and TNNT2. In some embodiments, a biomarker for FSHD provided herein is selected from KHDC1E and TNNT2. In some embodiments, a biomarker for FSHD provided herein is selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, or combination thereof. In some embodiments, a biomarker for FSHD provided herein is selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, or combination thereof. In some embodiments, a biomarker for FSHD provided herein is selected from IE6, IFNG, and EGAES3, or combinations thereof.

[0094] In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from ASF, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1E, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from ASF, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1E, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).

[0095] In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from KHDC1E, FAM110A, and TNNT2, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from KHDC1E, FAM1 10A, and TNNT2, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein). In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from KHDC1E and TNNT2, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from KHDC1E and TNNT2, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).

[0096] In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein). In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).

[0097] In some embodiments, the expression level (e.g., protein or mRNA level) of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein). In some embodiments, the expression level (e.g., protein or mRNA level) of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).

[0098] In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from IL6, IFNG, and LGALS3 andcombinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).

[0099] In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) provided herein may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of one or more biomarkers (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) provided herein may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein). [000100] In some embodiments, the expression level (e.g., protein or mRNA level) of inflammatory biomarkers including IL6, IFNG, and LGALS3 may be used for diagnosis or detection (e.g., early diagnosis or early detection) of FSHD. In some embodiments, the expression level (e.g., protein or mRNA level) of inflammatory biomarkers including IL6, IFNG, and LGALS3 may be used to indicate the efficacy of an FSHD therapeutic (e.g., an FSHD therapeutic known in the art or described herein).[000101] Plasma biomarker: As used herein, the term “plasma biomarker” is used interchangeably with “circulating biomarker,” and refers to a biomarker whose expression level (e.g., expression of RNA, protein, and / or relative levels of different isoforms) and / or activity level may be measured in a subject’s circulating blood or in a blood sample or a plasma sample or a serum sample. In some embodiments, the expression level (e.g., protein level and / or mRNA level) any one of the biomarkers described herein or any combinations of biomarkers described herein may be measured in a subject’s circulating blood or in a blood sample or a plasma sample or a serum sample from a subject (e.g., a subject having FSHD). In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the biomarkers described herein (e.g., biomarkers selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof) is measured in a subject’s circulating blood or in a blood sample or a plasma sample or a serum sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the biomarkers described herein (e.g., biomarkers selected from KHDC1L, FAM110A, and TNNT2, and combinations thereof) is measured in a subject’s circulating blood or in a bloodsample or a plasma sample or a serum sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the biomarkers described herein (e.g., biomarkers selected from KHDC1L and TNNT2, and combinations thereof) is measured in a subject’s circulating blood or in a blood sample or a plasma sample or a serum sample.[000102] FSHD transcriptome biomarker: As used herein the term “FSHD transcriptome biomarker” refers to a gene, whose transcription is regulated by DUX4. DUX4 levels affect expression levels (e.g., expression of RNA, protein, and / or relative levels of different isoforms) of FSHD transcriptome biomarker. DUX4 levels can affect expression levels (e.g., expression of RNA, protein, and / or relative levels of different isoforms) of FSHD transcriptome biomarker directly or indirectly. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s muscle biopsy sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2 and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2 and combinations thereof) is measured in a subject’s muscle biopsy sample.[000103] In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s tissue sample. In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s muscle tissue. In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s muscle biopsy sample. In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s tissue sample. In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s muscle tissue. In some embodiments, FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s muscle biopsy sample.[000104] Inflammatory biomarker: As used herein, the term “inflammatory biomarker” refers to a gene associated with inflammation whose expression level (e.g., expression of RNA, protein, and / or relative levels of different isoforms) may be measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein level and / or mRNA level) any one of the inflammatory biomarkers described herein or any combinations of biomarkers described herein may be measured in a subject’s tissue sample (e.g., a subject having FSHD). In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) is measured in a subject’s muscle biopsy sample.[000105] ASL: As used herein “ASL” (also known as Argininosuccinate lyase, or ASAL) encodes a member of the lyase 1 family. The protein encoded by ASL gene is an enzyme that is involved in the reversible breakdown of argininosuccinate into arginine and fumarate. In some embodiments, ASL may be of human (e.g., NCBI Gene ID 435), non-human primate(e.g., NCBI Gene ID 697109 or NCBI Gene ID 463444), or rodent (e.g., NCBI Gene ID 109900) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000048.4, NM_001024944.2, and NM_001024946.2).[000106] ATP23: As used herein “ATP23” (also known as ATP23 metallopeptidase and ATP synthase assembly factor homolog, KUB3, or XRCC6BP1) encodes a protein that interacts with the DNA binding subunit of DNA-dependent protein kinase. In some embodiments, the kinase is involved in double- stranded break repair, wherein higher expression increases double-stranded break repair. In some embodiments, ATP23 is a metalloprotease used in the biosynthesis of mitochondrial ATPase. In some embodiments, ATP23 may be of human (e.g., NCBI Gene ID 91419), non-human primate (e.g., NCBI Gene ID 712932 or NCBI Gene ID 452031), or rodent (e.g., NCBI Gene ID 68876) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001320408.2, NM_001320409.2, NM_001320410.2, and NM_033276.4).[000107] C3B: As used herein “CB3” (also known as C3, Compliment C3, C3A, ASP, AHUS5, ARMDp, CPAMD1, HEL-S-62p, or complement component 3) encodes a preproprotein that is proteolytically processed to generate alpha and beta subunits that form the mature protein, which is then further processed to generate numerous peptide products. Proteolytic cleavage of the C3 protein into C3A and C3B is generated in the classical pathway during activation. In some embodiments, CB3 plays a central role in the complement system. In some embodiments, CB3’s activation is required for the classical and alternative complement pathways. In some embodiments, C3B may be of human (e.g., NCBI Gene ID 718), non-human primate (e.g., NCBI Gene ID 703613 or NCBI Gene ID 102131458), or rodent (e.g., NCBI Gene ID 12266) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_000064.4). [000108] CBS: As used herein “CBS” (also known as cystathionine beta-synthase, CBSL, or HIP4) encodes an enzyme that catalyzes the first step of the trans sulfuration pathway, acting as a homotetramer converting homocysteine to cystathionine. CBS belongs to a family of lyases (hydro-lyases), which cleave carbon-oxygen bonds. In some embodiments, CBS may be of human (e.g., NCBI Gene ID 875), non-human primate (e.g., NCBI Gene ID 100423684 or NCBI Gene ID 450119), or rodent (e.g., NCBI Gene ID 12411) origin. In addition, multiple human transcript variants have been characterized that encode differentisoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000071.3, NM_001178008.3, NM_001178009.3, NM_001320298.2, and NM_001321072.1).[000109] CDK5RAP: As used herein “CDK5RAP3” (also known as CDK5 regulatory subunit associated protein 3, C53, IC53, LZAP, HSF-27, MST016, PP1553, or OK / SW-cl.114) encodes a protein involved in cell cycle regulation, cell damage, apoptosis, invasion, migration, metastasis, cytoskeleton remodeling, and proliferation. In some embodiments, CDK5RAP3 functions in signaling pathways governing transcriptional regulation and cell cycle progression. In some embodiments, CDK5RAP3 may be of human (e.g., NCBI Gene ID 80279), non-human primate (e.g., NCBI Gene ID 695189 or NCBI Gene ID 455182), or rodent (e.g., NCBI Gene ID 80280) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NP_001265126.1, NP_001265127.1, NP_001265145.1, NP_001265146.1, and NP_788276.1).[000110] EDEM2: As used herein “EDEM2” (also known as ER degradation enhancing alpha-mannosidase like protein 2, C20orf31, C20orf49, or bA4204.1) encodes an enzyme involved in endoplasmic reticulum-associated degradation of glycoproteins. In some embodiments, EDEM2 may be of human (e.g., NCBI Gene ID 55741), non-human primate (e.g., NCBI Gene ID 706150 or NCBI Gene ID 458197), or rodent (e.g., NCBI Gene ID 108687) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001145025.2 and NM_018217.3).[000111] FAM110A: As used herein “FAM110A” (also known as family with sequence similarity 110 member A, F10, C20orf55, or bA371L19.3) encodes a protein that is involved in the regulation of the cell cycle. In some embodiments, depletion of FAM110A leads to mitotic defects and delayed progression of mitosis. In some embodiments, FAM110A may be of human (e.g., NCBI Gene ID 83541), non-human primate (e.g., NCBI Gene ID 717055 or NCBI Gene ID 134806946), or rodent (e.g., NCBI Gene ID 73847) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001042353.3, NM_001289145.2, NM_001289146.2, NM_001289147.2, NM_031424.6, and NM_207121.5). [000112] ID1: As used herein “ID1” (also known as inhibitor of DNA binding 1, ID, DNA-binding protein inhibitor ID-1, HLH protein, or bHLHb24) encodes a helix-loop-helix protein. ID1 has no DNA binding activity and can inhibit basic HLA protein’s DNA binding and transcriptional activation. In some embodiments, ID1 can form heterodimers with HLHtranscription factors. In some embodiments, ID1 plays a role in cell growth, senescence, and differentiation. In some embodiments, ID1 may be of human (e.g., NCBI Gene ID 3397), nonhuman primate (e.g., NCBI Gene ID 713160 or NCBI Gene ID 469912), or rodent (e.g., NCBI Gene ID 15901) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_002165.4 and NM_181353.3).[000113] PBXIP1: As used herein “PBXIP1” (also known as PBX homeobox interacting protein 1, HPIP, Pre-B-Cell Leukemia Transcription Factor- Interacting Protein 1, Pre-B-Cell Leukemia Homeobox Interacting Protein 1, or Hematopoietic PBX-Interacting Protein) encodes a protein that inhibits transcriptional activation potential when interacting with PBX1 homeodomain protein, inhibiting its binding to DNA. In some embodiments, PBXIP1 may be of human (e.g., NCBI Gene ID 57326), non-human primate (e.g., NCBI Gene ID 717036 or NCBI Gene ID 458002), or rodent (e.g., NCBI Gene ID 229534) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001317734.2, NM_001317735.2, and NM_020524.4).[000114] STAR: As used herein “STAR” (also known as steroidogenic acute regulatory protein or STARD1) encodes a transport protein that plays a key role in acute regulation of steroid hormone synthesis. STAR regulates cholesterol transfer from outer mitochondrial membrane to the inner mitochondrial membrane, which leads to the cleavage of cholesterol into progesterone. In some embodiments, STAR may be of human (e.g., NCBI Gene ID 6770), non-human primate (e.g., NCBI Gene ID 699515 or NCBI Gene ID 746738), or rodent (e.g., NCBI Gene ID 20845) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_000349.3). [000115] TNNT2: As used herein “TNNT2” (also known as troponin T2, cardiac type, CMH2, RCM3, TnTC, cTnT, CMD1D, CMPD2, Cardiac muscle troponin T, or LVNC6) encodes the cardiac isoform of troponin T. TNNT2 regulates muscle contraction in response to intracellular calcium ion concentration. In some embodiments, TNNT2 may be of human (e.g., NCBI Gene ID 7139), non-human primate (e.g., NCBI Gene ID 709882 or NCBI Gene ID 457618), or rodent (e.g., NCBI Gene ID 21956) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000364.4, NM_001001430.3, NM_001001431.3, NM_001001432.3, NM_001276345.2, NM_001276346.2, NM_001276347.2, NM_001406723.1, NM_001406724.1, NM_001406725.1, NM_001406726.1,NM_OO 1406727.1, and NM_001406728.1. In some embodiments, an FSHD therapeutic (e.g., complex comprising an anti-TfRl Fab conjugated to a DUX4-targeting siRNA) reduces the protein level and mRNA level of TNNT2.[000116] TNNC1: As used herein “TNNC1” (also known as troponin Cl, slow skeletal and cardiac type, TNC, TN-C, TNNC, CMD1Z, CMH13, troponin C type 1, or troponin C) encodes a regulatory protein of striated muscle contraction located on actin filament. In some embodiments, TNNC1 comprises three subunits Tnl, TnT, and TnC. In some embodiments, Tnl is an inhibitor of actomyosin ATPase. In some embodiments, TnT contains a binding site for tropomyosin. In some embodiments, TnC, when bound to calcium, abolishes the inhibitory action of Tnl on actin filaments. In some embodiments, TNNC1 may be of human (e.g., NCBI Gene ID 7134), non-human primate (e.g., NCBI Gene ID 697047 or NCBI Gene ID 746369), or rodent (e.g., NCBI Gene ID 21924) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_003280.3).[000117] TNNI3: As used herein “TNNI3” (also known as troponin 13, cardiac type, CMH7, RCM1, cTnl, CMD2A, TNNC1, CMD1FF, Troponin I Type 3) encodes a tissue specific subtype of troponin I. TNNI3 is the inhibitory subunit of troponin, which blocks actinmyosin interactions mediating striated muscle relaxation. The TNNI3 gene encodes three genes: Tnl-skeletal-fast-twitch, Tnl-skeletal-slow-twitch, and Tnl-cardiac (cTNI). In some embodiments, TNNI3 may be of human (e.g., NCBI Gene ID 7137), non-human primate (e.g., NCBI Gene ID 698470 or NCBI Gene ID 100533985), or rodent (e.g., NCBI Gene ID 21954) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_000363.5).[000118] TYRP1: As used herein “TYRP1” (also known as tyrosinase related protein 1, TRP, CAS2, CATB, GP75, OCA3, TRP1, TYRP, or b-PROTEIN) encodes a melanosomal enzyme that belongs to the tyrosinase family. In some embodiments, TYRP1 plays an important role in the melanin synthesis. In some embodiments, TYRP1 is involved in the maintenance of melanosome structure. In some embodiments, TYRP1 may be of human (e.g., NCBI Gene ID 7306), non-human primate (e.g., NCBI Gene ID 714646 or NCBI Gene ID 464994), or rodent (e.g., NCBI Gene ID 22178) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM-000550.3).[000119] TRIM43: As used herein “TRIM43” (also known as tripartite motif containing 43, TRIM43A, IFP1, RNF21, or Tripartite Motif-Containing Protein 43) encodes a member of the tripartite motif (TRIM) family of proteins. In some embodiments, interferon upregulatesthe expression of TRIM43. In some embodiments, TRIM43 enables ubiquitin protein ligase activity. In some embodiments, TRIM43 is involved in the innate immune response, protein ubiquitination, and regulation of gene expression. In some embodiments, TRIM43 may be of human (e.g., NCBI Gene ID 129868), non-human primate (e.g., NCBI Gene ID 693908 or NCBI Gene ID 107973553), or rodent (e.g., NCBI Gene ID 666731) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_138800.3).[000120] LEUTX: As used herein “LEUTX” (also known as leucine twenty homeobox, Paired-Like Homeodomain Transcription Factor LEUTX, Paired-Like Homeobox Transcription Factor LEUTX, or PRD-LIKE Homeobox Transcription Factor LEUTX) encodes a paired-like homeobox transcription factor. In some embodiments, LEUTX enables DNA-binding transcription factor activity, RNA polymerase Il-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. In some embodiments, LEUTX, is involved in the regulation of RNA polymerase II transcription. In some embodiments, LEUTX is involved in embryogenesis. In some embodiments, LEUTX may be of human (e.g., NCBI Gene ID 342900), non-human primate (e.g., NCBI Gene ID 699783 or NCBI Gene ID 456028), or rodent (e.g., NCBI Gene ID 102642006) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001143832.2 and NM_001382345.1).[000121] MBD3L2: As used herein “MBD3L2” (also known as methyl-CpG binding domain protein 3 like 2, MBDL32, MBD3-Like Protein 2, or CTB-25J19.1) encodes a protein related to methyl-CpG-binding proteins but lacks the methyl-CpG binding domain. In some embodiments, MBD3L2 may be of human (e.g., NCBI Gene ID 125997), non-human primate (e.g., NCBI Gene ID 468692 or NCBI Gene ID 468692), or rodent (e.g., NCBI Gene ID 234988) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_144614.4).[000122] KHDC1L: As disclosed herein “KHDC1L” (also known as KH domain containing 1 like, RP11-257K9.7, Putative KHDCl-Like Protein, or H Homology Domain Containing 1-Like) encodes a member of the K-homology domain-containing 1 (KHDC1) family of proteins. In some embodiments, KHDC1L enables RNA binding activity and identical protein binding activity. In some embodiments, KHDC1L is involved in the activation of cysteine-type endopeptidase activity involved in apoptosis. In some embodiments, KHDC1L may be of human (e.g., NCBI Gene ID 100129128), non-human primate (e.g., NCBI Gene ID715519 or NCBI Gene ID 107975195), or rodent (e.g., NCBI Gene ID 368204) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_001126063.3). In some embodiments, an FSHD therapeutic (e.g., complex comprising an anti-TfRl Fab conjugated to a DUX4-targeting siRNA) reduces the protein level and mRNA level of KHDC1L.[000123] CCNA1: As disclosed herein “CCNA1” (also known as cyclin Al or CT146) encodes a member of the highly conserved cyclin family of proteins. In some embodiments, CCNA1 functions as a regulator of CDK kinases. In some embodiments, CCNA1 plays a role in controlling the germline meiotic cell cycle. In some embodiments, CCNA1 binds to CDK2 kinases. In some embodiments, CCNA1 binds to CDC2 kinases. In some embodiments, CCNA1 binds to Rb family proteins. In some embodiments, CCNA1 binds to transcription factor E2F1. In some embodiments, CCNA1 binds to the Kip / Cip family of CDK-inhibitor proteins. In some embodiments, CCNA1 may be of human (e.g., NCBI Gene ID 8900), nonhuman primate (e.g., NCBI Gene ID 699783 or NCBI Gene ID 467260), or rodent (e.g., NCBI Gene ID 102642006) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001111045.4, NM_001111046.2, NM_001111047.2, and NM-001413923.1).[000124] SLC34A2: As disclosed herein “SLC34A2” (also known as solute carrier family 34 member 2, PULAM, NPTIIb, NaPi2b, NAPI-3B, NAPI-IIb, or Sodium-Dependent Phosphate Transport Protein 2B) encodes a pH-sensitive sodium-dependent phosphate transporter. In some embodiments, SLC34A2 may be of human (e.g., NCBI Gene ID 10568), non-human primate (e.g., NCBI Gene ID 694217 or NCBI Gene ID 471424), or rodent (e.g., NCBI Gene ID 20531) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001177998.2, NM_001177999.2, and NM_006424.3).[000125] ZSCAN4: As disclosed herein “ZSCAN4” (also known as zinc finger and SCAN domain containing 4, ZNF494, Zinc Finger Protein 494, or FLJ35105) encodes a protein involved in telomere maintenance. In some embodiments, ZSCAN4 is an embryonic stem cell specific transcription factor required to regulate embryonic stem cell pluripotency. In some embodiments, ZSCAN4 binds telomeres, playing a key role in genomic stability in embryonic stem cells by regulating telomere elongation. In some embodiments, ZSCAN4 acts as an activator of spontaneous telomere sister chromatid exchange. In some embodiments, ZSCAN4 may be of human (e.g., NCBI Gene ID 201516), non-human primate (e.g., NCBIGene ID 711054 or NCBI Gene ID 100612816), or rodent (e.g., NCBI Gene ID 545912) origin. In addition, multiple human transcript variants have been characterized that encode different isoforms (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_001384833.1 and NM_152677.4).[000126] PRAMEF6: As disclosed herein “PRAMEF6” (also known as PRAME family member 6) enables ubiquitin ligase-substrate adaptor activity. In some embodiments, PRAMEF6 is involved in protease-mediated ubiquitin-dependent protein catabolic process. In some embodiments, PRAMEF6 is a part of the Cul2-RING ubiquitin ligase complex. In some embodiments, PRAMEF6 may be of human (e.g., NCBI Gene ID 440561), non-human primate (e.g., NCBI Gene ID 722781), or rodent (e.g., NCBI Gene ID 195555) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number: NM_001010889.2).[000127] H3Y1: As disclosed herein “H3Y1” (also known as H3.Y histone 1, H3.Y,Histone H3.Y1, Histone H3.Y, H3 Histone, Family 3B (H3.3B) Pseudogene, Histone Cluster 2, H3c Pseudogene, or H3.Y.1) enables nucleosomal DNA binding activity. In some embodiments, H3Y1 may be of human (e.g., NCBI Gene ID 391769) or non-human primate (e.g., NCBI Gene ID 718280) origin. In addition, human transcript variants have been characterized (e.g., as annotated under GenBank RefSeq Accession Number:NM-001355258.2).[000128] IL6: As disclosed herein “IE6” (also known as Interleukin 6, BSF2, HGF, HSF, IFNB2, IE-6, BSF-2, CDF, or IFN-beta-2) is a gene that encodes Interleukin 6, a pro- inflammatory cytokine and a critical mediator of the acute-phase response. In some embodiments, IE6 may be of human or non-human primate origin with transcript variants identified and characterized. Elevated IE6 expression has been associated with muscle inflammation, fibrosis, and impaired regeneration in muscular dystrophies, including FSHD.[000129] IFNG: As disclosed herein “IFNG” (also known as Interferon gamma, interferon-y, IFG, IFI, or IMD69) is a gene that encodes interferon gamma, a key cytokine involved in the activation of macrophages and promotion of inflammatory responses. In some embodiments, IFNG may be of human or non-human primate origin with transcript variants identified and characterized. Increased IFNG expression has been implicated in the pathogenesis of autoimmune and inflammatory muscle diseases.[000130] LGALS3: As disclosed herein “EGAES3” (also known as Galectin-3, CBP35, GAE3, GAEBP, GAEIG, E31, EGAES2, MAC2, lectin, or galactoside binding soluble 3) is a gene that encodes galectin-3, a P-galactoside-binding lectin involved in various biologicalprocesses including cell adhesion, fibrosis, and immune response regulation. In some embodiments, EGAES3 may be of human or non-human primate origin with transcript variants identified and characterized. Galectin-3 has been linked to chronic inflammation and tissue remodeling in muscular diseases.II. Biomarkers and methods of useA. Plasma Biomarkers[000131] The present disclosure, in some aspects, provide newly identified biomarkers (e.g., plasma biomarkers or circulating biomarkers) that may be used in methods for diagnosis FSHD, and / or methods for assessing the treatment efficacy of a therapeutic agent for FSHD. The biomarkers (e.g., plasma biomarkers or circulating biomarkers) disclosed herein are highly sensitive, may be used in non-invasive methods, enables early detection and / or continuous monitoring of FSHD. In some embodiments, a biomarker described herein is selected from ASF, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1E, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1. In some embodiments, a biomarker described herein is selected from KHDC1E, FAM110A, and TNNT2. In some embodiments, a biomarker described herein is selected from KHDC1E and TNNT2.Table 2. Examples of plasma biomarkers for FSHD[000132] Provided herein, in some aspects, are methods of diagnosing FSHD (e.g., early diagnosis before progression in disease severity). In some embodiments, such a method comprises: (i) measuring the expression level of one or more plasma biomarkers in a subject;and (ii) determining that the subject has FSHD based on the expression levels of the one or more plasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the expression level of one or more plasma biomarkers is the protein level of the one or more plasma biomarker. In some embodiments, the expression level of one or more plasma biomarkers is the RNA level of the one or more plasma biomarker. In some embodiments, the one or more plasma biomarkers are selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof. In some embodiments, the one or more plasma biomarkers are selected from KHDC1L, FAM110 A, TNNT2, and combinations thereof. In some embodiments, the one or more plasma biomarkers are selected from KHDC1L and TNNT2. In some embodiments, the one or more plasma biomarker is KHDC1L. In some embodiments, the one or more plasma biomarker is TNNT2. In some embodiments, a subject is determined to have FSHD if the one or more biomarker is upregulated, e.g., when KHDC1L and / or TNNT2 is upregulated, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, a subject is determined to have FSHD if the one or more biomarker is downregulated, e.g., when FAM110A is downregulated, relative to those of a healthy subject or a subject that does not have FSHD. [000133] In some embodiments, a method described herein further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD. Any therapeutic agents known in the art or described herein (e.g., a complex comprising an anti- TfRl antibody covalently linked to an oligonucleotide targeting DUX4).[000134] Further provided herein are methods of assessing the therapeutic efficacy of a therapeutic agent for treating FSHD. In some embodiments, such a method comprises measuring the expression levels of the one or more plasma biomarkers in the subject. In some embodiments, the expression level of one or more plasma biomarkers is the protein level of the one or more plasma biomarker. In some embodiments, the expression level of one or more plasma biomarkers is the RNA level of the one or more plasma biomarker. In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more plasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, are selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof. In some embodiments, the one or more plasma biomarkers are selected from KHDC1L, FAM110A,TNNT2, and combinations thereof. In some embodiments, the one or more plasma biomarkers are selected from KHDC1L and / or TNNT2. In some embodiments, the plasma biomarker is KHDC1L. In some embodiments, the one or more plasma biomarker is TNNT2.[000135] In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the one or more plasma biomarkers are restored those of a healthy subject or a subject that does not have FSHD. For example, if a plasma biomarker is upregulated in a subject having FSHD (e.g., KHDC1L and / or TNNT2), relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the plasma biomarker decreases or is restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. Conversely, if a plasma biomarker is downregulated (e.g. FAM110A), in a subject having FSHD, relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the plasma biomarker increases or is restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. In some embodiments, the expression level of one or more plasma biomarkers is the protein level of the one or more plasma biomarker. In some embodiments, the expression level of one or more plasma biomarkers is the RNA level of the one or more plasma biomarker.[000136] In some embodiments, in any one of the methods described herein, the subject is monitored for the expression level of the one or more plasma biomarkers. In some embodiments, in any one of the methods described herein, the subject is continuously monitored for the expression level of the one or more plasma biomarkers. In some embodiments, the expression level of one or more plasma biomarkers is the protein level of the one or more plasma biomarker. In some embodiments, the expression level of one or more plasma biomarkers is the RNA level of the one or more plasma biomarker.B. FSHD transcriptome biomarkers[000137] The present disclosure, in some aspects, provide newly identified biomarkers (e.g., FSHD transcriptome biomarker) that may be used in methods for diagnosis FSHD, and / or methods for assessing the treatment efficacy of a therapeutic agent for FSHD. The biomarkers (e.g., FSHD transcriptome biomarker) disclosed herein are highly sensitive, may be used in invasive or non-invasive methods, enables early detection and / or continuous monitoring of FSHD. In some embodiments, a biomarker described herein is selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 or combinations thereof. In some embodiments, a biomarker described herein is selected fromTRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, or combinations thereof.Table 3. Examples of FSHD transcriptome biomarkers[000138] Provided herein, in some aspects, are methods of diagnosing FSHD (e.g., early diagnosis before progression in disease severity). In some embodiments, such a method comprises: (i) measuring the expression level of one or more FSHD transcriptome biomarker in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the one or more FSHD transcriptome biomarker, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers. In some embodiments, the one or more FSHD transcriptome biomarker are selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof. In some embodiments, the one or more FSHD transcriptome biomarker are selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof. In some embodiments, a subject is determined to have FSHD if the one or more FSHD transcriptome biomarker is upregulated, e.g., when TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, and / or H3Y1 is upregulated, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, a subject is determined to have FSHD if the one or more FSHD transcriptome biomarker is upregulated, e.g., when TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, and / or TNNT2 is upregulated, relative to those of a healthy subject or a subject that does not have FSHD.[000139] Provided herein, in some aspects, are methods of diagnosing FSHD (e.g., early diagnosis before progression in disease severity). In some embodiments, such a method comprises: (i) measuring the expression level of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, such a method comprises: (i) measuring the expression level of FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers. In some embodiments, the FSHD transcriptome biomarker are TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers. In some embodiments, the FSHD transcriptome biomarker are TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2. In some embodiments, a subject is determined to have FSHD if the FSHD transcriptome biomarkers are upregulated, e.g., when TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are upregulated, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, a subject is determined to have FSHD if the FSHD transcriptome biomarkers are upregulated, e.g., when TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are upregulated, relative to those of a healthy subject or a subject that does not have FSHD.[000140] In some embodiments, a method described herein further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD. Any therapeutic agents known in the art or described herein (e.g., a complex comprising an anti- TfRl antibody covalently linked to an oligonucleotide targeting DUX4).[000141] Further provided herein are methods of assessing the therapeutic efficacy of a therapeutic agent for treating FSHD. In some embodiments, such a method comprises measuring the expression levels of the one or more FSHD transcriptome biomarker in the subject. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof) is measured in a subject’s muscle biopsy sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the FSHD transcriptome biomarkers described herein (e.g., biomarkers selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof) is measured in a subject’s muscle biopsy sample. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000142] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarker, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In someembodiments, the one or more FSHD transcriptome biomarkers are selected from TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and combinations thereof. In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarker, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, the one or more FSHD transcriptome biomarkers are selected from TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2, and combinations thereof. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000143] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarker in a subject , relative to those of the subject before, during, and / or after treatment. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000144] In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the one or more FSHD transcriptome biomarkers are restored those of a healthy subject or a subject that does not have FSHD. For example, if a FSHD transcriptome biomarker is upregulated in a subject having FSHD (e.g., TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, and / or H3Y1), relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the FSHD transcriptome biomarker decreases or is restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the one or more FSHD transcriptome biomarkers are restored those of a healthy subject or a subject that does not have FSHD. For example, if a FSHD transcriptome biomarker is upregulated in a subject having FSHD (e.g., TRIM43, EEUTX, MBD3E2, KHDC1E, CCNA1, SEC34A2, ZSCAN4, PRAMEF6, H3Y1, and / or TNNT2), relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the FSHD transcriptome biomarker decreases or is restoredto the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000145] Further provided herein are methods of assessing the therapeutic efficacy of a therapeutic agent for treating FSHD. In some embodiments, such a method comprises measuring the expression levels of the FSHD transcriptome biomarker including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 in the subject. In some embodiments, such a method comprises measuring the expression levels of the FSHD transcriptome biomarker including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 in the subject. In some embodiments, the expression level (e.g., protein or mRNA level) of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are measured in a subject’s muscle biopsy sample. In some embodiments, the expression level (e.g., protein or mRNA level) the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are measured in a subject’s muscle biopsy sample. In some embodiments, determining the treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarker in a subject, relative to those of the subject before, during, and / or after treatment. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, theexpression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000146] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, the FSHD transcriptome biomarkers are TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1. In some embodiments, the FSHD transcriptome biomarkers are TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.[000147] In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y1 are restored those of a healthy subject or a subject that does not have FSHD. For example, if the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, and H3Y 1 are upregulated in a subject having FSHD, relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the FSHD transcriptome biomarkers decrease or are restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, and TNNT2 are restored those of a healthy subject or a subject that does not have FSHD. For example, if the FSHD transcriptome biomarkers including TRIM43, LEUTX, MBD3L2, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1, TNNT2 areupregulated in a subject having FSHD, relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the FSHD transcriptome biomarkers decrease or are restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment.In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.In some embodiments, in any one of the methods described herein, the subject is monitored for the expression level of the one or more FSHD transcriptome biomarker. In some embodiments, in any one of the methods described herein, the subject is continuously monitored for the expression level of the one or more FSHD transcriptome biomarker. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the protein level of the one or more FSHD transcriptome biomarkers. In some embodiments, the expression level of one or more FSHD transcriptome biomarkers is the RNA level of the one or more FSHD transcriptome biomarkers.C. Inflammatory biomarkers[000148] The present disclosure, in some aspects, provide newly identified biomarkers (e.g., inflammatory biomarker) that may be used in methods for diagnosis FSHD, and / or methods for assessing the treatment efficacy of a therapeutic agent for FSHD. The biomarkers (e.g., inflammatory biomarker) disclosed herein are highly sensitive, may be used in invasive or non-invasive methods, enables early detection and / or continuous monitoring of FSHD. In some embodiments, a biomarker described herein is selected from IL6, IFNG, and LGALS3 or combinations thereof.Table 6. Examples of inflammatory biomarkers[000149] Provided herein, in some aspects, are methods of diagnosing FSHD (e.g., early diagnosis before progression in disease severity). In some embodiments, such a method comprises: (i) measuring the expression level of one or more inflammatory biomarkers in a subject; and (ii) determining that the subject has FSHD based on the expression levels of theone or more inflammatory biomarker, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers. In some embodiments, the one or more inflammatory biomarker are selected from IL6, IFNG, and LGALS3, and combinations thereof. In some embodiments, a subject is determined to have FSHD if the one or more inflammatory biomarker is upregulated, e.g., when IL6, IFNG, and LGALS3 is upregulated, relative to those of a healthy subject or a subject that does not have FSHD.[000150] Provided herein, in some aspects, are methods of diagnosing FSHD (e.g., early diagnosis before progression in disease severity). In some embodiments, such a method comprises: (i) measuring the expression level of inflammatory biomarkers including IL6, IFNG, and LGALS3 in a subject; and (ii) determining that the subject has FSHD based on the expression levels of the inflammatory biomarkers including IL6, IFNG, and LGALS3, relative to those of a healthy subject or a subject that does not have FSHD. In some embodiments, the expression level of one or more inflammatory bio markers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers. In some embodiments, the inflammatory biomarker are IL6, IFNG, and LGALS3. In some embodiments, a subject is determined to have FSHD if the inflammatory biomarkers are upregulated, e.g., when IL6, IFNG, and LGALS3 are upregulated, relative to those of a healthy subject or a subject that does not have FSHD.[000151] In some embodiments, a method described herein further comprises: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD. Any therapeutic agents known in the art or described herein (e.g., a complex comprising an anti- TfRl antibody covalently linked to an oligonucleotide targeting DUX4).[000152] Further provided herein are methods of assessing the therapeutic efficacy of a therapeutic agent for treating FSHD. In some embodiments, such a method comprises measuring the expression levels of the one or more inflammatory biomarker in the subject. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) is measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, andLGALS3, and combinations thereof) is measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) of any one or more of the inflammatory biomarkers described herein (e.g., biomarkers selected from IL6, IFNG, and LGALS3, and combinations thereof) is measured in a subject’s muscle biopsy sample. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.[000153] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more inflammatory biomarker, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, the one or more inflammatory biomarkers are selected from IL6, IFNG, and LGALS3, and combinations thereof. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.[000154] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more inflammatory biomarker in a subject , relative to those of the subject before, during, and / or after treatment. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.[000155] In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the one or more inflammatory biomarkers are restored those of a healthy subject or a subject that does not have FSHD. For example, if an inflammatory biomarker is upregulated in a subject having FSHD (e.g., IL6, IFNG, and LGALS3), relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the inflammatory biomarker decreases or is restored to the level in a healthy subject or a subject that does not have FSHD after treatment, relative to before treatment. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In someembodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.[000156] Further provided herein are methods of assessing the therapeutic efficacy of a therapeutic agent for treating FSHD. In some embodiments, such a method comprises measuring the expression levels of the inflammatory biomarker including IL6, IFNG, and LGALS3 in the subject. In some embodiments, the expression level (e.g., protein or mRNA level) of the inflammatory biomarkers including IL6, IFNG, and LGALS3 are measured in a subject’s tissue sample. In some embodiments, the expression level (e.g., protein or mRNA level) of the inflammatory biomarkers including IL6, IFNG, and LGALS3 are measured in a subject’s muscle tissue. In some embodiments, the expression level (e.g., protein or mRNA level) the inflammatory biomarkers including IL6, IFNG, and LGALS3 are measured in a subject’s muscle biopsy sample. In some embodiments, determining the treatment efficacy of the therapeutic agent based on the expression levels of the one or more inflammatory biomarker in a subject, relative to those of the subject before, during, and / or after treatment. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory bio markers is the RNA level of the one or more inflammatory biomarkers.[000157] In some embodiments, the method further comprises determining treatment efficacy of the therapeutic agent based on the expression levels of the inflammatory biomarkers including IL6, IFNG, and LGALS3, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent. In some embodiments, the inflammatory biomarkers are IL6, IFNG, and LGALS3. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.[000158] In some embodiments, a therapeutic agent is therapeutically effective if the expression levels of the inflammatory biomarkers including IL6, IFNG, and LGALS3 are restored those of a healthy subject or a subject that does not have FSHD. For example, if the inflammatory biomarkers including IL6, IFNG, and LGALS3 are upregulated in a subject having FSHD, relative to that of a healthy subject or a subject that does not have FSHD, a therapeutic agent is therapeutically effective if the expression level of the inflammatory biomarkers decrease or are restored to the level in a healthy subject or a subject that does nothave FSHD after treatment, relative to before treatment. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers. [000159] In some embodiments, in any one of the methods described herein, the subject is monitored for the expression level of the one or more inflammatory biomarker. In some embodiments, in any one of the methods described herein, the subject is continuously monitored for the expression level of the one or more inflammatory biomarker. In some embodiments, the expression level of one or more inflammatory biomarkers is the protein level of the one or more inflammatory biomarkers. In some embodiments, the expression level of one or more inflammatory biomarkers is the RNA level of the one or more inflammatory biomarkers.III. Agents and Methods for Treating FSHD[000160] Provided herein are agents suitable for use in methods of treating FSHD. In some embodiments, agents suitable for use in methods of treating FSHD comprise complexes that comprise a targeting agent, e.g., an antibody, covalently linked to a molecular pay load. In some embodiments, a complex comprises a muscle-targeting antibody covalently linked to an oligonucleotide. A complex may comprise an antibody that specifically binds a single antigenic site or that binds to at least two antigenic sites that may exist on the same or different antigens.[000161] A complex may be used to modulate the activity or function of at least one gene, protein, and / or (e.g., and) nucleic acid. In some embodiments, the molecular pay load present with a complex is responsible for the modulation of a gene, protein, and / or (e.g., and) nucleic acids. A molecular pay load may be a small molecule, protein, nucleic acid, oligonucleotide, or any molecular entity capable of modulating the activity or function of a gene, protein, and / or (e.g., and) nucleic acid in a cell. In some embodiments, a molecular pay load is an oligonucleotide that targets a DUX4 in muscle cells.[000162] In some embodiments, a complex comprises a muscle-targeting agent, e.g., an anti-transferrin receptor antibody, covalently linked to a molecular pay load, e.g., an antisense oligonucleotide (e.g., single stranded ASO or RNAi agent) that targets a DUX4.A. Muscle-Targeting Agents[000163] Some aspects of the disclosure provide muscle-targeting agents, e.g., for delivering a molecular payload to a muscle cell. In some embodiments, such muscle-targetingagents are capable of binding to a muscle cell, e.g., via specifically binding to an antigen on the muscle cell, and delivering an associated molecular payload to the muscle cell. In some embodiments, the molecular pay load is bound (e.g., covalently bound) to the muscle targeting agent and is internalized into the muscle cell upon binding of the muscle targeting agent to an antigen on the muscle cell, e.g., via endocytosis. It should be appreciated that various types of muscle-targeting agents may be used in accordance with the disclosure. For example, the muscle-targeting agent may comprise, or consist of, a nucleic acid (e.g., DNA or RNA), a peptide (e.g., an antibody), a lipid (e.g., a microvesicle), or a sugar moiety (e.g., a polysaccharide). Exemplary muscle-targeting agents are described in further detail herein; however, it should be appreciated that the exemplary muscle-targeting agents provided herein are not meant to be limiting.[000164] Some aspects of the disclosure provide muscle-targeting agents that specifically bind to an antigen on muscle, such as skeletal muscle, smooth muscle, or cardiac muscle. In some embodiments, any of the muscle-targeting agents provided herein bind to (e.g., specifically bind to) an antigen on a skeletal muscle cell, a smooth muscle cell, and / or (e.g., and) a cardiac muscle cell.[000165] By interacting with muscle-specific cell surface recognition elements (e.g., cell membrane proteins), both tissue localization and selective uptake into muscle cells can be achieved. In some embodiments, molecules that are substrates for muscle uptake transporters are useful for delivering a molecular payload into muscle tissue. Binding to muscle surface recognition elements followed by endocytosis can allow even large molecules such as antibodies to enter muscle cells. As another example molecular payloads conjugated to transferrin or anti-transferrin receptor antibodies can be taken up by muscle cells via binding to transferrin receptor, which may then be endocytosed, e.g., via clathrin-mediated endocytosis. [000166] The use of muscle-targeting agents may be useful for concentrating a molecular payload (e.g., oligonucleotide) in muscle while reducing toxicity associated with effects in other tissues. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells as compared to another cell type within a subject. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells (e.g., skeletal, smooth, or cardiac muscle cells) in an amount that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times greater than an amount in nonmuscle cells (e.g., liver, neuronal, blood, or fat cells). In some embodiments, a toxicity of the molecular payload in a subject is reduced by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%,25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% when it is delivered to the subject when bound to the muscle-targeting agent.[000167] In some embodiments, to achieve muscle selectivity, a muscle recognition element (e.g., a muscle cell antigen) may be required. As one example, a muscle-targeting agent may be a small molecule that is a substrate for a muscle- specific uptake transporter. As another example, a muscle-targeting agent may be an antibody that enters a muscle cell via transporter-mediated endocytosis. As another example, a muscle targeting agent may be a ligand that binds to cell surface receptor on a muscle cell. It should be appreciated that while transporter-based approaches provide a direct path for cellular entry, receptor-based targeting may involve stimulated endocytosis to reach the desired site of action. i. Muscle- Targeting Antibodies[000168] In some embodiments, the muscle-targeting agent is an antibody. Generally, the high specificity of antibodies for their target antigen provides the potential for selectively targeting muscle cells (e.g., skeletal, smooth, and / or (e.g., and) cardiac muscle cells). This specificity may also limit off-target toxicity. Examples of antibodies that are capable of targeting a surface antigen of muscle cells have been reported and are within the scope of the disclosure. For example, antibodies that target the surface of muscle cells are described in Arahata K., et al. “Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide” Nature 1988; 333: 861-3; Song K.S., et al. “Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins” J Biol Chem 1996; 271: 15160-5; and Weisbart R.H. et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin lib” Mol Immunol. 2003 Mar, 39(13) :78309; the entire contents of each of which are incorporated herein by reference. a. Anti- Transferrin Receptor Antibodies[000169] Some aspects of the disclosure are based on the recognition that agents binding to transferrin receptor, e.g., anti-transferrin-receptor antibodies, are capable of targeting muscle cell. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Accordingly, aspects of the disclosure provide binding proteins (e.g., antibodies) that bind to transferrin receptor. In someembodiments, binding proteins that bind to transferrin receptor are internalized, along with any bound molecular payload, into a muscle cell. As used herein, an antibody that binds to a transferrin receptor may be referred to interchangeably as an, transferrin receptor antibody, an anti-transferrin receptor antibody, or an anti-TfRl 1 antibody. Antibodies that bind, e.g., specifically bind, to a transferrin receptor may be internalized into the cell, e.g., through receptor-mediated endocytosis, upon binding to a transferrin receptor.[000170] It should be appreciated that anti-transferrin receptor antibodies may be produced, synthesized, and / or (e.g., and) derivatized using several known methodologies, e.g., library design using phage display. Exemplary methodologies have been characterized in the art and are incorporated by reference (Diez, P. et al. “High-throughput phage-display screening in array format”, Enzyme and microbial technology, 2015, 79, 34-41.; Hammers et al., “Antibody Phage Display: Technique and Applications” J Invest Dermatol. 2014, 134:2.; Engleman, Edgar (Ed.) “Human Hybridomas and Monoclonal Antibodies.” 1985, Springer.). In other embodiments, an anti-transferrin antibody has been previously characterized or disclosed. Antibodies that specifically bind to transferrin receptor are known in the art (see, e.g., US Patent. No. 4,364,934, filed 12 / 4 / 1979, “Monoclonal antibody to a human early thymocyte antigen and methods for preparing same”; US Patent No. 8,409,573, filed 6 / 14 / 2006, “Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells”; US Patent No. 9,708,406, filed 5 / 20 / 2014, “Anti-transferrin receptor antibodies and methods of use”; US 9,611,323, filed 12 / 19 / 2014, “Low affinity blood brain barrier receptor antibodies and uses therefor”; WO 2015 / 098989, filed 12 / 24 / 2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”; Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.; Lee et al. “Targeting Rat AntiMouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052.).[000171] Provided herein, in some aspects, are new anti-TfRl 1 antibodies for use as the muscle targeting agents (e.g., in muscle targeting complexes). In some embodiments, the anti- TfRl 1 antibody described herein binds to transferrin receptor with high specificity and affinity. In some embodiments, the anti-TfRl 1 antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, anti-TfRl 1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, etc. In some embodiments, anti-TfRl 1 antibodies provided herein bind to human transferrin receptor. In someembodiments, the anti-TfRl 1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 23 29, or 30. [000172] An example human TfRl amino acid sequence, corresponding to NCBI sequence NP_003225.2 (transferrin receptor protein 1 isoform 1, homo sapiens) is as follows: [000173] MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEEN ADNNTKANVTKPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTES PVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDEN LALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVA YSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGV LIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRA AAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVE PDHYVVVGAQRDAWGPGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWS AGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQN VKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTT MDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQ YRADIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEY HFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWT IQGAANALSGDVWDIDNEF (SEQ ID NO: 23).[000174] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001244232.1(transferrin receptor protein 1, Macaca mulatta) is as follows:[000175] MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLGVDEEEN TDNNTKPNGTKPKRCGGNICYGTIAVIIFFLIGFMIGYLGYCKGVEPKTECERLAGTESP AREEPEEDFPAAPRLYWDDLKRKLSEKLDTTDFTSTIKLLNENLYVPREAGSQKDENL ALYIENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVAY SKAATVTGKLVHANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLI YMDQTKFPIVKADLSFFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAA AEKLFGNMEGDCPSDWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEP DHYVVVGAQRDAWGPGAAKSSVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSA GDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDV KHPVTGRSLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTM DTYKELVERIPELNKVARAAAEVAGQFVIKLTHDTELNLDYERYNSQLLLFLRDLNQY RADVKEMGLSLQWLYSARGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRHVFWGSGSHTLSALLESLKLRRQNNSAFNETLFRNQLALATWTI QGAANALSGDVWDIDNEF (SEQ ID NO: 28)[000176] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence XP_005545315.1 (transferrin receptor protein 1, Macaca fascicularis) is as follows:[000177] MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLGVDEEENTDNNTKANGTKPKRCGGNICYGTIAVIIFFLIGFMIGYLGYCKGVEPKTECERLAGTES PAREEPEEDFPAAPRLYWDDLKRKLSEKLDTTDFTSTIKLLNENLYVPREAGSQKDEN LALYIENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVA YSKAATVTGKLVHANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGV LIYMDQTKFPIVKADLSFFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISR AAAEKLFGNMEGDCPSDWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGF VEPDHYVVVGAQRDAWGPGAAKSSVGTALLLKLAQMFSDMVLKDGFQPSRSIIFAS WSAGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGT TMDTYKELVERIPELNKVARAAAEVAGQFVIKLTHDTELNLDYERYNSQLLLFLRDLN QYRADVKEMGLSLQWLYSARGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRV EYYFLSPYVSPKESPFRHVFWGSGSHTLSALLESLKLRRQNNSAFNETLFRNQLALAT WTIQGAANALSGDVWDIDNEF (SEQ ID NO: 29).[000178] An example mouse transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001344227.1 (transferrin receptor protein 1, Mus musculus) is as follows:[000179] MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENADNNMKASVRKPKRFNGRLCFAAIALVIFFLIGFMSGYLGYCKRVEQKEECVKLAETE ETDKSETMETEDVPTSSRLYWADLKTLLSEKLNSIEFADTIKQLSQNTYTPREAGSQKD ESLAYYIENQFHEFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQSNGNLDPVESPEGYV AFSKPTEVSGKLVHANFGTKKDFEELSYSVNGSLVIVRAGEITFAEKVANAQSFNAIGV LIYMDKNKFPVVEADLALFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISR AAAEKLFGKMEGSCPARWNIDSSCKLELSQNQNVKLIVKNVLKERRILNIFGVIKGYE EPDRYVVVGAQRDALGAGVAAKSSVGTGLLLKLAQVFSDMISKDGFRPSRSIIFASWT AGDFGAVGATEWLEGYLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYTLMGKIMQ DVKHPVDGKSLYRDSNWISKVEKLSFDNAAYPFLAYSGIPAVSFCFCEDADYPYLGTR LDTYEALTQKVPQLNQMVRTAAEVAGQLIIKLTHDVELNLDYEMYNSKLLSFMKDLN QFKTDIRDMGLSLQWLYSARGDYFRATSRLTTDFHNAEKTNRFVMREINDRIMKVEYHFESPYVSPRESPFRHIFWGSGSHTESAEVENEKERQKNITAFNETEFRNQEAEATWTIQGVANAESGDIWNIDNEF (SEQ ID NO: 30)[000180] Appropriate methodologies may be used to obtain and / or (e.g., and) produce antibodies, antibody fragments, or antigen-binding agents, e.g., through the use of recombinant DNA protocols. In some embodiments, an antibody may also be produced through the generation of hybridomas (see, e.g., Kohler, G and Milstein, C. “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature, 1975, 256: 495-497). The antigen- of-interest may be used as the immunogen in any form or entity, e.g., recombinant or a naturally occurring form or entity. Hybridomas are screened using standard methods, e.g., ELISA screening, to find at least one hybridoma that produces an antibody that targets a particular antigen. Antibodies may also be produced through screening of protein expression libraries that express antibodies, e.g., phage display libraries. Phage display library design may also be used, in some embodiments, (see, e.g. U.S. Patent No 5,223,409, filed 3 / 1 / 1991, “Directed evolution of novel binding proteins”; WO 1992 / 18619, filed 4 / 10 / 1992, “Heterodimeric receptor libraries using phagemids”; WO 1991 / 17271, filed 5 / 1 / 1991, “Recombinant library screening methods”; WO 1992 / 20791, filed 5 / 15 / 1992, “Methods for producing members of specific binding pairs”; WO 1992 / 15679, filed 2 / 28 / 1992, and “Improved epitope displaying phage”). In some embodiments, an antigen-of-interest may be used to immunize a non-human animal, e.g., a rodent or a goat. In some embodiments, an antibody is then obtained from the non-human animal, and may be optionally modified using a number of methodologies, e.g., using recombinant DNA techniques. Additional examples of antibody production and methodologies are known in the art (see, e.g., Harlow et al.“Antibodies: A Laboratory Manual”, Cold Spring Harbor Laboratory, 1988.).[000181] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N- acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or aphospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1- 4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g., a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “Modified antibody, antibody-conjugate and process for the preparation thereof’.[000182] In some embodiments, the anti-TfRl l antibody of the present disclosure comprises a VL domain and / or (e.g., and) VH domain of any one of the anti-TfRl 1 antibodies selected from Table 4, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.[000183] In some embodiments, agents binding to transferrin receptor, e.g., anti-TfRl l antibodies, are capable of targeting muscle cell and / or (e.g., and) mediate the transportation of an agent across the blood brain barrier. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Antibodies that bind, e.g., specifically bind, to a transferrin receptor may be internalized into the cell, e.g., through receptor-mediated endocytosis, upon binding to a transferrin receptor. [000184] Provided herein, in some aspects, are humanized antibodies that bind to transferrin receptor with high specificity and affinity. In some embodiments, the humanized anti-TfRl l antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, the humanized anti-TfRl 1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, etc. In some embodiments, the humanized anti- TfRl 1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the humanized anti-TfRl 1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 23, 29, or 30.In some embodiments, the humanized anti-TfRl 1 antibodies described herein binds to TfRl but does not bind to TfR2.[000185] In some embodiments, an anti-TfRl antibody specifically binds a TfRl (e.g., a human or non-human primate TfRl) with binding affinity (e.g., as indicated by Kd) of at least about 10'4M, 10'5M, 10'6M, 10'7M, 10'8M, 10'9M, IO’10M, IO’11M, 10'12M, IO’13M, or less. In some embodiments, the anti-TfRl antibodies described herein binds to TfRl with a KD of sub-nanomolar range. In some embodiments, the anti-TfRl antibodies described herein selectively binds to transferrin receptor 1 (TfRl) but do not bind to transferrin receptor 2 (TfR2). In some embodiments, the anti-TfRl antibodies described herein binds to human TfRl and cyno TfRl (e.g., with a Kd of 10'7M, 10'8M, 10'9M, IO’10M, 10'11M, IO’12M, 10’13M, or less), but does not bind to a mouse TfRl. The affinity and binding kinetics of the anti- TfRl antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, binding of any one of the anti-TfRl antibody described herein does not complete with or inhibit transferrin binding to the TfRl. In some embodiments, binding of any one of the anti-TfRl antibody described herein does not complete with or inhibit HFE-beta-2-microglobulin binding to the TfRl.[000186] Any appropriate anti-TfRl antibodies known in the art may be used as the muscle-targeting agent in the complexes for treating FSHD disclosed herein. Examples of known anti-transferrin receptor antibodies, including associated references and binding epitopes, are listed in Table 4. In some embodiments, the anti-transferrin receptor antibody comprises the complementarity determining regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of any of the anti-transferrin receptor antibodies provided herein, e.g., anti-transferrin receptor antibodies listed in Table 4. In some embodiments, the anti-transferrin receptor antibody comprises the complementarity determining regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of any of the anti-transferrin receptor antibodies provided herein, e.g., anti-transferrin receptor antibodies listed in Table 4, and are human antibodies or humanized antibodies (e.g., comprise human or humanized framework regions). All references cited in Table 4 are hereby incorporated by reference in their entirety.Table 4. List of anti-transferrin receptor antibody clones, including associated references and binding epitope information.[000187] In some embodiments, anti-TfRl antibodies of the present disclosure include one or more of the CDR-H (e.g., CDR-H1, CDR-H2, and CDR-H3) amino acid sequences from any one of the anti-TfRl antibodies selected from Table 4. In some embodiments, anti- TfRl antibodies include the CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfRl antibodies selected from Table 4. In some embodiments, anti-TfRl antibodies include the CDR-H 1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfRl antibodies selected from Table 4.[000188] In some embodiments, anti-TfRl antibodies of the disclosure include any antibody that includes a heavy chain variable domain and / or (e.g., and) a light chain variable domain of any anti-TfRl antibody, such as any one of the anti-TfRl antibodies selected from Table 4. In some embodiments, anti-TfRl antibodies of the disclosure include any antibody that includes the heavy chain variable and light chain variable pairs of any anti-TfRl antibody, such as any one of the anti-TfRl antibodies selected from Table 4.[000189] Aspects of the disclosure provide anti-TfRl antibodies having a heavy chain variable (VH) and / or (e.g., and) a light chain variable (VL) domain amino acid sequence homologous to any of those described herein. In some embodiments, the anti-TfRl antibody comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the heavy chain variable sequence and / or any light chain variable sequence of any anti-TfRl antibody, such as any one of the anti-TfRl antibodies selected from Table 4. In some embodiments, the homologous heavy chain variable and / or (e.g., and) a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) may occur within a heavy chain variable and / or (e.g., and) a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, any of the anti-TfRl antibodies provided herein comprise a heavy chain variable sequence and a light chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of any anti-TfRl antibody, such as any one of the anti- TfRl antibodies selected from Table 4.[000190] In some embodiments, the anti-TfRl antibody of the present disclosure is a full- length IgGl antibody, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfRl antibodies as described herein may comprises a heavy chain constant region (CH) or a portion thereof (e.g., CHI, CH2, CH3, or a combination thereof). The heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgGl, IgG2, or IgG4. An example of human IgGl constant region is given below:ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 31) [000191] In some embodiments, the light chain of any of the anti-TfRl antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:RTVAAPSVEIEPPSDEQLKSGTASVVCLLNNEYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC (SEQ ID NO: 32)[000192] The anti-TfRl antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Lab, Lab’, E(ab’)2, Ev), single chain antibodies, bi-specific antibodies, or nanobodies. In some embodiments, the anti-TfRl antibody described herein is a scFv. In some embodiments, the anti-TfRl antibody described herein is a scFv-Fab (e.g., scFv fused to a portion of a constant region). In some embodiments, the anti-TfRl antibody described herein is an scFv fused to a constant region (e.g., human IgGl constant region as set forth in SEQ ID NO: 31).[000193] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations(e.g., amino acid substitutions) are introduced into the Fc region of an anti-TfRl antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or (e.g., and) CH3 domain (residues 341-447 of human IgGl) and / or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or (e.g., and) antigen-dependent cellular cytotoxicity.[000194] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CHI domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CHI domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.[000195] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or (e.g., and) CH3 domain (residues 341-447 of human IgGl) and / or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631, which are incorporated herein by reference.[000196] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (e.g., decrease or increase) half-life of the anti-TfRl antibody in vivo. See, e.g., International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.[000197] In some embodiments, one, two or more amino acid mutations (z.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the halflife of the anti-TfRl antibody in vivo. In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody in vivo. In some embodiments, the antibodies can have one or more amino acid mutations (e.g., substitutions) in the second constant (CH2) domain (residues 231-340 of human IgGl) and / or (e.g., and) the third constant (CH3) domain (residues 341-447 of human IgGl), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgGl of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as “YTE mutant” has been shown to display fourfold increased half-life as compared to wildtype versions of the same antibody (see Dall’Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.[000198] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-TfRl antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the Cl component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).[000199] In some embodiments, one or more amino in the constant region of an anti- TfRl antibody described herein can be replaced with a different amino acid residue such thatthe antibody has altered Clq binding and / or (e.g., and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N- terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94 / 29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and / or (e.g., and) to increase the affinity of the antibody for an Fey receptor. This approach is described further in International Publication No. WO 00 / 42072.[000200] In some embodiments, the heavy and / or (e.g., and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.[000201] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse / human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgGl-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.[000202] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or (e.g., and) phosphoglycosylation. In some embodiments, theone or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N- acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1- 4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g., a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO20 14065661, published on May 1, 2014, entitled, ''Modif ied antibody, antibody-conjugate and process for the preparation thereof’ .[000203] In some embodiments, any one of the anti-TfRl antibodies described herein may comprise a signal peptide in the heavy and / or (e.g., and) light chain sequence (e.g., a N- terminal signal peptide). In some embodiments, the anti-TfRl antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab’) heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide). In some embodiments, the signal peptide comprises the amino acid sequence of MGWSCIILFLVATATGVHS (SEQ ID NO: 35).[000204] In some embodiments, an antibody provided herein may have one or more post- translational modifications. In some embodiments, N-terminal cyclization, also called pyroglutamate formation (pyro-Glu), may occur in the antibody at N-terminal Glutamate (Glu) and / or Glutamine (Gin) residues during production. As such, it should be appreciated that an antibody specified as having a sequence comprising an N-terminal glutamate or glutamine residue encompasses antibodies that have undergone pyroglutamate formation resulting from a post-translational modification. In some embodiments, pyroglutamate formation occurs in a heavy chain sequence. In some embodiments, pyroglutamate formation occurs in a light chain sequence. b. Other Muscle- Targeting Antibodies[000205] In some embodiments, the muscle-targeting antibody is an antibody that specifically binds hemojuvelin, caveolin-3, Duchenne muscular dystrophy peptide, myosin libor CD63. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a myogenic precursor protein. Exemplary myogenic precursor proteins include, without limitation, ABCG2, M-Cadherin / Cadherin-15, Caveolin-1, CD34, FoxKl, Integrin alpha 7, Integrin alpha 7 beta 1, MYF-5, MyoD, Myogenin, NCAM-1 / CD56, Pax3, Pax7, and Pax9. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a skeletal muscle protein. Exemplary skeletal muscle proteins include, without limitation, alpha- Sarcoglycan, beta-Sarcoglycan, Calpain Inhibitors, Creatine Kinase MM / CKMM, eIF5A, Enolase 2 / Neuron- specific Enolase, epsilon-Sarcoglycan, FABP3 / H-FABP, GDF-8 / Myostatin, GDF-l l / GDF-8, Integrin alpha 7, Integrin alpha 7 beta 1, Integrin beta 1 / CD29, MCAM / CD146, MyoD, Myogenin, Myosin Light Chain Kinase Inhibitors, NCAM-1 / CD56, and Troponin I. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a smooth muscle protein. Exemplary smooth muscle proteins include, without limitation, alpha-Smooth Muscle Actin, VE-Cadherin, Caldesmon / CALDl, Calponin 1, Desmin, Histamine H2 R, Motilin R / GPR38, Transgelin / TAGLN, and Vimentin. However, it should be appreciated that antibodies to additional targets are within the scope of this disclosure and the exemplary lists of targets provided herein are not meant to be limiting. c. Antibody Features / Alterations[000206] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or (e.g., and) CH3 domain (residues 341-447 of human IgGl) and / or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or (e.g., and) antigen-dependent cellular cytotoxicity.[000207] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CHI domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CHI domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.[000208] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or (e.g., and) CH3 domain (residues 341-447 of human IgGl) and / or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631, which are incorporated herein by reference.[000209] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (e.g., decrease or increase) half-life of the antibody in vivo. See, e.g., International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375, and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.[000210] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the halflife of the anti-transferrin receptor antibody in vivo. In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody in vivo. In some embodiments, the antibodies can have one or more amino acid mutations (e.g., substitutions) in the second constant (CH2) domain (residues 231-340 of human IgGl) and / or (e.g., and) the third constant (CH3) domain (residues 341-447 of human IgGl), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgGl of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat.No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as “YTE mutant” has been shown to display fourfold increased half-life as compared to wildtype versions of the same antibody (see Dall’Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat. [000211] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-transferrin receptor antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the Cl component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).[000212] In some embodiments, one or more amino in the constant region of a muscletargeting antibody described herein can be replaced with a different amino acid residue such that the antibody has altered Clq binding and / or (e.g., and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N- terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94 / 29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and / or (e.g., and) to increase the affinity of the antibody for an Fey receptor. This approach is described further in International Publication No. WO 00 / 42072.[000213] In some embodiments, the heavy and / or (e.g., and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, anyvariant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.[000214] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse / human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgGl-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.[000215] As provided herein, antibodies of this disclosure may optionally comprise constant regions or parts thereof. For example, a VL domain may be attached at its C-terminal end to a light chain constant domain like CK or Ck. Similarly, a VH domain or portion thereof may be attached to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Antibodies may include suitable constant regions (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md. (1991)). Therefore, antibodies within the scope of this may disclosure include VH and VL domains, or an antigen binding portion thereof, combined with any suitable constant regions. ii. Muscle- Targeting Peptides[000216] Some aspects of the disclosure provide muscle-targeting peptides as muscletargeting agents. Short peptide sequences (e.g., peptide sequences of 5-20 amino acids in length) that bind to specific cell types have been described. For example, cell-targeting peptides have been described in Vines e., et al., A. “Cell-penetrating and cell-targeting peptides in drug delivery” Biochim Biophys Acta 2008, 1786: 126-38; Jarver P., et al., “In vivo biodistribution and efficacy of peptide mediated delivery” Trends Pharmacol Sci 2010; 31: 528-35; Samoylova T.I., et al., “Elucidation of muscle-binding peptides by phage display screening” Muscle Nerve 1999; 22: 460-6; U.S. Patent No. 6,329,501, issued on December 11, 2001, entitled “METHODS AND COMPOSITIONS FOR TARGETING COMPOUNDS TO MUSCLE”; and Samoylov A.M., et al., “Recognition of cell-specific binding of phage displayderived peptides using an acoustic wave sensor.” Biomol Eng 2002; 18: 269-72; the entire contents of each of which are incorporated herein by reference. By designing peptides to interact with specific cell surface antigens (e.g., receptors), selectivity for a desired tissue, e.g., muscle, can be achieved. Skeletal muscle-targeting has been investigated and a range of molecular payloads are able to be delivered. These approaches may have high selectivity for muscle tissue without many of the practical disadvantages of a large antibody or viral particle. Accordingly, in some embodiments, the muscle-targeting agent is a muscle-targeting peptide that is from 4 to 50 amino acids in length. In some embodiments, the muscle-targeting peptide is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. Muscle-targeting peptides can be generated using any of several methods, such as phage display.[000217] In some embodiments, a muscle-targeting peptide may bind to an internalizing cell surface receptor that is overexpressed or relatively highly expressed in muscle cells, e.g., a transferrin receptor, compared with certain other cells. In some embodiments, a muscletargeting peptide may target, e.g., bind to, a transferrin receptor. In some embodiments, a peptide that targets a transferrin receptor may comprise a segment of a naturally occurring ligand, e.g., transferrin. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 6,743,893, filed 11 / 30 / 2000, “RECEPTOR-MEDIATED UPTAKE OF PEPTIDES THAT BIND THE HUMAN TRANSFERRIN RECEPTOR”. In some embodiments, a peptide that targets a transferrin receptor is as described in Kawamoto, M. et al, “A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.” BMC Cancer. 2011 Aug 18; 11:359. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 8,399,653, filed 5 / 20 / 2011, “TRANSFERRIN / TRANSFERRIN RECEPTOR-MEDIATED SIRNA DELIVERY”.[000218] As discussed above, examples of muscle targeting peptides have been reported. For example, muscle- specific peptides were identified using phage display library presenting surface heptapeptides. As one example a peptide having the amino acid sequence ASSLNIA (SEQ ID NO: 36) bound to C2C12 murine myotubes in vitro, and bound to mouse muscle tissue in vivo. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence ASSLNIA (SEQ ID NO: 36). This peptide displayed improved specificity for binding to heart and skeletal muscle tissue after intravenous injection in mice with reduced binding to liver, kidney, and brain. Additional muscle- specific peptides havebeen identified using phage display. For example, a 12 amino acid peptide was identified by phage display library for muscle targeting in the context of treatment for DMD. See, Yoshida D., et al., “Targeting of salicylate to skin and muscle following topical injections in rats.” Int J Pharm 2002; 231: 177-84; the entire contents of which are hereby incorporated by reference. Here, a 12 amino acid peptide having the sequence SKTFNTHPQSTP (SEQ ID NO: 37) was identified and this muscle-targeting peptide showed improved binding to C2C12 cells relative to the ASSLNIA (SEQ ID NO: 36) peptide.[000219] An additional method for identifying peptides selective for muscle (e.g., skeletal muscle) over other cell types includes in vitro selection, which has been described in Ghosh D., et al., “Selection of muscle-binding peptides from context- specific peptide-presenting phage libraries for adenoviral vector targeting” J Virol 2005; 79: 13667-72; the entire contents of which are incorporated herein by reference. By pre-incubating a random 12-mer peptide phage display library with a mixture of non-muscle cell types, non-specific cell binders were selected out. Following rounds of selection, the 12 amino acid peptide TARGEHKEEELI (SEQ ID NO: 38) appeared most frequently. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence TARGEHKEEELI (SEQ ID NO: 38).[000220] A muscle-targeting agent may an amino acid-containing molecule or peptide. A muscle-targeting peptide may correspond to a sequence of a protein that preferentially binds to a protein receptor found in muscle cells. In some embodiments, a muscle-targeting peptide contains a high propensity of hydrophobic amino acids, e.g., valine, such that the peptide preferentially targets muscle cells. In some embodiments, a muscle-targeting peptide has not been previously characterized or disclosed. These peptides may be conceived of, produced, synthesized, and / or (e.g., and) derivatized using any of several methodologies, e.g., phage displayed peptide libraries, one-bead one-compound peptide libraries, or positional scanning synthetic peptide combinatorial libraries. Exemplary methodologies have been characterized in the art and are incorporated by reference (Gray, B.P. and Brown, K.C. “Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides” Chem Rev. 2014, 114:2, 1020-1081.; Samoylova, T.I. and Smith, B.F. “Elucidation of muscle-binding peptides by phage display screening.” Muscle Nerve, 1999, 22:4. 460-6.). In some embodiments, a muscle-targeting peptide has been previously disclosed (see, e.g., Writer M.J. et al. “Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display.” J. Drug Targeting. 2004; 12: 185; Cai, D. “BDNF-mediated enhancement of inflammation and injury in the aging heart.” Physiol Genomics. 2006, 24:3, 191-7.; Zhang, L. “Molecular profiling of heart endothelial cells.” Circulation, 2005, 112:11,1601-11.; McGuire, M.J. et al. “In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo.” J Mol Biol. 2004, 342:1, 171-82.). Exemplary muscle-targeting peptides comprise an amino acid sequence of the following group: CQAQGQLVC (SEQ ID NO: 39), CSERSMNFC (SEQ ID NO: 40), CPKTRRVPC (SEQ ID NO: 41), WLSEAGPVVTVRALRGTGSW (SEQ ID NO: 42), ASSLNIA (SEQ ID NO: 36), CMQHSMRVC (SEQ ID NO: 43), and DDTRHWG (SEQ ID NO: 44). In some embodiments, a muscle-targeting peptide may comprise about 2-25 amino acids, about 2-20 amino acids, about 2-15 amino acids, about 2-10 amino acids, or about 2-5 amino acids. Muscle-targeting peptides may comprise naturally-occurring amino acids, e.g., cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include P-amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a muscle-targeting peptide may be linear; in other embodiments, a muscletargeting peptide may be cyclic, e.g., bicyclic (see, e.g., Silvana, M.G. et al. Mol. Therapy, 2018, 26:1, 132-147.). iii. Muscle- Targeting Receptor Ligands[000221] A muscle-targeting agent may be a ligand, e.g., a ligand that binds to a receptor protein. A muscle-targeting ligand may be a protein, e.g., transferrin, which binds to an internalizing cell surface receptor expressed by a muscle cell. Accordingly, in some embodiments, the muscle-targeting agent is transferrin, or a derivative thereof that binds to a transferrin receptor. A muscle-targeting ligand may alternatively be a small molecule, e.g., a lipophilic small molecule that preferentially targets muscle cells relative to other cell types. Exemplary lipophilic small molecules that may target muscle cells include compounds comprising cholesterol, cholesteryl, stearic acid, palmitic acid, oleic acid, oleyl, linolene, linoleic acid, myristic acid, sterols, dihydrotestosterone, testosterone derivatives, glycerine, alkyl chains, trityl groups, and alkoxy acids. iv. Muscle- Targeting Aptamers[000222] A muscle-targeting agent may be an aptamer, e.g., an RNA aptamer, which preferentially targets muscle cells relative to other cell types. In some embodiments, a muscletargeting aptamer has not been previously characterized or disclosed. These aptamers may be conceived of, produced, synthesized, and / or (e.g., and) derivatized using any of several methodologies, e.g., Systematic Evolution of Ligands by Exponential Enrichment. Exemplary methodologies have been characterized in the art and are incorporated by reference (Yan, A.C.and Levy, M. “Aptamers and aptamer targeted delivery” RNA biology, 2009, 6:3, 316-20.; Germer, K. et al. “RNA aptamers and their therapeutic and diagnostic applications.” Int. J. Biochem. Mol. Biol. 2013; 4: 27-40.). In some embodiments, a muscle-targeting aptamer has been previously disclosed (see, e.g., Phillippou, S. et al. “Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.” Mol Ther Nucleic Acids. 2018, 10:199-214.; Thiel, W.H. et al. “Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.” Mol Ther. 2016, 24:4, 779-87.). Exemplary muscle-targeting aptamers include the A01B RNA aptamer and RNA Apt 14. In some embodiments, an aptamer is a nucleic acid-based aptamer, an oligonucleotide aptamer or a peptide aptamer. In some embodiments, an aptamer may be about 5-15 kDa, about 5-10 kDa, about 10-15 kDa, about 1-5 Da, about 1-3 kDa, or smaller. v. Other Muscle- Targeting Agents[000223] One strategy for targeting a muscle cell (e.g., a skeletal muscle cell) is to use a substrate of a muscle transporter protein, such as a transporter protein expressed on the sarcolemma. In some embodiments, the muscle-targeting agent is a substrate of an influx transporter that is specific to muscle tissue. In some embodiments, the influx transporter is specific to skeletal muscle tissue. Two main classes of transporters are expressed on the skeletal muscle sarcolemma, (1) the adenosine triphosphate (ATP) binding cassette (ABC) superfamily, which facilitate efflux from skeletal muscle tissue and (2) the solute carrier (SLC) superfamily, which can facilitate the influx of substrates into skeletal muscle. In some embodiments, the muscle-targeting agent is a substrate that binds to an ABC superfamily or an SLC superfamily of transporters. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a naturally-occurring substrate. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a non-naturally occurring substrate, for example, a synthetic derivative thereof that binds to the ABC or SLC superfamily of transporters.[000224] In some embodiments, the muscle-targeting agent is any muscle targeting agent described herein (e.g., antibodies, nucleic acids, small molecules, peptides, aptamers, lipids, sugar moieties) that target SLC superfamily of transporters. In some embodiments, the muscle-targeting agent is a substrate of an SLC superfamily of transporters. SLC transporters are either equilibrative or use proton or sodium ion gradients created across the membrane to drive transport of substrates. Exemplary SLC transporters that have high skeletal muscle expression include, without limitation, the SATT transporter (ASCT1; SLC1A4), GLUT4 transporter (SLC2A4), GLUT7 transporter (GLUT7; SLC2A7), ATRC2 transporter (CAT-2;SLC7A2), LAT3 transporter (KIAA0245; SLC7A6), PHT1 transporter (PTR4; SLC15A4), OATP-J transporter (0ATP5A1; SLC21A15), 0CT3 transporter (EMT; SLC22A3), 0CTN2 transporter (FLJ46769; SLC22A5), ENT transporters (ENT1; SLC29A1 and ENT2; SLC29A2), PAT2 transporter (SLC36A2), and SAT2 transporter (KIAA1382; SLC38A2). These transporters can facilitate the influx of substrates into skeletal muscle, providing opportunities for muscle targeting.[000225] In some embodiments, the muscle-targeting agent is a substrate of an equilibrative nucleoside transporter 2 (ENT2) transporter. Relative to other transporters, ENT2 has one of the highest mRNA expressions in skeletal muscle. While human ENT2 (hENT2) is expressed in most body organs such as brain, heart, placenta, thymus, pancreas, prostate, and kidney, it is especially abundant in skeletal muscle. Human ENT2 facilitates the uptake of its substrates depending on their concentration gradient. ENT2 plays a role in maintaining nucleoside homeostasis by transporting a wide range of purine and pyrimidine nucleobases. The hENT2 transporter has a low affinity for all nucleosides (adenosine, guanosine, uridine, thymidine, and cytidine) except for inosine. Accordingly, in some embodiments, the muscletargeting agent is an ENT2 substrate. Exemplary ENT2 substrates include, without limitation, inosine, 2',3'-dideoxyinosine, and calofarabine. In some embodiments, any of the muscletargeting agents provided herein are associated with a molecular pay load (e.g., oligonucleotide payload). In some embodiments, the muscle-targeting agent is covalently linked to the molecular pay load. In some embodiments, the muscle-targeting agent is non-covalently linked to the molecular payload.[000226] In some embodiments, the muscle-targeting agent is a substrate of an organic cation / camitine transporter (OCTN2), which is a sodium ion-dependent, high affinity carnitine transporter. In some embodiments, the muscle-targeting agent is carnitine, mildronate, acetylcarnitine, or any derivative thereof that binds to OCTN2. In some embodiments, the carnitine, mildronate, acetylcamitine, or derivative thereof is covalently linked to the molecular payload (e.g., oligonucleotide payload).[000227] A muscle-targeting agent may be a protein that is protein that exists in at least one soluble form that targets muscle cells. In some embodiments, a muscle-targeting protein may be hemojuvelin (also known as repulsive guidance molecule C or hemochromatosis type 2 protein), a protein involved in iron overload and homeostasis. In some embodiments, hemojuvelin may be full length or a fragment, or a mutant with at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to a functional hemojuvelin protein. In some embodiments, a hemojuvelin mutant may be a solublefragment, may lack a N-terminal signaling, and / or (e.g., and) lack a C-terminal anchoring domain. In some embodiments, hemojuvelin may be annotated under GenBank RefSeq Accession Numbers NM_001316767.1, NM_145277.4, NM_202004.3, NM_213652.3, or NM_213653.3. It should be appreciated that a hemojuvelin may be of human, non-human primate, or rodent origin.B. Molecular Payloads[000228] Some aspects of the disclosure provide molecular payloads, e.g., oligonucleotides designed to target DUX4 RNAs to modulate the expression or the activity of DUX4. In some embodiments, the disclosure provides oligonucleotides complementary with DUX4 RNA that are useful for reducing levels of DUX4 mRNA and / or protein associated with features of facioscapulohumeral muscular dystrophy (FSHD) pathology, including muscle atrophy, inflammation, and decreased differentiation potential and oxidative stress. In some embodiments, the oligonucleotides provided herein are designed to direct RNAi mediated degradation of DUX4 RNA. In some embodiments, the oligonucleotides are designed to efficiently engage the RNA-induced silencing complex (RISC) for degradation of the DUX4 RNA but also have reduced off-target effect. In some embodiments, the oligonucleotides are designed to have desirable bioavailability and / or serum-stability properties. In some embodiments, the oligonucleotides are designed to have desirable binding affinity properties. In some embodiments, the oligonucleotides are designed to have desirable toxicity and / or immunogenicity profiles.[000229] In some embodiments, the oligonucleotide comprises a strand having a region of complementarity to a DUX4 RNA. Exemplary oligonucleotides are described in further detail herein; however, it should be appreciated that the exemplary oligonucleotides provided herein are not meant to be limiting. i. Oligonucleotides[000230] In some embodiments, the oligonucleotides provided herein are designed to cause RNAi mediated degradation of DUX4 mRNA. In some embodiments, the oligonucleotide provided herein comprises an antisense strand that is complementary to a DUX4 mRNA. In some embodiments, the oligonucleotide provided herein further comprises a sense strand that forms a double-stranded oligonucleotide (e.g., siRNA). It should be appreciated that, in some embodiments, oligonucleotides in one format (e.g., antisense oligonucleotides) may be suitably adapted to another format (e.g., siRNA oligonucleotides) byincorporating functional sequences (e.g., antisense strand sequences) from one format to the other format.[000231] Any suitable oligonucleotide may be used as a molecular payload, as described herein. Examples of oligonucleotides useful for targeting DUX4 are provided in US Patent Number 9,988,628, published on February 2, 2017, entitled “AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY”; US Patent Number 9,469,851, published October 30, 2014, entitled “RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DUX4”; US Patent Application Publication 20120225034, published on September 6, 2012, entitled “AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY”; PCT Patent Application Publication Number WO 2013 / 120038, published on August 15, 2013, entitled “MORPHOLINO TARGETING DUX4 FOR TREATING FSHD”; Chen et al., “Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics,” Molecular Therapy, 2016, 24:8, 1405-1411.; and Ansseau et al., “Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy (FSHD),” Genes, 2017, 8, 93; the contents of each of which are incorporated herein in their entireties. In some embodiments, the oligonucleotide is an antisense oligonucleotide, a morpholino, an siRNA, a shRNA, or another oligonucleotide which hybridizes with the target DUX4 gene or mRNA.[000232] In some embodiments, the oligonucleotides described herein have a region of complementarity to a sequence as set forth as: Human DUX4, corresponding to NCBI sequence NM_001293798.2 (SEQ ID NO: 25) or NCBI Sequence: NM_001306068.3 (SEQ ID NO: 26) as below and / or (e.g., and) Mouse DUX4, corresponding to NCBI sequence NM_001081954.1 (SEQ ID NO: 27), as below. Other non-limiting exemplary human DUX4 mRNA include NCBI Sequence: NM_033178, GenBank accession numbers FJ439133, AF117653, HM101229, HM101230, HM101232, HM101233, HM101234, HM101235, HM101240, HM101241, HM101242, HM101243, HM101244, HM101245, HM101246, HM101247, HM101248, HM101249, HM101250, HM101251 and HM190160, HM190161, HM190162, HM190163, HM190164, HM190165, HM190166, HM190167, HM190168, HM190169, HM190170, HM190171, HM190172, HM190173, HM190174, HM190175, HM190176, HM190177, HM190178, HM190179, HM190180, HM190181, HM190182, HM190183, HM190184, HM190185, HM190186, HM190187, HM190188, HM190189, HM190190, HM190191, HM190192, HM190193, HM190194, HM190195, HM190196, each of which is incorporated herein by reference. In some embodiments, the oligonucleotide mayhave a region of complementarity to a hypomethylated, contracted D4Z4 repeat, as in Daxinger, et al., “Genetic and Epigenetic Contributors to FSHD,” published in Curr Opin Genet Dev in 2015, Lim J-W, et al., DICER / AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD Hum Mol Genet. 2015 Sep 1; 24(17): 4817-4828, the contents of each of which are incorporated in their entireties.[000233] In some embodiments, oligonucleotides may have a region of complementarity to a sequence set forth as follows, which is an example human DUX4 gene sequence (NM_001293798.2) (SEQ ID NO: 25):ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTG CTTTGAGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCC ATCGGCATTCCGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCC AGCTGAGGCAGCACCGGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCC AGAAGGCCGGCGAAAGCGGACCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTC CGAGCCTTTGAGAAGGATCGCTTTCCAGGCATCGCCGCCCGGGAGGAGCTGGCCA GAGAGACGGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGC CAGGCACCCGGGACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAG CGCGGCCCCCGGCGGGGGTCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCG GCGCGTGGGGAACGGGGCTTCCCGCACCCCACGTGCCCTGCGCGCCTGGGGCTCT CCCACAGGGGGCTTTCGTGAGCCAGGCAGCGAGGGCCGCCCCCGCGCTGCAGCCC AGCCAGGCCGCGCCGGCAGAGGGGATCTCCCAACCTGCCCCGGCGCGCGGGGATT TCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCTCTCCCACCCTCAGGCTCCT CGCTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGACCCGCAGCGCGAC GGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGCGGGGCCGC AGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGGCTG GGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGC TCCACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAG ATGCAAGGCATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTG CACTCCCCTGCGGCCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAG CAGGCGCAACCTCTCCTAGAAACGGAGGCCCCGGGGGAGCTGGAGGCCTCGGAA GAGGCCGCCTCGCTGGAAGCACCCCTCAGCGAGGAAGAATACCGGGCTCTGCTGG AGGAGCTTTAGGACGCGGGGTCTAGGCCCGGTGAGAGACTCCACACCGCGGAGAA CTGCCATTCTTTCCTGGGCATCCCGGGGATCCCAGAGCCGGCCCAGGTACCAGCAGACCTGCGCGCAGTGCGCACCCCGGCTGACGTGCAAGGGAGCTCGCTGGCCTCTCT GTGCCCTTGTTCTTCCGTGAAATTCTGGCTGAATGTCTCCCCCCACCTTCCGACGCTGTCTAGGCAAACCTGGATTAGAGTTACATCTCCTGGATGATTAGTTCAGAGATATATTAAAATGCCCCCTCCCTGTGGATCCTATAG[000234] In some embodiments, oligonucleotides may have a region of complementarity to a sequence set forth as follows, which is an example human DUX4 gene sequence(NM_001306068.3) (SEQ ID NO: 26):[000235] ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAGGACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTGAGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTCCGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACCGGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGACCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTCCAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTG TGCAGCGCGGCCCCCGGCGGGGGTCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCCCGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGCAGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCAACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCTCTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGACCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGCGGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGGCTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCCACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGGCATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGGCCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCGCAACCTCTCCTAGAAACGGAGGCCCCGGGGGAGCTGGAGGCCTCGGAAGAGGCCGCCTCGCTGGAAGCACCCCTCAGCGAGGAAGAATACCGGGCTCTGCTGGAGGAGCTTTAGGACGCGGGGTTGGGACGGGGTCGGGTGGTTCGGGGCAGGGCGGTGGCCTCTCTTTCGCGGGGAACACCTGGCTGGCTACGGAGGGGCGTGTCTCCGCCCCGCCCCCTCCACCGGGCTGACCGGCCTGGGATTCCTGCCTTCTAGGTCTAGGCC CGGTGAGAGACTCCACTCCGCGGAGAACTGCCTTTCTTTCCTGGGCATCCCGGGGATCCCAGAGCCGGCCCAGGTACCAGCAGACCTGCGCGCAGTGCGCACCCCGGCTGA CGTGCAAGGGAGCTCGCTGGCCTCTCTGTGCCCTTGTTCTTCCGTGAAATTCTGGC TGAATGTCTCCCCCCACCTTCCGACGCTGTCTAGGCAAACCTGGATTAGAGTTACA TCTCCTGGATGATTAGTTCAGAGATATATTAAAATGCCCCCTCCCTGTGGATCCTA TAG.[000236] In some embodiments, oligonucleotides may have a region of complementarity to a sequence set forth as follows, which is an example mouse DUX4 gene sequence (SEQ ID NO: 27) (NM_001081954.1):ATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCGGC GGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTT CAAGAAGAAGAGATACCTGAGCTTCAAGGAGAGGAAGGAGCTGGCCAAGCGAATGGGGGTCTCAGATTGCCGCATCCGCGTGTGGTTTCAGAACCGCAGGAATCGCAGT GGAGAGGAGGGGCATGCCTCAAAGAGGTCCATCAGAGGCTCCAGGCGGCTAGCCT CGCCACAGCTCCAGGAAGAGCTTGGATCCAGGCCACAGGGTAGAGGCATGCGCTCATCTGGCAGAAGGCCTCGCACTCGACTCACCTCGCTACAGCTCAGGATCCTAGGG CAAGCCTTTGAGAGGAACCCACGACCAGGCTTTGCTACCAGGGAGGAGCTGGCGC GTGACACAGGGTTGCCCGAGGACACGATCCACATATGGTTTCAAAACCGAAGAGC TCGGCGGCGCCACAGGAGGGGCAGGCCCACAGCTCAAGATCAAGACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCGGAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACCT CGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCTTTCCAAGTGGCA CAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAACGCAGGCTCTCTGGAACCCCTCCTTGATCAGCTGCTGGATGAAGTCCAAGTAGAAGAGCCTGC TCCAGCCCCTCTGAATTTGGATGGAGACCCTGGTGGCAGGGTGCATGAAGGTTCCC AGGAGAGCTTTTGGCCACAGGAAGAAGCAGGAAGTACAGGCATGGATACTTCTAG CCCCAGCGACTCAAACTCCTTCTGCAGAGAGTCCCAGCCTTCCCAAGTGGCACAGC CCTGTGGAGCGGGCCAAGAAGATGCCCGCACTCAAGCAGACAGCACAGGCCCTCT GGAACTCCTCCTCCTTGATCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTG CCAGTCCCACTGGATTGGGGTAGAAATCCTGGCAGCAGGGAGCATGAAGGTTCCC AGGACAGCTTACTGCCCCTGGAGGAAGCAGTAAATTCGGGCATGGATACCTCGAT CCCTAGCATCTGGCCAACCTTCTGCAGAGAATCCCAGCCTCCCCAAGTGGCACAGC CCTCTGGACCAGGCCAAGCACAGGCCCCCACTCAAGGTGGGAACACGGACCCCCT GGAGCTCTTCCTCTATCAACTGTTGGATGAAGTCCAAGTAGAAGAGCATGCTCCAG CCCCTCTGAATTGGGATGTAGATCCTGGTGGCAGGGTGCATGAAGGTTCGTGGGAGAGCTTTTGGCCACAGGAAGAAGCAGGAAGTACAGGCCTGGATACTTCAAGCCCC AGCGACTCAAACTCCTTCTTCAGAGAGTCCAAGCCTTCCCAAGTGGCACAGCGCC GTGGAGCGGGCCAAGAAGATGCCCGCACTCAAGCAGACAGCACAGGCCCTCTGG AACTCCTCCTCTTTGATCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCC AGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCATGGAGCATGAAGGTTCCCAG GACAGCTTACTGCCCCTGGAGGAAGCAGCAAATTCGGGCAGGGATACCTCGATCC CTAGCATCTGGCCAGCCTTCTGCAGAAAATCCCAGCCTCCCCAAGTGGCACAGCCC TCTGGACCAGGCCAAGCACAGGCCCCCATTCAAGGTGGGAACACGGACCCCCTGG AGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCC CCTGTGAATGTGGAGGAAACATGGGAGCAAATGGACACAACACCTATCTGCCTCT CACTTCAGAAGAATATCAGACTCTTCTAGATATGCTCTGA.[000237] In some embodiments, an oligonucleotide may have a region of complementarity to DUX4 gene sequences of multiple species, e.g., selected from human, mouse and non-human species. In some embodiments, the non-human species is a cynomolgus monkey. ii. Oligonucleotide Size / Sequence[000238] Oligonucleotides may be of a variety of different lengths, e.g., depending on the format. In some embodiments, an oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the oligonucleotide is 8 to 50 nucleotides in length, 8 to 40 nucleotides in length, 8 to 32 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 21 to 23 nucleotides in lengths, etc. In some embodiments, the oligonucleotide is 8 to 32 nucleotides, 15 to 29 nucleotides, 15 to 27 nucleotides, 15 to 20 nucleotides, 20 to 25 nucleotides, 21 to 27 nucleotides, 23 to 27 nucleotides, 25 to 30 nucleotides, or 25-32 nucleotides in length.[000239] In some embodiments, a complementary nucleic acid sequence of an oligonucleotide for purposes of the present disclosure is specifically hybridizable or specific for the target nucleic acid when binding of the sequence to the target molecule (e.g., mRNA) interferes with the normal function of the target (e.g., mRNA) to cause a loss of activity (e.g., inhibiting translation) or expression (e.g., degrading a target mRNA) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditionsof stringency. Thus, in some embodiments, an oligonucleotide may be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the consecutive nucleotides of a target nucleic acid. In some embodiments a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable or specific for a target nucleic acid. In some embodiments, oligonucleotides comprise one or more mismatched nucleobases relative to the target nucleic acid. In some embodiments, activity relating to the target is reduced by such mismatch, but activity relating to a non-target is reduced by a greater amount (z.e., selectivity for the target nucleic acid is increased and off- target effects are decreased). In some embodiments, the target nucleic acid is a pre-mRNA molecule or an mRNA molecule.[000240] In some embodiments, an oligonucleotide comprises region of complementarity to a target nucleic acid that is in the range of 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 nucleotides in length. In some embodiments, an oligonucleotide comprises region of complementarity to a target nucleic acid that is in the range of 8-32, 15-29, 15-27, 21-27, 23-27 nucleotides in length. In some embodiments, an oligonucleotide comprises a region of complementarity to a target nucleic acid that is in the range of 15-29, 15-27, 15 to 20, 20 to 25, 21-27, 23-27, 25-27, or 25-32 nucleotides in length. In some embodiments, a region of complementarity of an oligonucleotide to a target nucleic acid is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a target nucleic acid. In some embodiments, the region of complementarity is complementary with at least 12 consecutive nucleotides of a target nucleic acid. In some embodiments, the region of complementarity is complementary with at least 16 consecutive nucleotides of a target nucleic acid. In some embodiments, an oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of target nucleic acid. In some embodiments the oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.[000241] In some embodiments, it should be appreciated that methylation of the nucleobase uracil at the C5 position forms thymine. Thus, in some embodiments, a nucleotide or nucleoside having a C5 methylated uracil (or 5-methyl-uracil) may be equivalently identified as a thymine nucleotide or nucleoside.[000242] In some embodiments, one or more of the thymine bases (T’s) in any one of the oligonucleotides provided herein may independently and optionally be uracil bases (U’s), and / or any one or more of the U’s may independently and optionally be T’s. In some embodiments, one or more of the thymine bases (T’s) in any one of the oligonucleotides listed in Table 8 may independently and optionally be uracil bases (U’s), and / or any one or more of the U’s may independently and optionally be T’s. a. Oligonucleotide Modifications:[000243] The oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide or nucleoside and / or (e.g., and) combinations thereof. In addition, in some embodiments, oligonucleotides may exhibit one or more of the following properties: do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; have improved endosomal exit internally in a cell; minimizes TLR stimulation; or avoid pattern recognition receptors. Any of the modified chemistries or formats of oligonucleotides described herein can be combined with each other. For example, one, two, three, four, five, or more different types of modifications can be included within the same oligonucleotide.[000244] In some embodiments, certain nucleotide or nucleoside modifications may be used that make an oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide or oligoribonucleotide molecules; these modified oligonucleotides survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, modified intemucleoside linkages such as phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Accordingly, oligonucleotides of the disclosure can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide or nucleoside modification.[000245] In some embodiments, an oligonucleotide may be of up to 50 or up to 100 nucleotides in length in which 2 to 10, 2 to 1542 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides or nucleosides of the oligonucleotide are modified nucleotides / nucleosides. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 1542 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides or nucleosides of the oligonucleotide are modified nucleotides / nucleosides. The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides or nucleosides of the oligonucleotide are modified nucleotides / nucleosides. Optionally, the oligonucleotides may have every nucleotide or nucleoside except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides / nucleosides modified. Oligonucleotide modifications are described further herein. b. Modified Nucleosides[000246] In some embodiments, the oligonucleotide described herein comprises at least one nucleoside modified at the 2’ position of the sugar. In some embodiments, an oligonucleotide comprises at least one 2’-modified nucleoside. In some embodiments, all of the nucleosides in the oligonucleotide are 2’ -modified nucleosides.[000247] In some embodiments, the oligonucleotide described herein comprises one or more non-bicyclic 2’-modified nucleosides, e.g., 2’-deoxy, 2’-fluoro (2’-F), 2’-O-methyl (2’- O-Me), 2’-O-methoxyethyl (2’-M0E), 2’-O-aminopropyl (2’-O-AP), 2’-O- dimethylaminoethyl (2’-O-DMAOE), 2’-O-dimethylaminopropyl (2’-O-DMAP), 2’-O- dimethylaminoethyloxyethyl (2’-O-DMAEOE), or 2’-O-N-methylacetamido (2’-0-NMA) modified nucleoside.[000248] In some embodiments, the oligonucleotide described herein comprises one or more 2’ -4’ bicyclic nucleosides in which the ribose ring comprises a bridge moiety connecting two atoms in the ring, e.g., connecting the 2’-0 atom to the 4’-C atom via a methylene (LNA) bridge, an ethylene (ENA) bridge, or a (S)-constrained ethyl (cEt) bridge. Examples of LNAs are described in International Patent Application Publication WO / 2008 / 043753, published on April 17, 2008, and entitled ''RNA Antagonist Compounds For The Modulation Of PCSK9”. the contents of which are incorporated herein by reference in its entirety. Examples of ENAs are provided in International Patent Publication No. WO 2005 / 042777, published on May 12, 2005, and entitled ‘APP / ENA Antisense” Morita et al., Nucleic Acid Res., Suppl 1:241-242, 2001; Surono et al., Hum. Gene Ther., 15:749-757, 2004; Koizumi, Curr. Opin. Mol. Ther., 8:144-149, 2006 and Horie et al., Nucleic Acids Symp. Ser (Oxf), 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties. Examples of cEt are provided in US Patents 7,101,993; 7,399,845 and 7,569,686, each of which is herein incorporated by reference in its entirety.[000249] In some embodiments, the oligonucleotide comprises a modified nucleoside disclosed in one of the following United States Patent or Patent Application Publications: US Patent 7,399,845, issued on July 15, 2008, and entitled “6-Modified Bicyclic Nucleic Acid Analogs”; US Patent 7,741,457, issued on June 22, 2010, and entitled “6-Modified Bicyclic Nucleic Acid Analogs”; US Patent 8,022,193, issued on September 20, 2011, and entitled “6-Modified Bicyclic Nucleic Acid Analogs"'. US Patent 7,569,686, issued on August 4, 2009, and entitled “ Compounds And Methods For Synthesis Of Bicyclic Nucleic Acid Analogs”; US Patent 7,335,765, issued on February 26, 2008, and entitled “Novel Nucleoside And Oligonucleotide Analogues”; US Patent 7,314,923, issued on January 1, 2008, and entitled “Novel Nucleoside And Oligonucleotide Analogues”; US Patent 7,816,333, issued on October 19, 2010, and entitled “Oligonucleotide Analogues And Methods Utilizing The Same” and US Publication Number 2011 / 0009471 now US Patent 8,957,201, issued on February 17, 2015, and entitled “Oligonucleotide Analogues And Methods Utilizing The Same”, the entire contents of each of which are incorporated herein by reference for all purposes.[000250] In some embodiments, the oligonucleotide comprises at least one modified nucleoside that results in an increase in Tm of the oligonucleotide in a range of 1°C, 2 °C, 3°C, 4 °C, or 5 °C compared with an oligonucleotide that does not have the at least one modified nucleoside. The oligonucleotide may have a plurality of modified nucleosides that result in a total increase in Tm of the oligonucleotide in a range of 2 °C, 3 °C, 4 °C, 5 °C, 6 °C, 7 °C, 8 °C, 9 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or more compared with an oligonucleotide that does not have the modified nucleoside.[000251] The oligonucleotide may comprise a mix of nucleosides of different kinds. For example, an oligonucleotide may comprise a mix of 2’ -deoxyribonucleosides or ribonucleosides and 2’ -fluoro modified nucleosides. An oligonucleotide may comprise a mix of deoxyribonucleosides or ribonucleosides and 2’-0-Me modified nucleosides. An oligonucleotide may comprise a mix of 2’ -fluoro modified nucleosides and 2’-O-methyl modified nucleosides. An oligonucleotide may comprise a mix of bridged nucleosides and 2’- fluoro or 2’-O-methyl modified nucleosides. An oligonucleotide may comprise a mix of non- bicyclic 2’ -modified nucleosides (e.g., 2’-0-M0E) and 2’ -4’ bicyclic nucleosides (e.g., LNA, ENA, cEt). An oligonucleotide may comprise a mix of 2’-fluoro modified nucleosides and 2’- O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2’-4’ bicyclic nucleosides and 2’ -MOE, 2’ -fluoro, or 2’-0-Me modified nucleosides. An oligonucleotide may comprise a mix of non-bicyclic 2’-modified nucleosides (e.g., 2’-M0E, 2’-fluoro, or 2’- O-Me) and 2’-4’ bicyclic nucleosides (e.g., LNA, ENA, cEt).[000252] The oligonucleotide may comprise alternating nucleosides of different kinds. For example, an oligonucleotide may comprise alternating 2’ -deoxyribonucleosides or ribonucleosides and 2’ -fluoro modified nucleosides. An oligonucleotide may comprise alternating deoxyribonucleosides or ribonucleosides and 2’-0-Me modified nucleosides. An oligonucleotide may comprise alternating 2’ -fluoro modified nucleosides and 2’-0-Memodified nucleosides. An oligonucleotide may comprise alternating bridged nucleosides and 2’-fluoro or 2’-O-methyl modified nucleosides. An oligonucleotide may comprise alternating non-bicyclic 2’-modified nucleosides (e.g., 2’-0-M0E) and 2’-4’ bicyclic nucleosides (e.g., LNA, ENA, cEt). An oligonucleotide may comprise alternating 2’ -4’ bicyclic nucleosides and 2’ -MOE, 2’ -fluoro, or 2’-0-Me modified nucleosides. An oligonucleotide may comprise alternating non-bicyclic 2’-modified nucleosides (e.g., 2’-M0E, 2’-fluoro, or 2’-0-Me) and 2’- 4’ bicyclic nucleosides (e.g., LNA, ENA, cEt).[000253] In some embodiments, an oligonucleotide described herein comprises a 5 - vinylphosphonate modification, one or more abasic residues, and / or one or more inverted abasic residues. c. Internucleoside Linkages / Backbones[000254] In some embodiments, oligonucleotide may contain a phosphorothioate or other modified intemucleoside linkage. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between at least two nucleosides. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between all nucleosides. For example, in some embodiments, oligonucleotides comprise modified intemucleoside linkages at the first, second, and / or (e.g., and) third intemucleoside linkage at the 5’ or 3’ end of the nucleotide sequence.[000255] Phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3 ’alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.[000256] In some embodiments, oligonucleotides may have heteroatom backbones, such as methylene(methylimino) or MMI backbones; amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbones (see Summerton and Weller, U.S.Pat. No. 5,034,506); or peptide nucleic acid (PNA) backbones (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). d. Stereospecific Oligonucleotides[000257] In some embodiments, internucleotidic phosphorus atoms of oligonucleotides are chiral, and the properties of the oligonucleotides are adjusted based on the configuration of the chiral phosphorus atoms. In some embodiments, appropriate methods may be used to synthesize P-chiral oligonucleotide analogs in a stereocontrolled manner (e.g., as described in Oka N, Wada T, Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. Chem Soc Rev. 2011 Dec;40(12):5829-43.) In some embodiments, phosphorothioate containing oligonucleotides are provided that comprise nucleoside units that are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages. In some embodiments, such phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis, as described, for example, in US Patent 5,587,261, issued on December 12, 1996, the contents of which are incorporated herein by reference in their entirety. In some embodiments, chirally controlled oligonucleotides provide selective cleavage patterns of a target nucleic acid. For example, in some embodiments, a chirally controlled oligonucleotide provides single site cleavage within a complementary sequence of a nucleic acid, as described, for example, in US Patent Application Publication 20170037399 Al, published on February 2, 2017, entitled “CHIRAL DESIGN”, the contents of which are incorporated herein by reference in their entirety. e. Morpholinos[000258] In some embodiments, the oligonucleotide may be a morpholino-based compounds. Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).f. Gapmers[000259] In some embodiments, an oligonucleotide described herein is a gapmer. A gapmer oligonucleotide generally has the formula 5’-X-Y-Z-3', with X and Z as flanking regions around a gap region Y. In some embodiments, flanking region X of formula 5’-X-Y- Z-3' is also referred to as X region, flanking sequence X, 5’ wing region X, or 5’ wing segment. In some embodiments, flanking region Z of formula 5’-X-Y-Z-3' is also referred to as Z region, flanking sequence Z, 3’ wing region Z, or 3’ wing segment. In some embodiments, gap region Y of formula 5’-X-Y-Z-3' is also referred to as Y region, Y segment, or gapsegment Y. In some embodiments, each nucleoside in the gap region Y is a 2’- deoxyribonucleoside, and neither the 5’ wing region X or the 3’ wing region Z contains any 2’- deoxyribonucleosides.[000260] In some embodiments, the Y region is a contiguous stretch of nucleotides, e.g., a region of 6 or more DNA nucleotides, which are capable of recruiting an RNAse, such as RNAse H. In some embodiments, the gapmer binds to the target nucleic acid, at which point an RNAse is recruited and can then cleave the target nucleic acid. In some embodiments, the Y region is flanked both 5’ and 3’ by regions X and Z comprising high-affinity modified nucleosides, e.g., one to six high-affinity modified nucleosides. Examples of high affinity modified nucleosides include, but are not limited to, 2’ -modified nucleosides (e.g., 2’ -MOE, 2’0-Me, 2’-F) or 2’ -4’ bicyclic nucleosides (e.g., LNA, cEt, ENA). In some embodiments, the flanking sequences X and Z may be of 1-20 nucleotides, 1-8 nucleotides, or 1-5 nucleotides in length. The flanking sequences X and Z may be of similar length or of dissimilar lengths. In some embodiments, the gap-segment Y may be a nucleotide sequence of 5-20 nucleotides, 5- 15 twelve nucleotides, or 6-10 nucleotides in length.[000261] In some embodiments, the gap region of the gapmer oligonucleotides may contain modified nucleotides known to be acceptable for efficient Rnase H action in addition to DNA nucleotides, such as C4’ -substituted nucleotides, acyclic nucleotides, and arabinoconfigured nucleotides. In some embodiments, the gap region comprises one or more unmodified intemucleoside linkages. In some embodiments, one or both flanking regions each independently comprise one or more phosphorothioate intemucleoside linkages (e.g., phosphorothioate internucleoside linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides. In some embodiments, the gap region and two flanking regions each independently comprise modified intemucleoside linkages (e.g., phosphorothioate intemucleoside linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides.[000262] A gapmer may be produced using appropriate methods. Representative U.S. patents, U.S. patent publications, and PCT publications that teach the preparation of gapmers include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; 5,700,922; 5,898,031; 7,015,315; 7,101,993; 7,399,845; 7,432,250; 7,569,686; 7,683,036; 7,750,131; 8,580,756; 9,045,754; 9,428,534; 9,695,418; 10,017,764; 10,260,069; 9,428,534; 8,580,756; U.S. patent publication Nos. US20050074801, US20090221685; US20090286969, US20100197762, and US20110112170; PCT publication Nos. W02004069991;W02005023825; W02008049085 and W02009090182; and EP Patent No. EP2, 149,605, each of which is herein incorporated by reference in its entirety.[000263] In some embodiments, a gapmer is 10-40 nucleosides in length. For example, the gapmer may be 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 15-40, 15-35, 15-30, 15-25, 15- 20, 20-40, 20-35, 20-30, 20-25, 25-40, 25-35, 25-30, 30-40, 30-35, or 35-40 nucleosides in length. In some embodiments, a gapmer is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleosides in length.[000264] In some embodiments, the gap region Y in a gapmer is 5-20 nucleosides in length. For example, the gap region Y may be 5-20, 5-15, 5-10, 10-20, 10-15, or 15-20 nucleosides in length. In some embodiments, the gap region Y is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleosides in length. In some embodiments, each nucleoside in the gap region Y is a 2’ -deoxyribonucleoside. In some embodiments, all nucleosides in the gap region Y are 2’-deoxyribonucleosides. In some embodiments, one or more of the nucleosides in the gap region Y is a modified nucleoside (e.g., a 2’ modified nucleoside such as those described herein). In some embodiments, one or more cytosines in the gap region Y are optionally 5-methyl-cytosines. In some embodiments, each cytosine in the gap region Y is a 5-methyl-cytosines.[000265] In some embodiments, the 5 ’wing region of a gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of a gapmer (Z in the 5’-X-Y-Z-3' formula) are independently 1-20 nucleosides long. For example, the 5 ’wing region of a gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) may be independently 1-20, 1-15, 1-10, 1-7, 1-5, 1-3, 1-2, 2-5, 2-7, 3-5, 3-7, 5-20, 5-15, 5-10, 10-20, 10-15, or 15-20 nucleosides long. In some embodiments, the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleosides long. In some embodiments, the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) are of the same length. In some embodiments, the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) are of different lengths. In some embodiments, the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) is longer than the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula). In some embodiments, the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) is shorter than the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula).[000266] In some embodiments, a gapmer comprises a 5’-X-Y-Z-3' of 5-10-5, 4-12-4, 3- 14-3, 2-16-2, 1-18-1, 3-10-3, 2-10-2, 1-10-1, 2-8-2, 4-6-4, 3-6-3, 2-6-2, 4-7-4, 3-7-3, 2-7-2, 4- 8-4, 3-8-3, 2-8-2, 1-8-1, 2-9-2, 1-9-1, 2-10-2, 1-10-1, 1-12-1, 1-16-1, 2-15-1, 1-15-2, 1-14-3, 3- 14-1, 2-14-2, 1-13-4, 4-13-1, 2-13-3, 3-13-2, 1-12-5, 5-12-1, 2-12-4, 4-12-2, 3-12-3, 1-11-6, 6-11-1, 2-11-5, 5-11-2, 3-11-4, 4-11-3, 1-17-1, 2-16-1, 1-16-2, 1-15-3, 3-15-1, 2-15-2, 1-14-4, 4-14-1, 2-14-3, 3-14-2, 1-13-5, 5-13-1, 2-13-4, 4-13-2, 3-13-3, 1-12-6, 6-12-1, 2-12-5, 5-12-2, 3-12-4, 4-12-3, 1-11-7, 7-11-1, 2-11-6, 6-11-2, 3-11-5, 5-11-3, 4-11-4, 1-18-1, 1-17-2, 2-17-1, 1-16-3, 1-16-3, 2-16-2, 1-15-4, 4-15-1, 2-15-3, 3-15-2, 1-14-5, 5-14-1, 2-14-4, 4-14-2, 3-14-3, 1-13-6, 6-13-1, 2-13-5, 5-13-2, 3-13-4, 4-13-3, 1-12-7, 7-12-1, 2-12-6, 6-12-2, 3-12-5, 5-12-3, 1-11-8, 8-11-1, 2-11-7, 7-11-2, 3-11-6, 6-11-3, 4-11-5, 5-11-4, 1-18-1, 1-17-2, 2-17-1, 1-16-3, 3-16-1, 2-16-2, 1-15-4, 4-15-1, 2-15-3, 3-15-2, 1-14-5, 2-14-4, 4-14-2, 3-14-3, 1-13-6, 6-13-1, 2-13-5, 5-13-2, 3-13-4, 4-13-3, 1-12-7, 7-12-1, 2-12-6, 6-12-2, 3-12-5, 5-12-3, 1-11-8, 8-11-1, 2-11-7, 7-11-2, 3-11-6, 6-11-3, 4-11-5, 5-11-4, 1-19-1, 1-18-2, 2-18-1, 1-17-3, 3-17-1, 2-17-2, 1-16-4, 4-16-1, 2-16-3, 3-16-2, 1-15-5, 2-15-4, 4-15-2, 3-15-3, 1-14-6, 6-14-1, 2-14-5, 5-14-2, 3-14-4, 4-14-3, 1-13-7, 7-13-1, 2-13-6, 6-13-2, 3-13-5, 5-13-3, 4-13-4, 1-12-8, 8-12-1, 2-12-7, 7-12-2, 3-12-6, 6-12-3, 4-12-5, 5-12-4, 2-11-8, 8-11-2, 3-11-7, 7-11-3, 4-11-6, 6-11-4, 5-11-5, 1-20-1, 1-19-2, 2-19-1, 1-18-3, 3-18-1, 2-18-2, 1-17-4, 4-17-1, 2-17-3, 3-17-2, 1-16-5, 2-16-4, 4-16-2, 3-16-3, 1-15-6, 6-15-1, 2-15-5, 5-15-2, 3-15-4, 4-15-3, 1-14-7, 7-14-1, 2-14-6, 6-14-2, 3-14-5, 5-14-3, 4-14-4, 1-13-8, 8-13-1, 2-13-7, 7-13-2, 3-13-6, 6-13-3, 4-13-5, 5-13-4, 2-12-8, 8-12-2, 3-12-7, 7-12-3, 4-12-6, 6-12-4, 5-12-5, 3-11-8, 8-11-3, 4-11-7, 7-11-4, 5-11-6, 6-11-5, 1-21-1, 1-20-2, 2-20-1, 1-20-3, 3-19-1, 2-19-2, 1-18-4, 4-18-1, 2-18-3, 3-18-2, 1-17-5, 2-17-4, 4-17-2, 3-17-3, 1-16-6, 6-16-1, 2-16-5, 5-16-2, 3-16-4, 4-16-3, 1-15-7, 7-15-1, 2-15-6, 6-15-2, 3-15-5, 5-15-3, 4-15-4, 1-14-8, 8-14-1, 2-14-7, 7-14-2, 3-14-6, 6-14-3, 4-14-5, 5-14-4, 2-13-8, 8-13-2, 3-13-7, 7-13-3, 4-13-6, 6-13-4, 5-13-5, 1-12-10, 10-12-1, 2-12-9, 9-12-2, 3-12-8, 8-12-3,4-12-7, 7-12-4, 5-12-6, 6-12-5, 4-11-8, 8-11-4, 5-11-7, 7-11-5, 6-11-6, 1-22-1, 1-21-2, 2-21-1,1-21-3, 3-20-1, 2-20-2, 1-19-4, 4-19-1, 2-19-3, 3-19-2, 1-18-5, 2-18-4, 4-18-2, 3-18-3, 1-17-6,6-17-1, 2-17-5, 5-17-2, 3-17-4, 4-17-3, 1-16-7, 7-16-1, 2-16-6, 6-16-2, 3-16-5, 5-16-3, 4-16-4,1-15-8, 8-15-1, 2-15-7, 7-15-2, 3-15-6, 6-15-3, 4-15-5, 5-15-4, 2-14-8, 8-14-2, 3-14-7, 7-14-3, 4-14-6, 6-14-4, 5-14-5, 3-13-8, 8-13-3, 4-13-7, 7-13-4, 5-13-6, 6-13-5, 4-12-8, 8-12-4, 5-12-7, 7-12-5, 6-12-6, 5-11-8, 8-11-5, 6-11-7, or 7-11-6. The numbers indicate the number of nucleosides in X, Y, and Z regions in the 5’-X-Y-Z-3' gapmer.[000267] In some embodiments, one or more nucleosides in the 5’ wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) or the 3 ’wing region of a gapmer (Z in the 5’-X-Y-Z-3' formula) are modified nucleosides (e.g., high-affinity modified nucleosides). In some embodiments, the modified nucleoside (e.g., high-affinity modified nucleosides) is a 2’- modified nucleoside. In some embodiments, the 2’ -modified nucleoside is a 2’ -4’ bicyclic nucleoside or a non-bicyclic 2’ -modified nucleoside. In some embodiments, the high-affinity modified nucleoside is a 2’ -4’ bicyclic nucleoside (e.g., LNA, cEt, or ENA) or a non-bicyclic 2’-modified nucleoside (e.g., 2’-fluoro (2’-F), 2’-O-methyl (2’-O-Me), 2’-O-methoxyethyl (2’- MOE), 2’-O-aminopropyl (2’-O-AP), 2’-O-dimethylaminoethyl (2’-O-DMAOE), 2’-O- dimethylaminopropyl (2’-O-DMAP), 2’-O-dimethylaminoethyloxyethyl (2’-O-DMAEOE), or 2’-O-N-methylacetamido (2’-O-NMA)).[000268] In some embodiments, one or more nucleosides in the 5’ wing region of a gapmer (X in the 5’-X-Y-Z-3' formula) are high-affinity modified nucleosides. In some embodiments, each nucleoside in the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) is a high-affinity modified nucleoside. In some embodiments, one or more nucleosides in the 3 ’wing region of a gapmer (Z in the 5’-X-Y-Z-3' formula) are high-affinity modified nucleosides. In some embodiments, each nucleoside in the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) is a high-affinity modified nucleoside. In some embodiments, one or more nucleosides in the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z- 3' formula) are high-affinity modified nucleosides and one or more nucleosides in the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) are high-affinity modified nucleosides. In some embodiments, each nucleoside in the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) is a high-affinity modified nucleoside and each nucleoside in the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) is high-affinity modified nucleoside.[000269] In some embodiments, the 5 ’wing region of a gapmer (X in the 5’-X-Y-Z-3' formula) comprises the same high affinity nucleosides as the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula). For example, the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z- 3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) may comprise one or more non-bicyclic 2’-modified nucleosides (e.g., 2’-MOE or 2’-O-Me). In another example, the 5 ’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wingregion of the gapmer (Z in the 5’-X-Y-Z-3' formula) may comprise one or more 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt). In some embodiments, each nucleoside in the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’- X-Y-Z-3' formula) is a non-bicyclic 2’-modified nucleosides (e.g., 2’-M0E or 2’-0-Me). In some embodiments, each nucleoside in the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) is a 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt).[000270] In some embodiments, a gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z is independently 1-7 (e.g., 1, 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein each nucleoside in X and Z is a non- bicyclic 2’-modified nucleosides (e.g., 2’-MOE or 2’-O-Me) and each nucleoside in Y is a 2’- deoxyribonucleoside. In some embodiments, the gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z is independently 1-7 (e.g., 1, 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein each nucleoside in X and Z is a 2’-4’ bicyclic nucleosides (e.g., LNA or cEt) and each nucleoside in Y is a 2’- deoxyribonucleoside. In some embodiments, the 5’wing region of the gapmer (X in the 5’-X- Y-Z-3' formula) comprises different high affinity nucleosides as the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula). For example, the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) may comprise one or more non-bicyclic 2’ -modified nucleosides (e.g., 2’-MOE or 2’-O-Me) and the 3’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) may comprise one or more 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt). In another example, the 3’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) may comprise one or more non-bicyclic 2’-modified nucleosides (e.g., 2’-MOE or 2’-O-Me) and the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) may comprise one or more 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt).[000271] In some embodiments, a gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z is independently 1-7 (e.g., 1, 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein each nucleoside in X is a non- bicyclic 2’-modified nucleoside (e.g., 2’-MOE or 2’-O-Me), each nucleoside in Z is a 2’-4’ bicyclic nucleoside (e.g., LNA or cEt), and each nucleoside in Y is a 2’ -deoxyribonucleoside. In some embodiments, the gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z is independently 1-7 (e.g., 1, 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein each nucleoside in X is a 2’-4’ bicyclic nucleoside(e.g., LNA or cEt), each nucleoside in Z is a non-bicyclic 2’-modified nucleoside (e.g., 2’- MOE or 2’-0-Me) and each nucleoside in Y is a 2’ -deoxyribonucleoside.[000272] In some embodiments, the 5 ’wing region of a gapmer (X in the 5’-X-Y-Z-3' formula) comprises one or more non-bicyclic 2’ -modified nucleosides (e.g., 2’ -MOE or 2’-O- Me) and one or more 2’-4’ bicyclic nucleosides (e.g., LNA or cEt). In some embodiments, the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) comprises one or more non- bicyclic 2’-modified nucleosides (e.g., 2’-MOE or 2’-O-Me) and one or more 2’-4’ bicyclic nucleosides (e.g., LNA or cEt). In some embodiments, both the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and the 3 ’wing region of the gapmer (Z in the 5’-X-Y-Z-3' formula) comprise one or more non-bicyclic 2’-modified nucleosides (e.g., 2’-MOE or 2’-O- Me) and one or more 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt).[000273] In some embodiments, a gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z are independently 2-7 (e.g., 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein at least one but not all (e.g., 1, 2, 3, 4, 5, or 6) of positions 1, 2, 3, 4, 5, 6, or 7 in X (the 5’ most position is position 1) is a non- bicyclic 2’-modified nucleoside (e.g., 2’-MOE or 2’-O-Me), wherein the rest of the nucleosides in both X and Z are 2’ -4’ bicyclic nucleosides (e.g., LNA or cEt), and wherein each nucleoside in Y is a 2’deoxyribonucleoside. In some embodiments, the gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z are independently 2-7 (e.g., 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein at least one but not all (e.g., 1, 2, 3, 4, 5, or 6) of positions 1, 2, 3, 4, 5, 6, or 7 in Z (the 5’ most position is position 1) is a non-bicyclic 2’-modified nucleoside (e.g., 2’-MOE or 2’-O-Me), wherein the rest of the nucleosides in both X and Z are 2’-4’ bicyclic nucleosides (e.g., LNA or cEt), and wherein each nucleoside in Y is a 2’deoxyribonucleoside. In some embodiments, the gapmer comprises a 5’-X-Y-Z-3' configuration, wherein X and Z are independently 2-7 (e.g., 2, 3, 4, 5, 6, or 7) nucleosides in length and Y is 6-10 (e.g., 6, 7, 8, 9, or 10) nucleosides in length, wherein at least one but not all (e.g., 1, 2, 3, 4, 5, or 6) of positions 1, 2, 3, 4, 5, 6, or 7 in X and at least one of positions but not all (e.g., 1, 2, 3, 4, 5, or 6) of positions 1, 2, 3, 4, 5, 6, or 7 in Z (the 5’ most position is position 1) is a non-bicyclic 2’-modified nucleoside (e.g., 2’-M0E or 2’-0-Me), wherein the rest of the nucleosides in both X and Z are 2’-4’ bicyclic nucleosides (e.g., LNA or cEt), and wherein each nucleoside in Y is a 2’deoxyribonucleoside.[000274] Non-limiting examples of gapmers configurations with a mix of non-bicyclic 2’-modified nucleoside (e.g., 2’-M0E or 2’-0-Me) and 2’-4’ bicyclic nucleosides (e.g., LNA or cEt) in the 5’wing region of the gapmer (X in the 5’-X-Y-Z-3' formula) and / or the 3 ’wingregion of the gapmer (Z in the 5’-X-Y-Z-3' formula) include: BBB-(D)n-BBBAA; KKK-(D)n- KKKAA; LLL-(D)n-LLLAA; BBB-(D)n-BBBEE; KKK-(D)n-KKKEE; LLL-(D)n-LLLEE; BBB-(D)n-BBBAA; KKK-(D)n-KKKAA; LLL-(D)n-LLLAA; BBB-(D)n-BBBEE; KKK- (D)n-KKKEE; LLL-(D)n-LLLEE; BBB-(D)n-BBBAAA; KKK-(D)n-KKKAAA; LLL-(D)n- LLLAAA; BBB-(D)n-BBBEEE; KKK-(D)n-KKKEEE; LLL-(D)n-LLLEEE; BBB-(D)n- BBBAAA; KKK-(D)n-KKKAAA; LLL-(D)n-LLLAAA; BBB-(D)n-BBBEEE; KKK-(D)n- KKKEEE; LLL-(D)n-LLLEEE; BABA-(D)n-ABAB; KAKA-(D)n-AKAK; LALA-(D)n- ALAL; BEBE-(D)n-EBEB; KEKE-(D)n-EKEK; LELE-(D)n-ELEL; BABA-(D)n-ABAB; KAKA-(D)n-AKAK; LALA-(D)n-ALAL; BEBE-(D)n-EBEB; KEKE-(D)n-EKEK; LELE- (D)n-ELEL; ABAB-(D)n-ABAB; AKAK-(D)n-AKAK; ALAL-(D)n-ALAL; EBEB-(D)n- EBEB; EKEK-(D)n-EKEK; ELEL-(D)n-ELEL; ABAB-(D)n-ABAB; AKAK-(D)n-AKAK; ALAL-(D)n-ALAL; EBEB-(D)n-EBEB; EKEK-(D)n-EKEK; ELEL-(D)n-ELEL; AABB- (D)n-BBAA; BBAA-(D)n-AABB; AAKK-(D)n-KKAA; AALL-(D)n-LLAA; EEBB-(D)n- BBEE; EEKK-(D)n-KKEE; EELL-(D)n-LLEE; AABB-(D)n-BBAA; AAKK-(D)n-KKAA; AALL-(D)n-LLAA; EEBB-(D)n-BBEE; EEKK-(D)n-KKEE; EELL-(D)n-LLEE; BBB-(D)n- BBA; KKK-(D)n-KKA; LLL-(D)n-LLA; BBB-(D)n-BBE; KKK-(D)n-KKE; LLL-(D)n-LLE; BBB-(D)n-BBA; KKK-(D)n-KKA; LLL-(D)n-LLA; BBB-(D)n-BBE; KKK-(D)n-KKE; LLL- (D)n-LLE; BBB-(D)n-BBA; KKK-(D)n-KKA; LLL-(D)n-LLA; BBB-(D)n-BBE; KKK-(D)n- KKE; LLL-(D)n-LLE; ABBB-(D)n-BBBA; AKKK-(D)n-KKKA; ALLL-(D)n-LLLA; EBBB- (D)n-BBBE; EKKK-(D)n-KKKE; ELLL-(D)n-LLLE; ABBB-(D)n-BBBA; AKKK-(D)n- KKKA; ALLL-(D)n-LLLA; EBBB-(D)n-BBBE; EKKK-(D)n-KKKE; ELLL-(D)n-LLLE; ABBB-(D)n-BBBAA; AKKK-(D)n-KKKAA; ALLL-(D)n-LLLAA; EBBB-(D)n-BBBEE; EKKK-(D)n-KKKEE; ELLL-(D)n-LLLEE; ABBB-(D)n-BBBAA; AKKK-(D)n-KKKAA; ALLL-(D)n-LLLAA; EBBB-(D)n-BBBEE; EKKK-(D)n-KKKEE; ELLL-(D)n-LLLEE; AABBB-(D)n-BBB; AAKKK-(D)n-KKK; AALLL-(D)n-LLL; EEBBB-(D)n-BBB; EEKKK- (D)n-KKK; EELLL-(D)n-LLL; AABBB-(D)n-BBB; AAKKK-(D)n-KKK; AALLL-(D)n-LLL; EEBBB-(D)n-BBB; EEKKK-(D)n-KKK; EELLL-(D)n-LLL; AABBB-(D)n-BBBA; AAKKK- (D)n-KKKA; AALLL-(D)n-LLLA; EEBBB-(D)n-BBBE; EEKKK-(D)n-KKKE; EELLL- (D)n-LLLE; AABBB-(D)n-BBBA; AAKKK-(D)n-KKKA; AALLL-(D)n-LLLA; EEBBB- (D)n-BBBE; EEKKK-(D)n-KKKE; EELLL-(D)n-LLLE; ABBAABB-(D)n-BB; AKKAAKK- (D)n-KK; ALLAALLL-(D)n-LL; EBBEEBB-(D)n-BB; EKKEEKK-(D)n-KK; ELLEELL- (D)n-LL; ABBAABB-(D)n-BB; AKKAAKK-(D)n-KK; ALLAALL-(D)n-LL; EBBEEBB- (D)n-BB; EKKEEKK-(D)n-KK; ELLEELL-(D)n-LL; ABBABB-(D)n-BBB; AKKAKK-(D)n- KKK; ALLALLL-(D)n-LLL; EBBEBB-(D)n-BBB; EKKEKK-(D)n-KKK; ELLELL-(D)n-LLL; ABBABB-(D)n-BBB; AKKAKK-(D)n-KKK; ALLALL-(D)n-LLL; EBBEBB-(D)n- BBB; EKKEKK-(D)n-KKK; ELLELL-(D)n-LLL; EEEK-(D)n-EEEEEEEE; EEK-(D)n- EEEEEEEEE; EK-(D)n-EEEEEEEEEE; EK-(D)n-EEEKK; K-(D)n-EEEKEKE; K-(D)n- EEEKEKEE; K-(D)n-EEKEK; EK-(D)n-EEEEKEKE; EK-(D)n-EEEKEK; EEK-(D)n- KEEKE; EK-(D)n-EEKEK; EK-(D)n-KEEK; EEK-(D)n-EEEKEK; EK-(D)n-KEEEKEE; EK- (D)n-EEKEKE; EK-(D)n-EEEKEKE; and EK-(D)n-EEEEKEK;. “A” nucleosides comprise a 2'-modified nucleoside; “B” represents a 2’ -4’ bicyclic nucleoside; “K” represents a constrained ethyl nucleoside (cEt); “L” represents an LNA nucleoside; and “E” represents a 2'- MOE modified ribonucleoside; “D” represents a 2’ -deoxyribonucleoside; “n” represents the length of the gap segment (Y in the 5’-X-Y-Z-3' configuration) and is an integer between 1-20. [000275] In some embodiments, any one of the gapmers described herein comprises one or more modified nucleoside linkages (e.g., a phosphorothioate linkage) in each of the X, Y, and Z regions. In some embodiments, each intemucleoside linkage in the any one of the gapmers described herein is a phosphorothioate linkage. In some embodiments, each of the X, Y, and Z regions independently comprises a mix of phosphorothioate linkages and phosphodiester linkages. In some embodiments, each intemucleoside linkage in the gap region Y is a phosphorothioate linkage, the 5 ’wing region X comprises a mix of phosphorothioate linkages and phosphodiester linkages, and the 3 ’wing region Z comprises a mix of phosphorothioate linkages and phosphodiester linkages. iii. RNA Interference (RNAi)[000276] In some embodiments, the oligonucleotides provided herein are small interfering RNAs (siRNA), also known as short interfering RNA or silencing RNA. SiRNA, is a class of double- stranded RNA molecules, typically about 20-25 base pairs in length that target nucleic acids (e.g., mRNAs) for degradation via the RNA interference (RNAi) pathway in cells. Specificity of siRNA molecules may be determined by the binding of the antisense strand of the molecule to its target RNA. Effective siRNA molecules are generally less than 30 to 35 base pairs in length to prevent the triggering of non-specific RNA interference pathways in the cell via the interferon response, although longer siRNA can also be effective. In some embodiments, the siRNA molecules are 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more base pairs in length. In some embodiments, the siRNA molecules are 8 to 30 base pairs in length, 10 to 15 base pairs in length, 10 to 20 base pairs in length, 15 to 25 base pairs in length, 19 to 21 base pairs in length, 21 to 23 base pairs in length. In some embodiments, the siRNA molecules are 8 to 32 base pairs in length, 8 to 29 base pairs in length, 8 to 27 base pairs in length, 15 to 32 base pairs inlength, 15 to 29 base pairs in length, 15 to 27 base pairs in length, 21 to 31 base pairs in length, 21 to 29 base pairs in length, 21 to 27 base pairs in length, 21-23 base pairs in length, 23 to 32 base pairs in length, 23 to 29 base pairs in length, or 23 to 27 base pairs in length.[000277] Following selection of an appropriate target RNA sequence, siRNA molecules that comprise a nucleotide sequence complementary to all or a portion of the target sequence, i.e. an antisense sequence, can be designed and prepared using appropriate methods (see, e.g., PCT Publication Number WO 2004 / 016735; and U.S. Patent Publication Nos. 2004 / 0077574 and 2008 / 0081791).[000278] The siRNA molecule can be double stranded (i.e., a dsRNA molecule comprising an antisense strand and a complementary sense strand) or single- stranded (i.e., a ssRNA molecule comprising just an antisense strand). The siRNA molecules can comprise a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self- complementary sense and antisense strands. In some embodiments, the oligonucleotide described herein is an siRNA comprising an antisense strand and a sense strand.[000279] In some embodiments, the antisense strand of the siRNA molecule is 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more nucleotides in length. In some embodiments, the antisense strand is 8 to 50 nucleotides in length, 8 to 40 nucleotides in length, 8 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 19 to 21 nucleotides in length, 21 to 23 nucleotides in lengths. In some embodiments, the antisense strand is 8 to 32 nucleotides in length, 8 to 29 nucleotides in length, 8 to 27 nucleotides in length, 15 to 32 nucleotides in length, 15 to 29 nucleotides in length, 15 to 27 nucleotides in length, 21 to 31 nucleotides in length, 21 to 29 nucleotides in length, 21 to 27 nucleotides in length, 21-23 nucleotides in length, 23 to 32 nucleotides in length, 23 to 29 nucleotides in length, or 23 to 27 nucleotides in length.[000280] In some embodiments, the sense strand of the siRNA molecule is 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more nucleotides in length. In some embodiments, the sense strand is 8 to 50 nucleotides in length,8 to 40 nucleotides in length, 8 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 19 to 21 nucleotides in length, 21 to 23 nucleotides in lengths. In some embodiments, the sense strand is 8 to 32 nucleotides in length, 8 to 29 nucleotides in length, 8 to 27 nucleotides in length, 15 to 32 nucleotides in length, 15 to 29 nucleotides in length, 15 to 27 nucleotides in length, 21 to 31 nucleotides in length, 21 to 29nucleotides in length, 21 to 27 nucleotides in length, 21-23 nucleotides in length, 23 to 32 nucleotides in length, 23 to 29 nucleotides in length, or 23 to 27 nucleotides in length. [000281] In some embodiments, siRNA molecules comprise an antisense strand comprising a region of complementarity to a target region in a DUX4 mRNA. In some embodiments, the region of complementarity is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to a target region in a DUX4 mRNA. In some embodiments, the target region is a region of consecutive nucleotides in the DUX4 mRNA. In some embodiments, a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable or specific for a target RNA sequence.[000282] In some embodiments, siRNA molecules comprise an antisense strand that comprises a region of complementarity to a DUX4 mRNA sequence and the region of complementarity is in the range of 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 nucleotides in length. In some embodiments, a region of complementarity is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the region of complementarity is complementary with at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25 or more consecutive nucleotides of a DUX4 mRNA sequence. In some embodiments, the region of complementarity comprises a nucleotide sequence that contains no more than 1, 2, 3, 4, or 5 base mismatches compared to the complementary portion of a DUX4 mRNA sequence. In some embodiments, the region of complementarity comprises a nucleotide sequence that has up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.[000283] Double-stranded siRNA may comprise sense and antisense RNA strands that are the same length or different lengths. Double- stranded siRNA molecules can also be assembled from a single oligonucleotide in a stem-loop structure, wherein self-complementary sense and antisense regions of the siRNA molecule are linked by means of a nucleic acid based or non-nucleic acid-based linker(s), as well as circular single- stranded RNA having two or more loop structures and a stem comprising self-complementary sense and antisense strands, wherein the circular RNA can be processed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNAi. Small hairpin RNA (shRNA) molecules thus are also contemplated herein. These molecules comprise a specific antisense sequence in additionto the reverse complement (sense) sequence, typically separated by a spacer or loop sequence. Cleavage of the spacer or loop provides a single- stranded RNA molecule and its reverse complement, such that they may anneal to form a dsRNA molecule (optionally with additional processing steps that may result in addition or removal of one, two, three or more nucleotides from the 3’ end and / or (e.g., and) the 5’ end of either or both strands). A spacer can be of a sufficient length to permit the antisense and sense sequences to anneal and form a doublestranded structure (or stem) prior to cleavage of the spacer (and, optionally, subsequent processing steps that may result in addition or removal of one, two, three, four, or more nucleotides from the 3’ end and / or (e.g., and) the 5’ end of either or both strands). A spacer sequence may be an unrelated nucleotide sequence that is situated between two complementary nucleotide sequence regions which, when annealed into a double- stranded nucleic acid, comprise a shRNA.[000284] The overall length of the siRNA molecules can vary from about 14 to about 100 nucleotides depending on the type of siRNA molecule being designed. Generally, between about 14 and about 50 of these nucleotides are complementary to the RNA target sequence, i.e., constitute the specific antisense sequence of the siRNA molecule. For example, when the siRNA is a double- or single- stranded siRNA, the length can vary from about 14 to about 50 nucleotides, whereas when the siRNA is a shRNA or circular molecule, the length can vary from about 40 nucleotides to about 100 nucleotides.[000285] An siRNA molecule may comprise a 3’ overhang at one end of the molecule. The other end may be blunt-ended or have also an overhang (5’ or 3’). When the siRNA molecule comprises an overhang at both ends of the molecule, the length of the overhangs may be the same or different. In one embodiment, the siRNA molecule of the present disclosure comprises 3’ overhangs of about 1 to about 3 (e.g., 1, 2, 3) nucleotides on both ends of the molecule. In some embodiments, the siRNA molecule comprises 3’ overhangs of about 1 to about 3 nucleotides on the sense strand. In some embodiments, the siRNA molecule comprises 3’ overhangs of about 1 to about 3 (e.g., 1, 2, 3) nucleotides on the antisense strand. In some embodiments, the siRNA molecule comprises 3’ overhangs of about 1 to about 3 (e.g., 1, 2, 3) nucleotides on both the sense strand and the antisense strand.[000286] In some embodiments, the siRNA molecule comprises one or more modified nucleotides (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more). In some embodiments, the siRNA molecule comprises one or more modified nucleotides and / or (e.g., and) one or more modified intemucleoside linkages. In some embodiments, the modified nucleotide is a modified sugar moiety (e.g., a 2’ modified nucleotide). In some embodiments, the siRNA molecule comprisesone or more 2’ modified nucleotides, e.g., a 2’-deoxy, 2’-fluoro (2’-F), 2’-O-methyl (2’-O- Me), 2’-O-methoxyethyl (2’-M0E), 2’-O-aminopropyl (2’-O-AP), 2’-O-dimethylaminoethyl (2’-0-DMA0E), 2’-O-dimethylaminopropyl (2’-0-DMAP), 2’-O- dimethylaminoethyloxyethyl (2’-0-DMAE0E), or 2’-O-N-methylacetamido (2’-0-NMA). In some embodiments, each nucleotide of the siRNA molecule is a modified nucleotide (e.g., a 2’ -modified nucleotide). In some embodiments, the siRNA molecule comprises one or more 2’-O-methyl modified nucleotides. In some embodiments, the siRNA molecule comprises one or more 2’-F modified nucleotides. In some embodiments, the siRNA molecule comprises one or more 2’-O-methyl and 2’-F modified nucleotides.[000287] In some embodiments, the siRNA molecule contains a phosphorothioate or other modified intemucleotide linkage. In some embodiments, the siRNA molecule comprises phosphorothioate internucleoside linkages. In some embodiments, the siRNA molecule comprises phosphorothioate internucleoside linkages between at least two nucleotides. In some embodiments, the siRNA molecule comprises phosphorothioate intemucleoside linkages between all nucleotides. For example, in some embodiments, the siRNA molecule comprises modified intemucleotide linkages at the first, second, and / or (e.g., and) third internucleoside linkage at the 5’ or 3’ end of the siRNA molecule.[000288] In some embodiments, the modified intemucleotide linkages are phosphorus- containing linkages. In some embodiments, phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3’ alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3 ’-amino phosphoramidate and aminoalky Iphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.[000289] Any of the modified chemistries or formats of siRNA molecules described herein can be combined with each other. For example, one, two, three, four, five, or more different types of modifications can be included within the same siRNA molecule.[000290] In some embodiments, the antisense strand comprises one or more modified nucleotides (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more). In some embodiments, the antisense strand comprises one or more modified nucleotides and / or (e.g., and) one or more modified intemucleotide linkages. In some embodiments, the modified nucleotide comprises a modified sugar moiety (e.g., a 2’ modified nucleotide). In some embodiments, the antisense strand comprises one or more 2’ modified nucleotides, e.g., a 2’-deoxy, 2’-fluoro (2’-F), 2’-O-methyl (2’-O-Me), 2’-O-methoxyethyl (2’-MOE), 2’-O-aminopropyl (2’-O-AP), 2’-O- dimethylaminoethyl (2’-O-DMAOE), 2’-O-dimethylaminopropyl (2’-O-DMAP), 2’-O- dimethylaminoethyloxyethyl (2’-O-DMAEOE), or 2’-O-N-methylacetamido (2’-O-NMA). In some embodiments, each nucleotide of the antisense strand is a modified nucleotide (e.g., a 2’- modified nucleotide). In some embodiments, the antisense strand comprises one or more 2’-O- methyl modified nucleotides. In some embodiments, the antisense strand comprises one or more 2’-F modified nucleotides. In some embodiments, the antisense strand comprises one or more 2’-O-methyl and 2’-F modified nucleotides.[000291] In some embodiments, antisense strand contains a phosphorothioate or other modified intemucleotide linkage. In some embodiments, the antisense strand comprises phosphorothioate internucleoside linkages. In some embodiments, the antisense strand comprises phosphorothioate internucleoside linkages between at least two nucleotides. In some embodiments, the antisense strand comprises phosphorothioate internucleoside linkages between all nucleotides. For example, in some embodiments, the antisense strand comprises modified intemucleotide linkages at the first, second, and / or (e.g., and) third internucleoside linkage at the 5’ or 3’ end of the siRNA molecule. In some embodiments, the two intemucleoside linkages at the 3’ end of the antisense strands are phosphorothioate intemucleoside linkages.[000292] In some embodiments, the modified intemucleotide linkages are phosphorus- containing linkages. In some embodiments, phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3’alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3 ’-amino phosphoramidate and aminoalky Iphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196;5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.[000293] Any of the modified chemistries or formats of the antisense strand described herein can be combined with each other. For example, one, two, three, four, five, or more different types of modifications can be included within the same antisense strand.[000294] In some embodiments, the sense strand comprises one or more modified nucleotides (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more). In some embodiments, the sense strand comprises one or more modified nucleotides and / or (e.g., and) one or more modified intemucleotide linkages. In some embodiments, the modified nucleotide comprises a modified sugar moiety (e.g., a 2’ modified nucleotide). In some embodiments, the sense strand comprises one or more 2’ modified nucleotides, e.g., a 2’-deoxy, 2’-fluoro (2’-F), 2’-O-methyl (2’-O-Me), 2’-O-methoxyethyl (2’-MOE), 2’-O-aminopropyl (2’-O-AP), 2’-O- dimethylaminoethyl (2’-O-DMAOE), 2’-O-dimethylaminopropyl (2’-O-DMAP), 2’-O- dimethylaminoethyloxyethyl (2’-O-DMAEOE), or 2’-O-N-methylacetamido (2’-O-NMA). In some embodiments, each nucleotide of the sense strand is a modified nucleotide (e.g., a 2’- modified nucleotide). In some embodiments, the sense strand comprises one or more phosphorodiamidate morpholinos. In some embodiments, the sense strand is a phosphorodiamidate morpholino oligomer (PMO). In some embodiments, the sense strand comprises one or more 2’-O-methyl modified nucleotides. In some embodiments, the sense strand comprises one or more 2’-F modified nucleotides. In some embodiments, the sense strand comprises one or more 2’-O-methyl and 2’-F modified nucleotides.[000295] In some embodiments, the sense strand contains a phosphorothioate or other modified intemucleotide linkage. In some embodiments, the sense strand comprises phosphorothioate internucleoside linkages. In some embodiments, the sense strand comprises phosphorothioate internucleoside linkages between at least two nucleotides. In some embodiments, the sense strand comprises phosphorothioate internucleoside linkages between all nucleotides. For example, in some embodiments, the sense strand comprises modified intemucleotide linkages at the first, second, and / or (e.g., and) third intemucleoside linkage at the 5’ or 3’ end of the sense strand. In some embodiments, the sense strand comprises phosphodiester intemucleoside linkage. In some embodiments, the sense strand does not comprise phosphorothioate intemucleoside linkage. In some embodiments, the modified intemucleotide linkages are phosphoms-containing linkages. In some embodiments, phosphorus-containing linkages that may be used include, but are not limited to,phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3 ’alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.[000296] Any of the modified chemistries or formats of the sense strand described herein can be combined with each other. For example, one, two, three, four, five, or more different types of modifications can be included within the same sense strand.[000297] In some embodiments, the antisense or sense strand of the siRNA molecule comprises modifications that enhance or reduce RNA-induced silencing complex (RISC) loading. In some embodiments, the antisense strand of the siRNA molecule comprises modifications that enhance RISC loading. In some embodiments, the sense strand of the siRNA molecule comprises modifications that reduce RISC loading and reduce off-target effects. In some embodiments, the antisense strand of the siRNA molecule comprises a 2'-O- methoxyethyl (2’-M0E) modification. The addition of the 2'-O-methoxyethyl (2’-M0E) group at the cleavage site improves both the specificity and silencing activity of siRNAs by facilitating the oriented RNA-induced silencing complex (RISC) loading of the modified strand, as described in Song et al., (2017) Mol Ther Nucleic Acids 9:242-250, incorporated herein by reference in its entirety. In some embodiments, the antisense strand of the siRNA molecule comprises a 2'-Ome-phosphorodithioate modification, which increases RISC loading as described in Wu et al., (2014) Nat Commun 5:3459, incorporated herein by reference in its entirety.[000298] In some embodiments, the sense strand of the siRNA molecule comprises a 5’- morpholino, which reduces RISC loading of the sense strand and improves antisense strand selection and RNAi activity, as described in Kumar et al., (2019) Chem Commun (Camb) 55(35):5139-5142, incorporated herein by reference in its entirety. In some embodiments, the sense strand of the siRNA molecule is modified with a synthetic RNA-like high affinity nucleotide analogue, Locked Nucleic Acid (LNA), which reduces RISC loading of the sensestrand and further enhances antisense strand incorporation into RISC, as described in Elman et al., (2005) Nucleic Acids Res. 33(1): 439-447, incorporated herein by reference in its entirety. In some embodiments, the sense strand of the siRNA molecule comprises a 5' unlocked nucleic acid (UNA) modification, which reduce RISC loading of the sense strand and improve silencing potency of the antisense strand, as described in Snead et al., (2013) Mol Ther Nucleic Acids 2(7) :e 103, incorporated herein by reference in its entirety. In some embodiments, the sense strand of the siRNA molecule comprises a 5-nitroindole modification, which decreased the RNAi potency of the sense strand and reduces off-target effects as described in Zhang et al., (2012) Chembiochem 13(13): 1940- 1945, incorporated herein by reference in its entirety. In some embodiments, the sense strand comprises a 2’-O’methyl (2’-O-Me) modification, which reduces RISC loading and the off-target effects of the sense strand, as described in Zheng et al., FASEB (2013) 27(10): 4017-4026, incorporated herein by reference in its entirety. In some embodiments, the sense strand of the siRNA molecule is fully substituted with morpholino, 2’- MOE or 2’-O-Me residues, and are not recognized by RISC as described in Kole et al., (2012) Nature reviews. Drug Discovery 11(2): 125- 140, incorporated herein by reference in its entirety. In some embodiments the antisense strand of the siRNA molecule comprises a 2’- MOE modification and the sense strand comprises a 2’-O-Me modification (see e.g., Song et al., (2017) Mol Ther Nucleic Acids 9:242-250). In some embodiments at least one (e.g., at least 2, at least 3, at least 4, at least 5, at least 10) siRNA molecule is linked (e.g., covalently) to a muscle-targeting agent. In some embodiments, the muscle-targeting agent may comprise, or consist of, a nucleic acid (e.g., DNA or RNA), a peptide (e.g., an antibody), a lipid (e.g., a microvesicle), or a sugar moiety (e.g., a polysaccharide). In some embodiments, the muscletargeting agent is an antibody. In some embodiments, the muscle-targeting agent is an antitransferrin receptor antibody (e.g., any one of the anti-TfRl antibodies provided in Tables 2-7). In some embodiments, the muscle-targeting agent may be linked to the 5’ end of the sense strand of the siRNA molecule. In some embodiments, the muscle-targeting agent may be linked to the 3’ end of the sense strand of the siRNA molecule. In some embodiments, the muscle-targeting agent may be linked internally to the sense strand of the siRNA molecule. In some embodiments, the muscle-targeting agent may be linked to the 5’ end of the antisense strand of the siRNA molecule. In some embodiments, the muscle-targeting agent may be linked to the 3’ end of the antisense strand of the siRNA molecule. In some embodiments, the muscle-targeting agent may be linked internally to the antisense strand of the siRNA molecule.C. Linkers[000299] Complexes described herein generally comprise a linker that covalently links any one of the anti-TfRl antibodies described herein to a molecular pay load. A linker comprises at least one covalent bond. In some embodiments, a linker may be a single bond, e.g., a disulfide bond or disulfide bridge, that covalently links an anti-TfRl antibody to a molecular payload. However, in some embodiments, a linker may covalently link any one of the anti-TfRl antibodies described herein to a molecular pay load through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker. A linker is typically stable in vitro and in vivo, and may be stable in certain cellular environments. Additionally, typically a linker does not negatively impact the functional properties of either the anti-TfRl antibody or the molecular payload. Examples and methods of synthesis of linkers are known in the art (see, e.g., Kline, T. et al. “Methods to Make Homogenous Antibody Drug Conjugates.” Pharmaceutical Research, 2015, 32:11, 3480-3493.; Jain, N. et al. “Current ADC Linker Chemistry” Pharm Res. 2015, 32:11, 3526-3540.; McCombs, J.R. and Owen, S.C. “Antibody Drug Conjugates: Design and Selection of Linker, Pay load and Conjugation Chemistry” AAPS J. 2015, 17:2, 339-351.).[000300] A linker typically will contain two different reactive species that allow for attachment to both the anti-TfRl antibody and a molecular pay load. In some embodiments, the two different reactive species may be a nucleophile and / or an electrophile. In some embodiments, a linker contains two different electrophiles or nucleophiles that are specific for two different nucleophiles or electrophiles. In some embodiments, a linker is covalently linked to an anti-TfRl antibody via conjugation to a lysine residue or a cysteine residue of the anti- TfRl antibody. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfRl antibody via a maleimide-containing linker, wherein optionally the maleimide- containing linker comprises a maleimidocaproyl or maleimidomethyl cyclohexane- 1- carboxylate group. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfRl antibody or thiol functionalized molecular payload via a 3 -arylpropionitrile functional group. In some embodiments, a linker is covalently linked to a lysine residue of an anti-TfRl antibody. In some embodiments, a linker is covalently linked to an anti-TfRl antibody and / or (e.g., and) a molecular pay load, independently, via an amide bond, a carbamate bond, a hydrazide, a triazole, a thioether, and / or a disulfide bond.[000301] Examples of complexes that may be used as a therapy for ESHD is provided in WO2021188390 and WO2023043953, the entire contents of which are incorporated herein by reference.IV. Therapeutic Agents for Treating FSHD[000302] In some embodiments, a subject of the present disclosure that has Facioscapulohumeral muscular dystrophy (FSHD) is undergoing treatment for FSHD with any suitable therapeutic agents. Two types of FSHD, Type 1 and Type 2, have been described. Type 1 is associated with deletions in D4Z4 repeat regions on chromosome 4 which contains the DUX4 gene. In some embodiments, Type 1 is associated with deletions in D4Z4 repeat regions on chromosome 4 allelic variant 4qA which contains the DUX4 gene. Type 2 is associated with mutations in the SMCHD1 gene, DNMT3B gene, or LRIF1 gene (see, e.g., Jia et al., “Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings” Neuromuscul Disord. (2021), 31(11): 1101-1112. Both Type 1 and Type 2 FSHD are characterized by aberrant production of the DUX4 protein after fetal development outside of the testes. Facioscapulohumeral dystrophy, the genetic basis for the disease, and related symptoms are described in the art (see, e.g., Campbell, A.E., et al., “Facioscapulohumeral dystrophy: Activating an early embryonic transcriptional program in human skeletal muscle” Human Mol Genet. (2018); and Tawil, R. “Facioscapulohumeral muscular dystrophy” Handbook Clin. Neurol. (2018), 148: 541-548.) FSHD Type 1 is associated with Online Mendelian Inheritance in Man (OMIM) Entry # 158900. FSHD Type 2 is associated with OMIM Entry # 158901.[000303] In some embodiments, the subject is undergoing a treatment for FSHD with a therapeutic agent (e.g., complexes that comprise a targeting agent, e.g., an antibody, covalently linked to a molecular pay load). In some embodiments, a therapeutic agent is a complex that comprises a targeting agent, e.g., an antibody, covalently linked to a molecular payload. In some embodiments, a complex comprises a muscle-targeting antibody covalently linked to an oligonucleotide. A complex may comprise an antibody that specifically binds a single antigenic site or that binds to at least two antigenic sites that may exist on the same or different antigens. In some embodiments, the molecular payload is an oligonucleotide that targets DUX4.[000304] In some embodiments, a therapeutic agent is a complex as described herein. In some embodiments, a complex for use in accordance with the present disclosure for treating FSHD comprises a muscle-targeting agent, e.g., an anti-TfRl antibody, covalently linked to a molecular payload, e.g., an antisense oligonucleotide that targets DUX4, such as a nucleic acid comprising a disease-associated repeat, e.g., a DUX4 allele. In some embodiments, the oligonucleotide is an antisense oligonucleotide that targets a DUX4 RNA to reduce expressionor activity of DUX4 (e.g., reduce the level of a mutant or wild-type DUX4 RNA, or the activity of a DUX4 gene product). In some embodiments, a complex comprises a muscletargeting antibody (e.g., an anti-transferrin receptor 1 (TfRl) antibody) covalently linked to one or more oligonucleotides. In some embodiments, complexes described herein comprise a linker that covalently links an antibody (e.g., an anti-TfRl antibody) described herein to an oligonucleotide (e.g., an oligonucleotide comprising a RNAi oligonucleotide such as an siRNA). A linker comprises at least one covalent bond.[000305] In some embodiments, non-limiting examples of complexes that may be used for treating FSHD in accordance with the present disclosure are provided in US11111309, US11286305, US11390682, US11518816, US11787869, US11795233, US11795234, US12018087, US12012460, US20240309107, US20240287201, US20230088865, US20230272065, US2024011018, US20230045314, US20230285582, US20230118799, US20230321264, US20240066140, US20240238435, US11912779, US11555190, and W02024 / 011135, the entire contents each of which are incorporated herein by reference. [000306] In some embodiments, a complex for use in accordance with the present disclosure for treating FSHD comprises an anti-TfRl antibody covalently linked to one or more oligonucleotides, wherein the anti-TfRl antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPING RSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLV TVSS and / or (e.g., and) a light chain variable region (VL) comprising the amino acid sequence ofDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGV PSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIK, wherein the one or more oligonucleotides of the complexes is an RNAi oligonucleotide comprising a sense strand comprising a nucleobase sequence of CGACGGAGACUCGUUUGGA and an antisense strand comprising a nucleobase sequence of UCCAAACGAGUCUCCGUCGUU.[000307] In some embodiments, the anti-TfRl antibody is covalently linked to the one or more oligonucleotides linker via a linker at the 5’ end of the sense strand.[000308] In some embodiments, the linker comprises 5'-[6-[[[4-[(3-mercapto-2,5-dioxo- 1- pyrrolidinyl)methyl] cyclohexyl] carbonyl] amino]hexyl hydrogen phosphate] linker.[000309] In some embodiments, the sense strand comprises the structure: Cm*Gm*AmCmGmGmAfGfAfCmUmCmGmUmUmUmGm*Gm*Am, wherein: Am, Cm, Gm, and Um are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and2’-O-methyl uridine, respectively; Af, Cf, Gf, and Uf are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence of between two nucleosides represents a phosphodiester internucleoside linkage.[000310] In some embodiments, the antisense strand comprises the structure: Um*Cf*CmAmAmAfCmGmAmGmUmCmUmCfCmGfUmCmGm*Um*Um, wherein: Am, Cm, Gm, and Um are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and 2’-O-methyl uridine, respectively; Af, Cf, Gf, and Uf are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester internucleoside linkage.[000311] In some embodiments, the sense strand comprises the structure: 5'-[6-[[[4-[(3- mercapto-2,5 -dioxo- 1- pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]hexyl hydrogen phosphate-(Cm*Gm*AmCmGmGmAfGfAfCmUmCmGmUmUmUmGm*Gm*Am), wherein: Am, Cm, Gm, and Um are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and 2’-O-methyl uridine, respectively; Af, Cf, Gf, and Uf are 2’ -fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester intemucleoside linkage.[000312] In some embodiments, complexes described herein comprise a structure of formula (I): [R^ni-R2, in which each R1independently comprises a compound comprising an oligonucleotide (e.g., an RNAi oligonucleotide) and R2comprises an antibody (e.g., an anti- TfRl antibody), and wherein in each complex nl is independently an integer (e.g., one or greater) representing the number of instances of R1in each complex. In some embodiments, each R1independently comprises a group comprising an oligonucleotide. In some embodiments, each R1independently comprises a group that comprises additional elements in addition to an oligonucleotide. In some embodiments, R2comprises an antibody e.g., an anti- TfRl antibody) comprising a heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region, and a light chain comprising a light chain variable region (VL) and a light chain constant region. In some embodiments, each R1of a complex is independently covalently linked to a different amino acid residue (e.g., lysine or cysteine) of R2.[000313] In some embodiments, in each complex, nl is independently an integer (e.g., one or greater). In some embodiments, the antibody comprises a sequence as set forth in Table5. For example, in some embodiments, the antibody comprises a heavy chain complementarity determining region 1 (CDR-H1) comprising a sequence as set forth in SEQ ID NOs: 1, 7, or 12, a heavy chain complementarity determining region 2 (CDR-H2) comprising a sequence as set forth in SEQ ID NOs: 2, 8, or 13, a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence as set forth in SEQ ID NOs: 3, 9, or 14; and / or comprises a light chain complementarity determining region 1 (CDR-L1) comprising a sequence as set forth in SEQ ID NOs: 4, 10, or 15, a light chain complementarity determining region 2 (CDR- L2) comprising a sequence as set forth in SEQ ID NOs: 5 or 11, and a light chain complementarity determining region 3 (CDR-L3) comprising a sequence as set forth in SEQ ID NO: 6 or 16. In some embodiments, the antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 17 and / or comprises a light chain variable region (VL) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 18. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and / or comprises a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 19 and / or comprises a light chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 20. In some embodiments, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and / or comprises a light chain comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody is a Fab fragment, a full- length IgG, a Fab' fragment, a F(ab')2 fragment, an scFv, or an Fv. In some embodiments, the antibody is a Fab fragment.[000314] In some embodiments, the value of nl of each or any complex is an integer up to the number of amino acid residues in the antibody to which conjugation is desired or targeted e.g., the number of lysine residues). In some embodiments, in each complex the value of nl is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27. In some embodiments, in each complex the value of nl is 1. In some embodiments, in each complex the value of nl is independently in the range of 1-27, 1-26, 1-10, 1-5, or 1-3. In some embodiments, compositions are provided (e.g., formulations comprising tris(hydroxymethyl)aminomethane and / or sucrose, as described herein) that comprise a plurality of different complexes. In some embodiments, the plurality of different complexes comprise a common targeting agent (e.g., an antibody) and a common oligonucleotide (e.g., an RNAi oligonucleotide, such as a DUX4-targeting RNAioligonucleotide). In such embodiments, different complex types are characterized by having different numbers of oligonucleotides covalently linked to an antibody. For example, in some embodiments, compositions are provided that comprise a plurality of complexes comprising a structure of formula (I): [ R11Ni -R2, in which each R1independently comprises a compound comprising an oligonucleotide (e.g., a DUX4-targeting RNAi oligonucleotide) and R2comprises an antibody (e.g., anti-TfRl antibody), and in which nl is an integer representing the number of instances of R1in a complex, and in which different complexes of the composition may have different nl values (e.g., nl values in the range of 1-27, 1-26, 1-10, 1-5, or 1-3). In some embodiments, in each complex the value of nl is independently selected from1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27. In some embodiments, in each complex the value of nl is 1. In some embodiments, the average value of nl of complexes of the composition is in the range of 0.5 to 5 (e.g., 0.5-5, 1-5, 1-4, 1- 3, 3-5, 0.5-4, 0.5-3, 0.5-2, 0.5-1.5, 0.5-1, 0.7-1.5, 1-1.6, 1-1.5, 1-1.4, 1-1.3, 1-1.2, 1.1-1.5, 0.8-2, 0.8-1.5, 0.8-1.3, 0.8-1.2, 0.8-1.1, 0.9-3, 0.9-2, 0.9-1.8, 0.9-1.6, 0.9-1.5, 0.9-1.4, 0.9-1.3, or 0.9- 1.2). In some embodiments, the average value of nl of complexes of the composition is 1. [000315] In some embodiments, a composition described herein comprises an antibody that is not conjugated to an oligonucleotide (e.g., in trace amounts) and an antibody conjugated to one or more oligonucleotides. In some embodiments, the antibody that is not conjugated to an oligonucleotide may be referred to as a compound comprising a structure of formula (I): [R^ni-R2, for which nl is zero. Accordingly, in some embodiments, a composition for administration to a subject in the methods described herein comprises compounds (e.g., complexes) comprising a structure of formula (I): [ R11ni -R2, for which each R1independently comprises a group comprising an oligonucleotide, R2comprises an antibody and nl is independently an integer of zero or greater that reflects the number of instances of R1in each compound (e.g., complex). In some embodiments, the fraction of compounds comprising a structure of formula (I): [R^ni-R2, in a composition, for which nl is zero, compared with all compounds of that structure in the composition for which nl is one or greater, is less than 10%, less than 5%, less than 1% less than 0.5%, less than 0.1%, less than 0.05%, or less than 0.01%. As such, in some embodiments, the average value of nl of complexes in a composition disclosed herein is in the range of 0.5 to 5 (e.g., 0.5-5, 1-5, 1-4, 1-3, 3-5, 0.5-4, 0.5-3, 0.5-2, 0.5-1.5, 0.5-1, 0.7-1.5, 1-1.6, 1-1.5, 1-1.4, 1-1.3, 1-1.2, 1.1-1.5, 0.8-2, 0.8-1.5, 0.8-1.3, 0.8-1.2, 0.8-1.1, 0.9-3, 0.9-2, 0.9-1.8, 0.9-1.6, 0.9-1.5, 0.9-1.4, 0.9-1.3, or 0.9-1.2). In some embodiments, the average value of nl of complexes of the composition is 1.[000316] In some embodiments, each instance of R1in a complex is covalently linked to a different amino acid residue of the antibody. In some embodiments, an amino acid to which R1is covalently linked comprises an 8-amino group (e.g., lysine, arginine). In some embodiments, an amino acid to which R1is covalently linked is a lysine. In some embodiments, an amino acid to which R1is covalently linked is a cysteine. In some embodiments, R1is directly covalently linked to an amino acid residue of the antibody. However, in some embodiments, R1is indirectly covalently linked to an amino acid of the antibody, e.g., covalently linked to a glycosylation site on the amino acid. In some embodiments, R1is not covalently linked to an amino acid residue residing in a CDR region of the antibody.[000317] In some embodiments, complexes provided herein (e.g., in compositions or formulations described herein) comprise a structure of formula (I): | R1|H i-R2, in which each instance of R1independently comprises a group of the formula (la):(la), or a pharmaceutically acceptable salt thereof, in which R3comprises an oligonucleotide, e.g., an RNAi oligonucleotide; and R1is covalently linked e.g., indirectly or directly linked, e.g., directly linked) to R2at attachment point A. In some embodiments, R2comprises an antibody comprising a sequence as set forth in Table 5. For example, in some embodiments, R2comprises an antibody comprising a heavy chain complementarity determining region 1 (CDR-H1) comprising a sequence as set forth in SEQ ID NOs: 1, 7, or 12, a heavy chain complementarity determining region 2 (CDR-H2) comprising a sequence as set forth in SEQ ID NOs: 2, 8, or 13, a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence as set forth in SEQ ID NOs: 3, 9, or 14; and / or comprising a light chain complementarity determining region 1 (CDR-L1) comprising a sequence as set forth in SEQ ID NOs: 4, 10, or 15, a light chain complementarity determining region 2 (CDR-L2) comprising a sequence as set forth in SEQ ID NOs: 5, or 11, and a light chain complementarity determining region 3 (CDR-L3) comprising a sequence asset forth in SEQ ID NO: 6 or 16. In some embodiments, R2comprises an antibody comprising a heavy chain variable region (VH) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 17 and / or comprising a light chain variable region (VL) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 17 and / or comprising a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a heavy chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 19 and / or comprising a light chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 20. In some embodiments, R2comprises an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and / or comprising a light chain comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, R2comprises an antibody that is a Fab fragment, a full-length IgG, a Fab' fragment, a F(ab')2 fragment, an scFv, or an Fv. In some embodiments, R2comprises an antibody that is a Fab fragment. In some embodiments, R3comprises an RNAi oligonucleotide (e.g., an siRNA) comprising an antisense strand comprising a nucleobase sequence of SEQ ID NO: 22 and a structure (5’^3’) of VP- mU*fG*mCmCmAmGmAmAmUmUmUmCmAfCmGmGmAmAmGmAmA*mC*mA (SEQ ID NO: 34), and a sense strand comprising a nucleobase sequence of SEQ ID NO: 21 and a structure (5’— >3’) of mU*mU*mCmUfUmCmCmGfUfGfAmAmAfUmUmCmUmGfG*mC*mA (SEQ ID NO: 33), wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O- methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5'- (E)-Vinylphosphonate. In some embodiments, in each complex nl is independently an integer (e.g., one or greater). In some embodiments, in each complex nl is 1.[000318] In some embodiments, complexes provided herein (e.g., in compositions or formulations described herein) comprise a structure of formula (I): | R1|H i-R2, in which each R1comprises a group of the formula (lb):(lb), or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O- methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’ -fluoro adenosine, 2’ -fluoro cytidine, 2’ -fluoro guanosine, and 2’- fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester intemucleoside linkage; and “VP” represents 5'-(E)-Vinylphosphonate; and wherein the oligonucleotide is an RNAi oligonucleotide (e.g., siRNA) comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21); wherein nl is an integer (e.g., one or greater) representing the number of instances of R1in each complex, and each R1is covalently linked to R2at attachment point A. In some embodiments, R2comprises an antibody comprising a sequence as set forth in Table 5. For example, in some embodiments, R2comprises an antibody comprising a heavy chain complementarity determining region 1 (CDR-H1) comprising a sequence as set forth in SEQ ID NOs: 1, 7, or 12, a heavy chain complementarity determining region 2 (CDR-H2) comprising a sequence as set forth in SEQ ID NOs: 2, 8, or 13, a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence as set forth in SEQ ID NOs: 3, 9, or 14; and / or comprising a light chain complementarity determining region 1 (CDR-L1) comprising a sequence as set forth in SEQ ID NOs: 4, 10, or 15, a light chain complementarity determining region 2 (CDR-L2) comprising a sequence as set forth in SEQ ID NOs: 5, or 11, and a light chain complementarity determining region 3 (CDR-L3) comprising a sequence as set forth in SEQ ID NO: 6 or 16. In some embodiments, R2comprises an antibody comprising a heavy chain variable region (VH) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 17 and / or comprising a light chain variable region (VL) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO:18. In some embodiments, R2comprises an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 17 and / or comprising a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a heavy chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 19 and / or comprising a light chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 20. In some embodiments, R2comprises an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and / or comprising a light chain comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, R2comprises an antibody that is a Fab fragment, a full-length IgG, a Fab' fragment, a F(ab')2 fragment, an scFv, or an Fv. In some embodiments, R2comprises an antibody that is a Fab fragment.[000319] In some embodiments, complexes provided herein (e.g., in compositions or formulations described herein) comprise a structure of formula (I): | R1|ni - R2, in which each R1comprises a group of the formula (Ic), in which the antisense strand and the sense strand form a double stranded oligonucleotide:(Ic), or a pharmaceutically acceptable salt thereof, wherein R1is covalently linked to R2at attachment point A. In some embodiments, nl is an integer (e.g., one or greater) representing the number of instances of R1in each complex. In some embodiments, R2comprises an antibody comprising a sequence as set forth in Table 5. For example, in some embodiments, R2comprises an antibody comprising a heavy chain complementarity determining region 1 (CDR-H1) comprising a sequence as set forth in SEQ ID NOs: 1, 7, or 12, a heavy chain complementarity determining region 2 (CDR-H2) comprising a sequence as set forth in SEQ ID NOs: 2, 8, or 13, a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence as set forth in SEQ ID NOs: 3, 9, or 14; and / or comprising a light chain complementarity determining region 1 (CDR-L1) comprising a sequence as set forth in SEQ ID NOs: 4, 10, or 15, a light chain complementarity determining region 2 (CDR-L2) comprising a sequence as set forth in SEQ ID NOs: 5, or 11, and a light chain complementarity determining region 3 (CDR-L3) comprising a sequence as set forth in SEQ ID NO: 6 or 16. In some embodiments, R2comprises an antibody comprising a heavy chain variable region (VH) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 17 and / or comprising a light chain variable region (VL) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 17 and / or comprising a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a heavy chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ IDNO: 19 and / or comprising a light chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 20. In some embodiments, R2comprises an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and / or comprising a light chain comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, R2comprises an antibody that is a Fab fragment, a full-length IgG, a Fab' fragment, a F(ab')2 fragment, an scFv, or an Fv. In some embodiments, R2comprises an antibody that is a Fab fragment.[000320] In some embodiments, complexes provided herein (e.g., in compositions or formulations described herein) comprise a structure of the formula (Id):(Id), or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O- methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’ -fluoro adenosine, 2’ -fluoro cytidine, 2’ -fluoro guanosine, and 2’- fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester intemucleoside linkage; and “VP” represents 5'-(E)-Vinylphosphonate; and wherein the oligonucleotide is an RNAi oligonucleotide (e.g., siRNA) comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21); wherein R2comprises an antibody comprising a sequence as set forth in Table 5; wherein nl is an integer (e.g., one or greater) representing the number of instances of the group enclosed by square brackets, wherein each instance of the group enclosed by square brackets is covalently linked to a different amino acid residue of the antibody, optionally wherein each different amino acid residue is a lysine. In some embodiments, R2comprises an antibody comprising a heavy chain complementarity determining region 1 (CDR-H1) comprising a sequence as setforth in SEQ ID NOs: 1, 7, or 12, a heavy chain complementarity determining region 2 (CDR- H2) comprising a sequence as set forth in SEQ ID NOs: 2, 8, or 13, a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence as set forth in SEQ ID NOs: 3, 9, or 14; and / or comprising a light chain complementarity determining region 1 (CDR-L1) comprising a sequence as set forth in SEQ ID NOs: 4, 10, or 15, a light chain complementarity determining region 2 (CDR-L2) comprising a sequence as set forth in SEQ ID NOs: 5, or 11, and a light chain complementarity determining region 3 (CDR-L3) comprising a sequence as set forth in SEQ ID NO: 6 or 16. In some embodiments, R2comprises an antibody comprising a heavy chain variable region (VH) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 17 and / or comprising a light chain variable region (VL) comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 17 and / or comprising a VL comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, R2comprises an antibody comprising a heavy chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 19 and / or comprising a light chain comprising an amino acid sequence at least 85% (e.g., at least 95%) identical to SEQ ID NO: 20. In some embodiments, R2comprises an a...

Claims

CLAIMSWhat is claimed is:

1. A method comprising:(i) measuring the expression level of one or more plasma biomarkers in a subject; and(ii) determining that the subject has FSHD based on the expression levels of the one or more plasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD.

2. The method of claim 1, further comprising: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD.

3. The method of claim 2, further comprising: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more plasma biomarkers in the subject.

4. A method comprising:(i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and(ii) measuring the expression level of one or more plasma biomarkers in a subject.

5. The method of claim 4, further comprising determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more plasma biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

6. The method of any one of claims 1-5, wherein the one or more plasma biomarkers are selected from ASL, ATP23, C3B, CBS, CDK5RAP3, EDEM2, FAM110A, ID1, KHDC1L, PBXIP1, STAR, TNNT2, TNNC1, TNNI3, TNNT2 / TNNC1 / TNNI3, TYRP1, and combinations thereof.

7. The method of any one of claims 1-5, wherein the one or more plasma biomarkers are selected from KHDC1L, FAM110A, TNNT2, and combinations thereof.

8. The method of any one of claims 1-7, wherein the expression levels of the one or more biomarkers is upregulated in the subject, relative to those of a healthy subject or a subject thatdoes not have FSHD, optionally wherein the one or more biomarkers are selected from KHDC1L, TNNT2, and combinations thereof.

9. The method of any one of claims 1-8, wherein the expression levels of the one or more plasma biomarkers are measured in a blood sample obtained from the subject.

10. The method of any one of claims 1-9, wherein the subject is continuously monitored for the expression level of the one or more plasma biomarkers.

11. A method comprising:(i) measuring the expression level of one or more FSHD transcriptome biomarkers in a subject; and(ii) determining that the subject has FSHD based on the expression levels of the one or more FSHD transcriptome biomarkers, relative to those of a healthy subject or a subject that does not have FSHD.

12. The method of claim 11, further comprising: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD.

13. The method of claim 12, further comprising: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more FSHD transcriptome biomarkers in the subject.

14. A method comprising:(i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and(ii) measuring the expression level of one or more FSHD transcriptome biomarkers in a subject.

15. The method of claim 14, further comprising determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more FSHD transcriptome biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

16. The method of any one of claims 11-15, wherein the one or more transcriptome biomarkers are one or more FSHD transcriptome biomarkers selected from TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2, or combinations thereof, optionally wherein the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

17. The method of any one of claims 11-16, wherein the expression levels of the one or more transcriptome biomarkers are upregulated in the subject, relative to those of a healthy subject or a subject that does not have FSHD, optionally wherein the one or more FSHD transcriptome biomarkers are selected from TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y 1 and TNNT2, or combinations thereof, further optionally wherein the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

18. The method of any one of claims 11-17, wherein the expression levels of the one or more FSHD transcriptome biomarkers are downregulated in the subject after administering to the subject a therapeutic agent for treating FSHD, relative to those prior to administering to the subject a therapeutic agent for treating FSHD, optionally wherein the one or more FSHD transcriptome biomarkers comprise TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y 1 and TNNT2, and combinations thereof, further optionally wherein the one or more FSHD transcriptome biomarkers are TRIM43, LEUTX, MBDL32, KHDC1L, CCNA1, SLC34A2, ZSCAN4, PRAMEF6, H3Y1 and TNNT2.

19. The method of any one of claims 11-19, wherein the expression levels of the one or more FSHD transcriptome biomarkers are measured in a muscle sample obtained from the subject, optionally wherein the muscle tissue sample is obtained via muscle biopsy.

20. The method of any one of claims 11-19, wherein the subject is continuously monitored for the expression level of the one or more FSHD transcriptome biomarkers.

21. A method comprising:(i) measuring the expression level of one or more inflammatory biomarkers in a subject; and(ii) determining that the subject has FSHD based on the expression levels of the one or more inflammatory biomarkers, relative to those of a healthy subject or a subject that does not have FSHD.

22. The method of claim 21, further comprising: (iii) treating the subject by administering to the subject a therapeutic agent for treating FSHD.

23. The method of claim 22, further comprising: (iv) assessing the efficacy of the treatment by measuring the expression levels of the one or more inflammatory biomarkers in the subject.

24. A method comprising:(i) administering to a subject having FSHD a therapeutic agent for treating FSHD; and(ii) measuring the expression level of one or more inflammatory biomarkers in a subject.

25. The method of claim 24, further comprising determining treatment efficacy of the therapeutic agent based on the expression levels of the one or more inflammatory biomarkers, relative to those of a healthy subject or a subject that does not have FSHD, or relative to those of the subject before receiving the therapeutic agent.

26. The method of any one of claims 21-25, wherein the one or more inflammatory biomarkers is selected from IL6, IFNG, and LGALS3, or combinations thereof, optionally wherein the one or more inflammatory biomarkers are IL6, IFNG, and LGALS3.

27. The method of any one of claims 21-26, wherein the expression levels of the one or more inflammatory biomarkers are upregulated in the subject, relative to those of a healthy subject or a subject that does not have FSHD, optionally wherein the one or more inflammatory biomarkers are selected from IL6, IFNG, and LGALS3, or combinations thereof, further optionally wherein the one or more transcriptome biomarkers are, IL6, IFNG, and LGALS3.

28. The method of any one of claims 21-27, wherein the expression levels of the one or more inflammatory biomarkers are downregulated in the subject after administering to the subject a therapeutic agent for treating FSHD, relative to those prior to administering to the subject a therapeutic agent for treating FSHD, optionally wherein the one or moreinflammatory biomarkers comprise IL6, IFNG, and LGALS3, and combinations thereof, further optionally wherein the one or more inflammatory biomarkers are IL6, IFNG, and LGALS3.

29. The method of any one of claims 21-28, wherein the expression levels of the one or more inflammatory biomarkers are measured in a muscle sample obtained from the subject, optionally wherein the muscle tissue sample is obtained via muscle biopsy.

30. The method of any one of claims 21-29, wherein the subject is continuously monitored for the expression level of the one or more inflammatory biomarkers.

31. The method of any one of claims 2-10, 12-20, and 22-30, wherein the therapeutic agent comprises a complex comprising an anti-transferrin receptor 1 (TfRl) antibody covalently linked to a molecular pay load that modulates DUX4 expression, optionally wherein the molecular payload comprises an oligonucleotide targeting DUX4.

32. The method of claim 31, wherein the anti-TfRl antibody comprises the CDRs of an anti-TfRl antibody provided in Table 4 or Table 5.

33. The method of any one of claims 2-10, 12-20, and 22-32, wherein the therapeutic agent is a complex comprising a structure of formula (I): [R^ni-R2, wherein each R1comprises a group of the formula (la):(la), or a pharmaceutically acceptable salt thereof, wherein R3comprises an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of SEQ ID NO: 22 and a structure (5’— >3’) of VP-mU*fG*mCmCmAmGmAmAmUmUmUmCmAfCmGmGmAmAmGmAmA*mC*mA (SEQID NO: 34), and a sense strand comprising a nucleobase sequence of SEQ ID NO: 21 and a structure (5’^3’) of mU*mU*mCmUfUmCmCmGfUfGfAmAmAfUmUmCmUmGfG*mC*mA (SEQ ID NO: 33), wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’-O-methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence of between two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5'- (E)- Vinylpho sphonate ; wherein R2comprises a Fab, and wherein the Fab comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5, optionally wherein the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18, further optionally wherein the Fab comprises a VH comprising an N-terminal pyroglutamate, further optionally wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein R1is covalently linked to R2at attachment point A; and wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab, optionally wherein each different amino acid residue is a lysine.

34. The method of any one of claims 2-10, 12-20, and 22-32, wherein the therapeutic agent is a complex comprising a structure of formula (I): [R^ni-R2, wherein each R1comprises a group of the formula (lb):(lb), or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-0-methyl adenosine, 2’-O-methyl cytidine, 2’-0- methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’-fluoro adenosine, 2’-fluoro cytidine, 2’-fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence of between two nucleosides represents a phosphodiester internucleoside linkage; and “VP” represents 5'- (E)-Vinylphosphonate, such that the oligonucleotide is an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21); wherein R2comprises a Fab, and wherein the Fab comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5, optionally wherein the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18, further optionally wherein the Fab comprises a VH comprising an N-terminal pyroglutamate, further optionally wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein R1is covalently linked to R2at attachment point A; and wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab, optionally wherein each different amino acid residue is a lysine.

35. The method of any one of claims 2-10, 12-20, and 22-32, wherein the therapeutic agent is a complex comprising a structure of formula (I): [R^ni-R2, whereinR1comprises a group of the formula (Ic), in which the antisense strand and the sense strand form a double stranded oligonucleotide:(Ic), or a pharmaceutically acceptable salt thereof, wherein R2comprises a Fab comprising a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5, optionally wherein the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18, further optionally wherein the Fab comprises a VH comprising an N-terminal pyroglutamate,further optionally wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein R1is covalently linked to R2at attachment point A; wherein nl is an integer representing the number of instances of R1, wherein each instance of R1is covalently linked to a different amino acid residue of the Fab, optionally wherein each different amino acid residue is a lysine.

36. The method of any one of claims 2-10, 12-20, and 22-32, wherein the therapeutic agent is a complex comprising a structure of the formula (Id):(Id), or a pharmaceutically acceptable salt thereof, wherein: mA, mC, mG, and mU are 2’-O-methyl adenosine, 2’-O-methyl cytidine, 2’- O-methyl guanosine, and 2’-O-methyl uridine, respectively; fA, fC, fG, and fU are 2’ -fluoro adenosine, 2’ -fluoro cytidine, 2’ -fluoro guanosine, and 2’-fluoro uridine, respectively; * between two nucleosides represents a phosphorothioate linkage; the absence ofbetween two nucleosides represents a phosphodiester intemucleoside linkage; and “VP” represents 5’-(E)-Vinylphosphonate, such that the oligonucleotide is an RNAi oligonucleotide comprising an antisense strand comprising a nucleobase sequence of UGCCAGAAUUUCACGGAAGAACA (SEQ ID NO: 22) and a sense strand comprising a nucleobase sequence of UUCUUCCGUGAAAUUCUGGCA (SEQ ID NO: 21; wherein R2comprises a Fab, and wherein the Fab comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 selected from Table 5, optionally wherein the Fab comprises a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 18,further optionally wherein the Fab comprises a VH comprising an N-terminal pyroglutamate, further optionally wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; wherein nl is an integer representing the number of instances of the group enclosed by square brackets, wherein each instance of the group enclosed by square brackets is covalently linked to a different amino acid residue of the Fab, optionally wherein each different amino acid residue is a lysine.

Images